WO2016107832A1

WO2016107832A1 - Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection

Info

Publication number: WO2016107832A1
Application number: PCT/EP2015/081257
Authority: WO
Inventors: Zhanling CHENG; Min Wang; Song Yang
Original assignee: F. Hoffmann-La Roche Ag; Hoffmann-La Roche Inc.
Priority date: 2014-12-30
Filing date: 2015-12-28
Publication date: 2016-07-07
Also published as: EP3240537B1; CN107108610A; US10196391B2; JP6506845B2; US20170298067A1; EP3240537A1; CN107108610B; JP2018500374A

Abstract

The invention provides novel compounds having the general formula (I): wherein R¹, R², R³, Q, U,W, Z, X and Y are as described herein, compositions including the compounds and methods of using the compounds. These compounds are HbsAg inhibitors and are useful as medicaments for the treatment or prophylaxis of HBV infection.

Description

Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis B virus infection

The present invention relates to organic compounds useful for therapy and/or prophylaxis in a mammal, and in particular to HBsAg (HBV Surface antigen) inhibitors useful for treating HBV infection. FIELD OF THE INVENTION

The present invention relates to novel tetrahydropyridopyrimidines and

tetrahydropyridopyridines having pharmaceutical activity, their manufacture, pharmaceutical compositions containing them and their potential use as medicaments.

The present invention relates to compounds of formula I

wherein R 1 to R 3^J, Q, U, W, X, Y and Z are as described below, or to pharmaceutically acceptable salts, or to enantiomers thereof.

The hepatitis B virus (HBV) is an enveloped, partially double-stranded DNA virus. The compact 3.2 kb HBV genome consists of four overlapping open reading frames (ORF), which encode for the core, polymerase (Pol), envelope and X-proteins. The Pol ORF is the longest and the envelope ORF is located within it, while the X and core ORFs overlap with the Pol ORF. The lifecycle of HBV has two main events: 1) generation of closed circular DNA (cccDNA) from relaxed circular (RC DNA), and 2) reverse transcription of pregenomic RNA (pgRNA) to produce RC DNA. Prior to the infection of host cells, the HBV genome exists within the virion as RC DNA. It has been determined that HBV virions are able to gain entry into host cells by non-specifically binding to the negatively charged proteoglycans present on the surface of human hepatocytes (Schulze, A., P. Gripon & S. Urban. Hepatology, 46, (2007), 1759-68) and via the specific binding of HBV surface antigens (HBsAg) to the hepatocyte sodium- taurocholate cotransporting polypeptide (NTCP) receptor (Yan, H. et al. / Virol, 87, (2013),

Yingxian Zhu/Nov. 5, 2015 7977-91). Once the virion has entered the cell, the viral cores and the encapsidated RC DNA are transported by host factors, via a nuclear localization signal, into the nucleus through the

ImpP/Impa nuclear transport receptors. Inside the nucleus, host DNA repair enzymes convert the RC DNA into cccDNA. cccDNA acts as the template for all viral mRNAs and as such, is responsible for HBV persistence in infected individuals. The transcripts produced from cccDNA are grouped into two categories; Pregenomic RNA (pgRNA) and subgenomic RNA. Subgenomic transcripts encode for the three envelopes (L, M and S) and X proteins, and pgRNA encodes for Pre-Core, Core, and Pol proteins (Quasdorff, M. & U. Protzer. / Viral Hepat, 17, (2010), 527- 36). Inhibition of HBV gene expression or HBV RNA synthesis leads to the inhibition of HBV viral replication and antigens production (Mao, R. et al. PLoS Pathog, 9, (2013), el003494; Mao, R. et al. / Virol, 85, (2011), 1048-57). For instance, IFN-a was shown to inhibit HBV replication and viral HBsAg production by decreasing the transcription of pgRNA and subgenomic RNA from the HBV covalently closed circular DNA (cccDNA) minichromosome. (Belloni, L. et al. / Clin Invest, 122, (2012), 529-37; Mao, R. et al. / Virol, 85, (2011), 1048-57). All HBV viral mRNAs are capped and polyadenylated, and then exported to the cytoplasm for translation. In the cytoplasm, the assembly of new virons is initiated and nascent pgRNA is packaged with viral Pol so that reverse transcription of pgRNA, via a single stranded DNA intermediate, into RC DNA can commence. The mature nucleocapsids containing RC DNA are enveloped with cellular lipids and viral L, M, and S proteins and then the infectious HBV particles are then released by budding at the intracellular membrane (Locarnini, S. Semin Liver Dis, (2005), 25 Suppl 1, 9-19). Interestingly, non-infectious particles are also produced that greatly outnumber the infectious virions. These empty, enveloped particles (L, M and S) are referred to as subviral particles.

Importantly, since subviral particles share the same envelope proteins and as infectious particles, it has been surmised that they act as decoys to the host immune system and have been used for HBV vaccines. The S, M, and L envelope proteins are expressed from a single ORF that contains three different start codons. All three proteins share a 226aa sequence, the S -domain, at their C- termini. M and L have additional pre-S domains, Pre-S2 and Pre-S2 and Pre-Sl, respectively. However, it is the S-domain that has the HBsAg epitope (Lambert, C. & R. Prange. Virol J, (2007), 4, 45).

The control of viral infection needs a tight surveillance of the host innate immune system which could respond within minutes to hours after infection to impact on the initial growth of the virus and limit the development of a chronic and persistent infection. Despite the available current treatments based on IFN and nucleos(t)ide analogues, the Hepatitis B virus (HBV) infection remains a major health problem worldwide which concerns an estimated 350 million chronic carriers who have a higher risk of liver cirrhosis and hepatocellular carcinoma.

The secretion of antiviral cytokines in response to HBV infection by the hepatocytes and/or the intra-hepatic immune cells plays a central role in the viral clearance of infected liver. However, chronically infected patients only display a weak immune response due to various escape strategies adopted by the virus to counteract the host cell recognition systems and the subsequent antiviral responses.

Many observations showed that several HBV viral proteins could counteract the initial host cellular response by interfering with the viral recognition signaling system and subsequently the interferon (IFN) antiviral activity. Among these, the excessive secretion of HBV empty sub viral particles (SVPs, HBsAg) may participate to the maintenance of the immunological tolerant state observed in chronically infected patients (CHB). The persistent exposure to HBsAg and other viral antigens can lead to HBV- specific T-cell deletion or to progressive functional impairment (Kondo et al. Journal of Immunology (1993), 150, 4659-4671; Kondo et al. Journal of Medical Virology (2004), 74, 425-433; Fisicaro et al. Gastroenterology, (2010), 138, 682-93;). Moreover HBsAg has been reported to suppress the function of immune cells such as monocytes, dendritic cells (DCs) and natural killer (NK) cells by direct interaction (Op den Brouw et al. Immunology, (2009b), 126, 280-9; Woltman et al. PLoS One, (2011), 6, el5324; Shi et al. / Viral Hepat.

(2012), 19, e26-33; Kondo et al. ISRN Gasteroenterology, (2013), Article ID 935295).

HBsAg quantification is a significant biomarker for prognosis and treatment response in chronic hepatitis B. However the achievement of HBsAg loss and seroconversion is rarely observed in chronically infected patients but remains the ultimate goal of therapy. Current therapy such as Nucleos(t)ide analogues are molecules that inhibit HBV DNA synthesis but are not directed at reducing HBsAg level. Nucleos(t)ide analogs, even with prolonged therapy, have demonstrated rates of HBsAg clearance comparable to those observed naturally (between - \%- 2%) (Janssen et al. Lancet, (2005), 365, 123-9; Marcellin et al. N. Engl. J. Med., (2004), 351, 1206-17; Buster et al. Hepatology, (2007), 46, 388-94). Therefore, there is an unmet medical need to target HBsAg for HBV treatment (Wieland, S. F. & F. V. Chisari. / Virol, (2005), 79, 9369-80; Kumar et al. / Virol, (2011), 85, 987-95; Woltman et al. PLoS One, (2011), 6, el5324; Op den Brouw et al. Immunology, (2009b), 126, 280-9).

SUMMARY OF THE INVENTION

The present invention relates to the use of a compound of formula I,

wherein

R¹ is hydrogen, Ci_₆alkyl, or haloCi_₆alkyl;

R is Ci_₆alkyl, C₂_₆alkenyl, Ci_₆alkoxy, hydrogen, hydroxy, haloCi_₆alkyl, phenylCi_₆alkoxy, amino, Ci_₆alkylamino or diCi_₆alkylamino;

R is phenyl; phenyl substituted by one, two or three substituents independently selected from Ci-₆alkyl, C₃-₇cycloalkyl, halogen, haloC_1-6alkyl, cyano, nitro, -C(=0)OR⁴, -OR⁵, -S0₂R⁶ and - 0 7 8

C(= )NR R ; thiophenyl; thiophenyl substituted by one, two or three substituents independently selected from Ci_₆alkyl, Ci_₆alkyoxy and halogen; furanyl; furanyl substituted by one, two or three substituents independently selected from C_halky, Ci_₆alkyoxy and halogen; N-containing heteroaryl; or N-containing heteroaryl substituted with one, two or three substituents

independently selected from C_halky, Ci_₆alkyoxy, halogen, haloCi_₆alkyl, cyano, nitro, - C(=0)OR⁴, -OR⁵ and -S0₂R⁶; wherein,

R⁴ is hydrogen or Ci_₆alkyl;

R⁵ is hydrogen, Ci_₆alkyl, haloCi_₆alkyl, hydroxyCi_₆alkyl, Ci_₆alkoxyCi_₆alkyl or phenylCi_₆alkyl;

R⁶ is Ci_₆alkyl, haloCi_₆alkyl, amino, Ci_₆alkyamino or diCi_₆alkyamino;

7 8

R' and R° are independently selected from hydrogen, Ci_₆alkyl, haloCi_₆alkyl, hydroxyCi- ₆alkyl and Ci_₆alkoxyCi_₆alkyl;

Q is hydrogen, Ci_₆alkyl, Ci_₆alkoxy, halogen, or haloCi_₆alkyl;

U, W and Z are independently selected from C and N;

one of X and Y is N, and the other one is C or N;

or pharmaceutically acceptable salts, or enantiomers for the preparation of a medicament for the treatment or prophylaxis of HBV infection. The present invention also relates to a compound of formula I, wherein

R¹ is hydrogen, Ci_₆alkyl, or haloCi_₆alkyl;

R is Ci_₆alkyl, C₂_₆alkenyl, Ci_₆alkoxy, hydrogen, hydroxy, haloCi_₆alkyl, phenylCi_₆alkoxy, amino, Ci_₆alkylamino or diCi_₆alkylamino; R is phenyl; phenyl substituted by one, two or three substituents independently selected from Ci_₆alkyl, C₃_₇cycloalkyl, halogen, haloCi_₆alkyl, cyano, nitro, -C(=0)OR⁴, -OR⁵, -S0₂R⁶ and -

7 8

C(=0)NR R ; thiophenyl; thiophenyl substituted by one, two or three substituents independently selected from Ci_₆alkyl, Ci_₆alkyoxy and halogen; furanyl; furanyl substituted by one, two or three substituents independently selected from C_halky, Ci_₆alkyoxy and halogen; N-containing heteroaryl; or N-containing heteroaryl substituted with one, two or three substituents

R⁴ is hydrogen or Ci_₆alkyl;

7 8

Q is hydrogen, Ci_₆alkyl, Ci_₆alkoxy, halogen, or haloCi_₆alkyl;

U, W and Z are independently selected from C and N;

one of X and Y is N, and the other one is C or N;

with the proviso that 6-(4-nitrophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine is excluded;

or pharmaceutically acceptable salts, or enantiomers thereof.

DETAILED DESCRIPTION OF THE INVENTION DEFINITIONS

As used herein, the term "Ci_₆alkyl" alone or in combination signifies a saturated, linear- or branched chain alkyl group containing 1 to 6, particularly 1 to 4 carbon atoms, for example methyl, ethyl, propyl, isopropyl, 1 -butyl, 2-butyl, iert-butyl and the like. Particular "Ci_₆alkyl" groups are methyl, ethyl, isopropyl and iert-butyl.

The term "C₃_₇cycloalkyl", alone or in combination, refers to a saturated carbon ring containing from 3 to 7 carbon atoms, particularly from 3 to 6 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Particular "C₃_ ₇cycloalkyl" groups are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

The term "Ci_₆alkoxy" alone or in combination signifies a group Ci_₆alkyl-0-, wherein the "Ci_₆alkyl" is as defined above; for example methoxy, ethoxy, propoxy, iso-propoxy, w-butoxy, zso-butoxy, 2-butoxy, iert-butoxy and the like. Particular "Ci_₆alkoxy" groups are methoxy and ethoxy.

The term "halogen" means fluorine, chlorine, bromine or iodine.

The term "haloCi_₆alkyl" denotes a Ci_₆alkyl group wherein at least one of the hydrogen atoms of the Ci_₆alkyl group has been replaced by same or different halogen atoms, particularly fluoro atoms. Examples of haloalkyl include monofluoro-, difluoro- or trifluoro-methyl, -ethyl or -propyl, for example 3,3,3-trifluoropropyl, 3,3- difluoropropyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, fluoromethyl, difluoromethyl or trifluoromethyl. Particular "haloCi_₆alkyl" group is difluoromethyl or trifluoromethyl.

The term "C2-₆alkenyl" denotes a monovalent linear or branched hydrocarbon group of 2 to

6 carbon atoms with at least one double bond. In particular embodiments, C₂-₆alkenyl has 2 to 4 carbon atoms with at least one double bond. Examples of C₂-₆alkenyl include ethenyl, propenyl, prop-2-enyl, isopropenyl, n-butenyl, and iso-butenyl. Particular "C₂-₆alkenyl" group is propenyl or ethenyl.

The term "amino" denotes a group of the formula -NR'R" wherein R' and R" are independently hydrogen, Ci_₆alkyl, Ci_₆alkoxy, C₃_₇cycloalkyl, heteroC₃_₇cycloalkyl, aryl or heteroaryl. Alternatively, R' and R", together with the nitrogen to which they are attached, can form a heteroC₃_₇cycloalkyl. The term "Ci_₆alkylamino" denotes a group wherein R' is hydrogen and R" is a Ci_₆alkyl. Examples of Ci_₆alkylamino groups include methylamino and ethylamino. The term "diCi_₆alkylamino" denotes a group wherein R' and R" are both Ci_₆alkyl. Examples of diCi_₆alkylamino groups include dimethylamino, methylethylamino, diethylamino and di(l- methylethyl) amino .

The term "heteroaryl" denotes a monovalent aromatic heterocyclic mono- or bicyclic ring system of 5 to 12 ring atoms, comprising 1, 2, 3 or 4 heteroatoms selected from N, O and S, the remaining ring atoms being carbon. Examples of heteroaryl moieties include pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, triazinyl, azepinyl, diazepinyl, isoxazolyl, benzofuranyl, isothiazolyl, benzothienyl, indolyl, isoindolyl, isobenzofuranyl, benzimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzooxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, quinolinyl, isoquinolinyl, quinazolinyl, or

quinoxalinyl.

The term " V-containing heteroaryl" refers to a heteroaryl group as defined above wherein at least one of the heteroatoms is N. Examples for 'W-containing heteroaryl" include pyrrolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, triazinyl, azepinyl, diazepinyl, isoxazolyl, isothiazolyl, indolyl, isoindolyl, benzimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzooxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, quinolinyl, isoquinolinyl, quinazolinyl, or quinoxalinyl. Particular " V-containing heteroaryl" is pyridinyl, pyrimidinyl, thiazolyl, isoquinolinyl or quinolinyl. More particularly " V-containing heteroaryl" is pyridinyl

The term "enantiomer" denotes two stereoisomers of a compound which are non- superimposable mirror images of one another.

The compounds according to the present invention may exist in the form of their pharmaceutically acceptable salts. The term "pharmaceutically acceptable salt" refers to conventional acid-addition salts or base-addition salts that retain the biological effectiveness and properties of the compounds of formula I and are formed from suitable non-toxic organic or inorganic acids or organic or inorganic bases. Acid-addition salts include for example those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as /7-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, and the like. Base-addition salts include those derived from ammonium, potassium, sodium and, quaternary ammonium hydroxides, such as for example, tetramethyl ammonium hydroxide. The chemical modification of a pharmaceutical compound into a salt is a technique well known to pharmaceutical chemists in order to obtain improved physical and chemical stability, hygroscopicity, flowability and solubility of compounds. It is for example described in Bastin R.J., et al., Organic Process Research & Development 2000, 4, 427-435; or in Ansel, H., et al., In: Pharmaceutical Dosage Forms and Drug Delivery Systems, 6th ed. (1995), pp. 196 and 1456-1457. Particular are the sodium salts of the compounds of formula I.

Compounds of the general formula I which contain one or several chiral centers can either be present as racemates, diastereomeric mixtures, or optically active single isomers. The racemates can be separated according to known methods into the enantiomers. Particularly, diastereomeric salts which can be separated by crystallization are formed from the racemic mixtures by reaction with an optically active acid such as e.g. D- or L-tartaric acid, mandelic acid, malic acid, lactic acid or camphorsulfonic acid. INHIBITOR OF HBsAg

The present invention provides organic compounds useful for therapy and/or prophylaxis in a mammal, and in particular to HBsAg (HBV Surface antigen) inhibitors useful for treating HBV infection.

One embodiment of the present is (i) the use of a compound of formula I

wherein

R¹ is hydrogen, Ci_₆alkyl, or haloCi_₆alkyl;

R is phenyl; phenyl substituted by one, two or three substituents independently selected from Ci_₆alkyl, C₃_₇cycloalkyl, halogen, haloC_1-6alkyl, cyano, nitro, -C(=O)OR⁴, -OR⁵, -SO₂R⁶ and -

7 8

C(=O)NR R ; thiophenyl; thiophenyl substituted by one, two or three substituents independently selected from Ci_₆alkyl, Ci_₆alkyoxy and halogen; furanyl; furanyl substituted by one, two or three substituents independently selected from C_halky, Ci_₆alkyoxy and halogen; N-containing heteroaryl; or N-containing heteroaryl substituted with one, two or three substituents

independently selected from C_halky, Ci_₆alkyoxy, halogen, haloCi_₆alkyl, cyano, nitro, - C(=O)OR⁴, -OR⁵ and -SO₂R⁶; wherein,

R⁴ is hydrogen or Ci_₆alkyl;

R⁶ is Ci-₆alkyl, haloCi_₆alkyl, amino, Ci_₆alkyamino or diCi_₆alkyamino;

7 8

Q is hydrogen, Ci_₆alkyl, Ci_₆alkoxy, halogen, or haloCi_₆alkyl;

U, W and Z are independently selected from C and N;

one of X and Y is N, and the other one is C or N; or pharmaceutically acceptable salts, or enantiomers for the preparation of a medicament for the treatment or prophylaxis of HBV infection.

Another embodiment of the present invention is (ii) a compound of formula I, wherein R¹ is hydrogen, Ci_₆alkyl, or haloCi_₆alkyl;

R is Ci-₆alkyl, C₂_₆alkenyl, Ci_₆alkoxy, hydrogen, hydroxy, haloCi_₆alkyl, phenylCi_₆alkoxy, amino, Ci_₆alkylamino or diCi_₆alkylamino;

R is phenyl; phenyl substituted by one, two or three substituents independently selected from Ci-₆alkyl, C₃-₇cycloalkyl, halogen, haloCi_₆alkyl, cyano, nitro, -C(=0)OR⁴, -OR⁵, -S0₂R⁶ and -

7 8

C(=0)NR R ; thiophenyl; thiophenyl substituted by one, two or three substituents independently selected from Ci_₆alkyl, Ci_₆alkyoxy and halogen; furanyl; furanyl substituted by one, two or three substituents independently selected from C_halky, Ci_₆alkyoxy and halogen; N-containing heteroaryl; or N-containing heteroaryl substituted with one, two or three substituents independently selected from C_halky, Ci_₆alkyoxy, halogen, haloCi_₆alkyl, cyano, nitro, - C(=0)OR⁴, -OR⁵ and -S0₂R⁶; wherein,

R⁴ is hydrogen or Ci_₆alkyl;

7 8

Q is hydrogen, Ci_₆alkyl, Ci-₆alkoxy, halogen, or haloCi_₆alkyl;

U, W and Z are independently selected from C and N;

one of X and Y is N, and the other one is C or N;

or pharmaceutically acceptable salts, or enantiomers thereof.

A further embodiment of present invention is (iii) a compound of formula I according to embodiment (ii), wherein

R¹ is hydrogen or Ci_₆alkyl;

R is Ci-₆alkyl, C₂-₆alkenyl, Ci_₆alkoxy, hydrogen, hydroxy, phenylCi_₆alkoxy or Ci_

6alkylamino; R is phenyl; phenyl substituted by one, two or three substituents independently selected from Ci_₆alkyl, C₃_₇cycloalkyl, halogen, haloCi_₆alkyl, cyano, nitro, -C(=0)OR⁴, -OR⁵, -S0₂R⁶ and -

C(=0)NR 7 R 8 ; thiazolyl; quinolyl substituted by Ci_₆alkoxy; isoquinolyl substituted by Ci_ ₆alkoxy; pyrimidinyl substituted with one or two substituents independently selected from Ci_ ₆alkyoxy and halogen; pyridinyl; or pyridinyl substituted with one or two substituents independently selected from Ci_₆alkyoxy and halogen; wherein,

R⁴ is hydrogen or Ci_₆alkyl;

R⁵ is hydrogen, Ci_₆alkyl, haloCi_₆alkyl, hydroxyCi_₆alkyl, Ci_₆alkoxyCi_₆alkyl or phenylCi-₆alkyl;

RR⁶⁶ iiss CCii__₆₆aallkyl, haloCi_₆alkyl, Ci_₆alkyamino or diCi_₆alkyamino;

R 7' and R 8° are independently selected from hydrogen, Ci_₆alkyl, haloCi_₆alkyl, hydroxyCi-

₆alkyl and Ci-₆alkoxyCi_₆alkyl;

Q is hydrogen, Ci-₆alkyl, Ci-₆alkoxy or halogen;

U is C, W is C, and Z is C; or one of U, W and Z is N, and the other two are C;

one of X and Y is N, and the other one is C or N;

or pharmaceutically acceptable salts, or enantiomers thereof.

A further embodiment of the present invention is (iv) a compound of formula I according to embodiment (ii) or (iii), or pharmaceutically acceptable salts, or enantiomers thereof, wherein U is C;

W is C:

X is N

Y is C or N;

Z is C or N.

Another embodiment of the present invention is (v) a compound of formula I according to embodiments (ii) to (iv), or pharmaceutically acceptable salts, or enantiomers thereof, wherein

R 1 is hydrogen, R 2 is hydrogen, Q is hydrogen.

Another embodiment of the present invention is (vi) a compound of formula I according to anyone of embodiments (ii) to (v), or pharmaceutically acceptable salts, or enantiomers thereof, wherein R is phenyl substituted by one, two or three substituents independently selected from halogen, cyano, nitro, carboxy, -OR⁵ and -S0₂R⁶, wherein R⁵ is Ci_₆alkyl, haloCi_₆alkyl, hydroxyCi_₆alkyl, Ci_₆alkoxyCi_₆alkyl or phenylCi_₆alkyl; R⁶ is Ci_₆alkyl; or pyridinyl substituted by one or two substituents independently selected from halogen and Ci_₆alkoxy. A further embodiment of the present invention is (vii) a compound of formula I according to anyone of embodiments (ii) to (vi), or pharmaceutically acceptable salts, or enantiomers thereof, wherein R is phenyl substituted by one, two or three substituents independently selected from fluoro, chloro, cyano, nitro, carboxy, methoxy, ethoxy, propoxy, difluoromethoxy, trifluoromethoxy, hydroxyethoxy, hydroxypropoxy, methoxyethoxy, methoxypropoxy, benzyloxy and methylsulfonyl; or pyridinyl substituted by one or two substituents independently selected from fluoro, chloro and methoxy.

Another embodiment of the present invention is (viii) a compound of formula I according to embodiment (ii) or (iii), wherein

R¹ is hydrogen;

R is hydrogen;

R is phenyl substituted by one, two or three substituents independently selected from halogen, cyano and -OR⁵, wherein R⁵ is Ci_₆alkyl, hydroxyCi_₆alkyl or Ci_₆alkoxyCi_₆alkyl; or pyridinyl substituted by one or two substituents independently selected from halogen and Ci_₆alkoxy;

Q is hydrogen;

U is C;

W is C, Z is C; or one of W and Z is N, and the other one is C;

X is N;

Y is C or N;

or pharmaceutically acceptable salts, or enantiomers thereof.

A further embodiment of present invention is (ix) a compound of formula I according to embodiment (ii), (iii) or (viii), wherein

R¹ is hydrogen;

R is hydrogen;

R is phenyl substituted by one, two or three substituents independently selected from fluoro, chloro, cyano, methoxy, ethoxy, hydroxypropoxy and methoxypropoxy; or pyridinyl substituted by one or two substituents independently selected from fluoro, chloro and methoxy;

Q is hydrogen;

U is C;

W is C, Z is C; or one of W and Z is N, and the other one is C;

X is N;

Y is C or N; or pharmaceutically acceptable salts, or enantiomers thereof.

Another embodiment of the present invention is (x) the use of a compound having general formula I:

wherein

R¹ is hydrogen, Ci_₆alkyl, or haloCi_₆alkyl;

R is phenyl; phenyl substituted by one, two or three groups independently selected from Ci_

₆alkyl, C3_₇cycloalkyl, halogen, haloCi_₆alkyl, cyano, nitro, -C(=0)OR⁴, -OR⁵ and -S0₂R⁶; thiophenyl; thiophenyl substituted by one, two or three groups independently selected from Ci_

₆alkyl, Ci_₆alkyoxy and halogen; furanyl; furanyl substituted by one, two or three groups independently selected from C_halky, Ci_₆alkyoxy and halogen; N-containing heteroaryl; or N- containing heteroaryl substituted with one, two or three groups independently selected from Ci_

₆alky, Ci_₆alkyoxy, halogen, haloCi_₆alkyl, cyano, nitro, C(=0)OR⁴, OR⁵ and -S0₂R⁶; wherein, R⁴ is hydrogen or Ci_₆alkyl;

Q is hydrogen, Ci_₆alkyl, Ci_₆alkoxy, halogen, or haloCi_₆alkyl;

U, W and Z are independently selected from C and N;

one of X and Y is N, and the other one is C or N;

or pharmaceutically acceptable salts, or enantiomers for the preparation of a medicament for the treatment or prophylaxis of HBV infection.

A further embodiment of the present invention is (xi) a compound of formula I, wherein R¹ is hydrogen, Ci-₆alkyl, or haloCi_₆alkyl; R is Ci-₆alkyl, C₂_₆alkenyl, Ci_₆alkoxy, hydrogen, hydroxy, haloCi_₆alkyl, phenylCi_₆alkoxy, amino, Ci_₆alkylamino or diCi_₆alkylamino;

R is phenyl; phenyl substituted by one, two or three groups independently selected from Ci_ ₆alkyl, C₃_₇cycloalkyl, halogen, haloCi_₆alkyl, cyano, nitro, -C(=0)OR⁴, -OR⁵ and -S0₂R⁶; thiophenyl; thiophenyl substituted by one, two or three groups independently selected from Ci_ ₆alkyl, Ci_₆alkyoxy and halogen; furanyl; furanyl substituted by one, two or three groups independently selected from C_halky, Ci_₆alkyoxy and halogen; N-containing heteroaryl; or N- containing heteroaryl substituted with one, two or three groups independently selected from Ci_ ₆alky, Ci-₆alkyoxy, halogen, haloCi-₆alkyl, cyano, nitro, C(=0)OR⁴, OR⁵ and -S0₂R⁶; wherein, R⁴ is hydrogen or Ci_₆alkyl;

Q is hydrogen, Ci_₆alkyl, Ci_₆alkoxy, halogen, or haloCi_₆alkyl;

U, W and Z are independently selected from C and N;

one of X and Y is N, and the other one is C or N;

or pharmaceutically acceptable salts, or enantiomers thereof. Another embodiment of present invention is (xii) a compound of formula I according to embodiment (xi), wherein

R¹ is hydrogen or Ci_₆alkyl;

R is Ci_₆alkyl, C₂_₆alkenyl, Ci_₆alkoxy, hydrogen, hydroxy, phenylCi_₆alkoxy or Ci_

6alkylamino;

R is phenyl; phenyl substituted by one, two or three groups independently selected from Ci_ ₆alkyl, C₃_₇cycloalkyl, halogen, cyano, nitro, -C(=0)OR⁴, -OR⁵ and -S0₂R⁶; N-containing heteroaryl; or N-containing heteroaryl substituted with one or two groups independently selected from Ci_₆alkyoxy and halogen; wherein,

R⁴ is hydrogen or Ci_₆alkyl;

R⁶ is Ci_₆alkyl, haloCi_₆alkyl, Ci_₆alkyamino or diCi_₆alkyamino;

Q is hydrogen, Ci-₆alkyl, Ci-₆alkoxy or halogen; U is C, W is C, and Z is C; or one of U, W and Z is N, and the other two are C; one of X and Y is N, and the other one is C or N;

or pharmaceutically acceptable salts, or enantiomers thereof.

A further embodiment of the present invention is (xiii) a compound of formula I according to embodiment (xi) or (xii), or pharmaceutically acceptable salts, or enantiomers thereof, wherein

U is C;

W is C;

X is N;

Y is C or N;

Z is C or N.

Another embodiment of the present invention is (xiv) a compound of formula I according to anyone of embodiments (xi) to (xiii), or pharmaceutically acceptable salts, or enantiomers thereof, wherein R 1 is hydrogen, R 2 is hydrogen, Q is hydrogen.

Another embodiment of the present invention is (xv) a compound of formula I according to anyone of embodiments (xi) to (xiv), or pharmaceutically acceptable salts, or enantiomers thereof, wherein R is phenyl substituted by one, two or three groups independently selected from halogen, cyano, nitro, carboxy, -OR⁵ and -S0₂R⁶, wherein R⁵ is Ci_₆alkyl, haloCl-6alkyl, hydroxyCi_₆alkyl, Ci_₆alkoxyCi_₆alkyl or phenylCi_₆alkyl; R⁶ is Ci_6alkyl.

A further embodiment of the present invention is (xvi) a compound of formula I according to anyone of embodiments (xi) to (xv), or pharmaceutically acceptable salts, or enantiomers thereof, wherein R is phenyl substituted by one, two or three groups independently selected from fluoro, chloro, cyano, nitro, carboxy, methoxy, ethoxy, propoxy, difluoromethoxy, trifluoromethoxy, hydroxyethoxy, hydroxypropoxy, methoxyethoxy, methoxypropoxy, benzyloxy and methylsulfonyl.

Another embodiment of the present invention is (xvii) a compound of formula I according to embodiment (xi) or (xii), wherein

R¹ is hydrogen; R is hydrogen;

R is phenyl substituted by one, two or three groups independently selected from halogen, cyano and -OR⁵, wherein R⁵ is Ci_₆alkyl, hydroxyCi_₆alkyl or Ci_₆alkoxyCi_₆alkyl; or pyridinyl substituted by halogen and Ci_₆alkoxy;

Q is hydrogen;

U is C;

W is C, Z is C; or one of W and Z is N, and the other one is C;

X is N;

Y is C or N;

or pharmaceutically acceptable salts, or enantiomers thereof.

A further embodiment of present invention is (xviii) a compound of formula I according to embodiment (xi), (xii) or (xvii), wherein

R¹ is hydrogen;

R is hydrogen;

R is phenyl substituted by one, two or three groups independently selected from fluoro, chloro, cyano, methoxy, ethoxy, hydroxypropoxy and methoxypropoxy; or pyridinyl substituted by fluoro and methoxy;

Q is hydrogen;

U is C;

W is C, Z is C; or one of W and Z is N, and the other one is C;

X is N;

Y is C or N;

or pharmaceutically acceptable salts, or enantiomers thereof.

Particular compounds of formula I according to the invention are the following:

6-(4-Methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 2-(5-Fluoro-2-pyridyl)-6-(4-methylsulfonylphenyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

2-(5-Methyl-2-pyridyl)-6-(4-methylsulfonylphenyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

2-(3-Methyl-2-pyridyl)-6-(4-methylsulfonylphenyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine; 2-(5-Methoxy-2-pyridyl)-6-(4-methylsulfonylphenyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

2-(5-Chloro-2-pyridyl)-6-(4-methylsulfonylphenyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

8-Ethyl-6-(4-methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

N-Methyl-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl] benzenesulfonamide ;

N,N-Dimethyl-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl] benzenesulfonamide;

6-(3,4-Difluorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(3-Methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

2-(2-Pyridyl)-6-[4-(trifluoromethylsulfonyl)phenyl]-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(3,5-Difluorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(2,4-Difluorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

Methyl 2-fluoro-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzoate;

Methyl 5-bromo-2-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzoate;

6-(3,4-Difluoro-5-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 2,3-Difluoro-5-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]phenol;

6-[3,4-Difluoro-5-(3-methoxypropoxy)phenyl]-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(3-Benzyloxy-4,5-difluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(3-Ethoxy-4,5-difluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(3,4-Difluoro-5-propoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-[3,4-Difluoro-5-(2-methoxyethoxy)phenyl]-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(3,4-Difluoro-5-methoxy-phenyl)-2-(4-methoxy-2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(3,4-Difluoro-5-methoxy-phenyl)-2-(6-methoxy-2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine; 6-(3,4-Difluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(4,5-Difluoro-2-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-(3,4-Difluoro-5-methoxy-phenyl)-2-pyrazin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

6-(3,4-Difluoro-5-methoxy-phenyl)-2-pyrimidin-4-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(3,4-Difluoro-2-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; Ethyl 4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzoate;

4-[2-(2-Pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzoic acid;

6-(2-Nitrophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(2-Methoxy-4-nitro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine 2,6-Bis(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(5-Chloro-2-pyridyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

2-(2-Pyridyl)-6-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(2-Benzyloxy-4-fluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 2-(2-Pyridyl)-6-(3-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(3-Fluoro-5-methyl-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-(3-Bromo-5-fluoro-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-(3-Cyclopropyl-5-fluoro-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

2-Pyrimidin-2-yl-6-[3-(trifluoromethoxy)phenyl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-[3-Methoxy-4-(3-methoxypropoxy)phenyl]-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(4-Chlorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(4-Benzyloxyphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(p-Tolyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

8-Methyl-6-(4-nitrophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(3,4-Dichlorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(4-Methoxyphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(3-Bromo-4-fluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(4-Bromo-3-fluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(4-Benzyloxy-3-fluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-(4-Ethoxy-3-fluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-(3-Fluoro-4-propoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-[3-Fluoro-4-(3-methoxypropoxy)phenyl]-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-[3-Methoxy-4-(2-methoxyethoxy)phenyl]-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-[4-Methoxy-3-(2-methoxyethoxy)phenyl]-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(3,4-Dimethoxyphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

2-Methoxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzonitrile; 6-(2,3-Difluoro-4-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(4-Chloro-3-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-[3-(Difluoromethoxy)phenyl]-2-pyrimidin^

6-(4-Benzyloxy-3,5-difluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

2-Methoxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzoic acid; 2-Ethoxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzoic acid;

2- Butoxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzoic acid; 6-(5-Chloro-4-methoxy-pyrimidin-2-yl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(5-Chloro-2-methoxy-pyrimidin-4-yl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(3-Fluoro-4-methoxy-2-pyridyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-(5-Fluoro-4-methoxy-2-pyridyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-(5-Fluoro-6-methoxy-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(3,5-Dimethoxyphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-(8-Methoxy-3-isoquinolyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-(2-Methoxy-7-quinolyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

3- Methoxy-5-(2-pyriimdin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)benzoniM^ 2-Fluoro-6-methoxy-4-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl)benzonitrile; 6-(4-Chloro-3-fluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(3-Chloro-4-fluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(4-Methylsulfonylphenyl)-2-(2-pyridyl)-3,5,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-one; 4-Methoxy-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

4-Ethoxy-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

4-Benzyloxy-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(4-Methylsulfonylphenyl)-4-[(E)-prop-l-enyl]-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido [4 , 3 - d] pyrimidine ;

6-(4-Methylsulfonylphenyl)-4-propyl-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d] pyrimidine;

4-Ethyl-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d] pyrimidine;

4-Methyl-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d] pyrimidine;

N-Methyl-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d] pyrimidin-4- amine ;

6-(4-Methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihydro-5H- l,6-naphthyridine;

6-(4-Fluoro-3-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(3-Fluoro-5-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(3-Methoxyphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

3-[2,3-Difluoro-5-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl]phenoxy]propan-l-ol;

2-[2,3-Difluoro-5-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl] phenoxy] ethanol ;

2-(3,4-Difluoro-5-methoxy-phenyl)-6-pyrimidin-2-yl-3,4-dihydro-lH-2,7-naphthyridine; 2-(3,4-Difluoro-5-methoxy-phenyl)-6-(2-pyridyl)-3,4-dihydro-lH-2,7-naphthyridine;

6-(3,4-Difluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-l,6-naphthyridine; 6-(3-Chloro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-(6-Fluoro-4-methoxy-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-[3-Methoxy-5-(trifluoromethyl)phenyl]-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

3-Fluoro-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)benzonitrile; Methyl 3-fluoro-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl)benzoate;

3-Fluoro-N-methyl-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl)benzamide;

3-Fluoro-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)-N-(2,2,2- trifluoroethyl)benzamide ;

3-Fluoro-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)benzamide; 3-Fluoro-N-(3-methoxypropyl)-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl)benzamide;

3-Fluoro-N-(5-hydroxypentyl)-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl)benzamide;

6-(6-Chloro-4-methoxy-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(2,6-Difluoro-4-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-(4,6-Difluoro-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-(4-Fluoro-6-methoxy-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(2-Fluoro-6-methoxy-4-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(4,6-Dichloro-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(2,6-Dichloro-4-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-(4-Chloro-6-methoxy-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(2-Chloro-6-methoxy-4-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(3-Fluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-[3-Fluoro-5-(trifluoromethoxy)phenyl]-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine; 2-(2-Pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)thiazole;

or pharmaceutically acceptable salts, or enantiomers thereof.

More particularly, the invention relates to the following compounds of formula I:

6-(3,4-Difluoro-5-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5 H -pyrido[4,3- d]pyrimidine;

6-[3,4-Difluoro-5-(3-methoxypropoxy)phenyl]-2-(2-pyridyl)-7,8-dihydro-5 H -pyrido[4,3- d]pyrimidine;

6-(3-Ethoxy-4,5-difluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5 H -pyrido[4,3-d]pyrimidine; 6-(3,4-Difluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5 H -pyrido[4,3- d]pyrimidine;

6-(3,4-Difluoro-5-methoxy-phenyl)-2-pyrazin-2-yl-7,8-dihydro-5 H -pyrido[4,3- d]pyrimidine;

2-Methoxy-4-[2-(2-pyridyl)-7,8-dihydro-5 H -pyrido[4,3-d]pyrimidin-6-yl]benzonitrile; 6-(5-Fluoro-4-methoxy-2-pyridyl)-2-(2-pyridyl)-7,8-dihydro-5 H -pyrido[4,3-d]pyrimidine;

2- Fluoro-6-methoxy-4-(2-pyrimidin-2-yl-7,8-dihydro-5 H -pyrido[4,3-d]pyrimidin-6- yl)benzonitrile;

6-(3-Chloro-4-fluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5 H -pyrido[4,3- d]pyrimidine;

6-(3-Fluoro-5-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5 H -pyrido[4,3-d]pyrimidine;

3- [2,3-Difluoro-5-[2-(2-pyridyl)-7,8-dihydro-5 H -pyrido[4,3-d]pyrimidin-6- yl]phenoxy]propan-l-ol;

2-(3,4-Difluoro-5-methoxy-phenyl)-6-pyrimidin-2-yl-3,4-dihydro- 1 H -2,7-naphthyridine; 2-(3,4-Difluoro-5-methoxy-phenyl)-6-(2-pyridyl)-3,4-dihydro-l H -2,7-naphthyridine; 6-(3-Chloro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5 H -pyrido[4,3- d]pyrimidine;

6-(6-Fluoro-4-methoxy-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(4,6-Dichloro-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-(3-Fluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; or pharmaceutically acceptable salts, or enantiomers thereof. SYNTHESIS

The compounds of the present invention can be prepared by any conventional means.

Suitable processes for synthesizing these compounds as well as their starting materials are provided in the schemes below and in the examples. All substituents, in particular, R 1 to R 3 , Q, U, W, X, Y and Z are as defined above unless otherwise indicated. Furthermore, and unless explicitly otherwise stated, all reactions, reaction conditions, abbreviations and symbols have the meanings well known to a person of ordinary skill in organic chemistry.

General synthetic route for Compound la (Scheme 1)

Scheme 1

R³-L

II III

DMFDMA

VI la

L is CI, Br, I, O-mesyl or O-tosyl

The compound of formula la can be prepared according to Scheme 1.

Compound II is heated with compound III in the presence of a catalyst such as Pd₂(dba)3 or Pd(OAc)₂, a ligand such as Ruphos, Sphos or BINAP and a base such as Cs₂C0₃ or i-BuONa in a suitable solvent such as 1, 4-dioxane or toluene, to afford compound IV. Deprotection of compound IV under an acidic condition affords compound V. Reaction of compound V with DMFDMA in the absence or presence of a suitable solvent such as DMF or acetonitrile generates intermediate VI. Compound la can be obtained by cyclization of intermediate VI with compound VII in the presence of a base such as K₂CO₃, NaOMe or Et₃N, in a suitable solvent such as EtOH or MeOH.

General synthetic route for Compound lb (Scheme 2)

Scheme 2

lb

L is CI, Br, I, O-mesyl or O-tosyl

The compound of formula lb can be prepared according to Scheme 2.

Treatment of compound V with compound V-2 in the presence of a base such as NaH in a suitable solvent such as THF gives compound V-l. Compound V-l can be converted to compound VI-1 by reacting with DMFDMA in a suitable solvent such as acetonitrile.

Cyclization of compound VI-1 with compound VII affords compound VII- 1. The reaction can be carried out under basic condition such as K₂CO₃, NaOMe or Et₃N, in a suitable solvent such as EtOH or MeOH.

General synthetic route for Compound Ic (Scheme 3)

Scheme 3

Ic-4 Ic

L is CI, Br, I, O-mesyl or O-tosyl;

FG is OH, NH₂, boronic acid or pinacol ester

The compound of formula Ic can be prepared according to Scheme 3.

Cyclization of intermediate VIII with compound VII affords Compound Ic-1. The reaction can be carried out in the presence of a base such as K₂CO₃, NaOMe or Et₃N, in a suitable solvent such as EtOH or MeOH. Debenzylation under hydrogenation condition by using Pd/C in a suitable solvent such as THF, MeOH or EtOH affords compound Ic-2. Compound Ic-3 can be obtained by reaction of compound Ic-2 with compound II in the presence of a base such as CS₂CO₃ or K₂CO₃ in a suitable solvent such as DMF or DMA. Compound Ic-3 was converted to compound Ic-4 by using POCI₃. Compound Ic can be obtained by reacting of compound Ic-4 with compound IX in the presence of a catalyst such as Pd₂(dba)₃, Pd(OAc)₂, Pd(PPh₃)₄ or PdCl₂(dppf) and a base such as K₂CO₃ or CS₂CO₃, in a suitable solvent such as 1,4-dioxane, THF, 1,2-dimethoxyethane, DMF, DMA or DMSO .

General synthetic route for Compound Id (Scheme 4) Scheme 4

L is CI, Br, I, O-mesyl or O-tosyl

The compound of formula Id can be prepared according to Scheme 4.

Coupling of intermediate IX with intermediate X in the presence of a catalyst such as

Pd(PPh₃)₄, Pd(dppf)Cl₂ or Pd₂(dba)₃, in a suitable solvent such as 1,4-dioxane, CHC1₃ or THF can afford compound Id-1. Removal of Boc protection under acidic condition affords compound Id-2. Compound Id can be obtained by coupling of compound Id-2 with compound II in the presence of a catalyst such as Pd₂(dba)₃ or Pd(OAc)₂ and a base such as Cs₂C0₃ or i-BuONa, in a suitable solvent such as 1,4-dioxane, DMF or DMA .

General synthetic route for Compound Ie (Scheme 5)

Scheme 5

The compound of formula Ie can be prepared according to Scheme 5.

Coupling of compound XII with compound II in the presence of a catalyst such as Pd₂(dba)₃ or Pd(OAc)₂ and a base such as Cs₂C0₃ or i-BuONa, in a suitable solvent such as 1,4- dioxane, DMF or DMA gives compound Ie-1. Demethylation of compound Ie-1 by treating compound Ie-1 with HBr in AcOH can afford compound Ie-2. Compound Ie-2 can be converted to compound Ie-3 by reacting with trifluoromethanesulfonic anhydride in the presence of a base such as pyridine. Coupling of compound Ie-3 with compound XI in the presence of a catalyst such as Pd(PPh₃)₄, Pd(dppf)Cl₂ or Pd₂(dba)₃ in a suitable solvent such as 1,4-dioxane, CHC1₃ or THF affords compound Ie.

This invention also relates to a process for the preparation of a compound of formula I comprising

(a) cyclization of a compound of formula (A)

with a compound of formula (B)

(b) coupling of a compound of formula (C)

with a compound of formula (D)

R— FG

(D);

(c) coupling of a compound of formula (E)

with a compound of formula (F) R³-L

(F); or

(d) coupling of a compound of formula (G)

with a compound of formula (H)

wherein R 1 to R 3 , Q, U, W and Z are defined as in embodiments (i) to (xviii), FG is OH, NH₂, boronic acid or pinacol ester, L is CI, Br, I, O-mesyl or O-tosyl.

PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATION

The invention also relates to a compound of formula I for use as therapeutically active substance.

Another embodiment provides pharmaceutical compositions or medicaments containing the compounds of the invention and a therapeutically inert carrier, diluent or excipient, as well as methods of using the compounds of the invention to prepare such compositions and medicaments. In one example, compounds of formula (I) may be formulated by mixing at ambient temperature at the appropriate pH, and at the desired degree of purity, with physiologically acceptable carriers, i.e., carriers that are non-toxic to recipients at the dosages and concentrations employed into a galenical administration form. The pH of the formulation depends mainly on the particular use and the concentration of compound, but preferably ranges anywhere from about 3 to about 8. In one example, a compound of formula (I) is formulated in an acetate buffer, at pH 5. In another embodiment, the compounds of formula (I) are sterile. The compound may be stored, for example, as a solid or amorphous composition, as a lyophilized formulation or as an aqueous solution. Compositions are formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The "effective amount" of the compound to be administered will be governed by such considerations, and is the minimum amount necessary to inhibit HBsAg. For example, such amount may be below the amount that is toxic to normal cells, or the mammal as a whole.

In one example, the pharmaceutically effective amount of the compound of the invention administered parenterally per dose will be in the range of about 0.01 to 100 mg/kg, alternatively about 0.01 to 100 mg/kg of patient body weight per day, with the typical initial range of compound used being 0.3 to 15 mg/kg/day. In another embodiment, oral unit dosage forms, such as tablets and capsules, preferably contain from about 0.1 to about 1000 mg of the compound of the invention.

The compounds of the invention may be administered by any suitable means, including oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intrathecal and epidural and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.

The compounds of the present invention may be administered in any convenient administrative form, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc. Such compositions may contain components conventional in pharmaceutical preparations, e.g., diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents.

A typical formulation is prepared by mixing a compound of the present invention and a carrier or excipient. Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel, Howard C, et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004;

Gennaro, Alfonso R., et al. Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe, Raymond C. Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005. The formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament).

An example of a suitable oral dosage form is a tablet containing about 0.1 to 1000 mg of the compound of the invention compounded with about 0 to 2000 mg anhydrous lactose, about 0 to 2000 mg sodium croscarmellose, about 0 to 2000 mg polyvinylpyrrolidone (PVP) K30, and about 0 to 2000 mg magnesium stearate. The powdered ingredients are first mixed together and then mixed with a solution of the PVP. The resulting composition can be dried, granulated, mixed with the magnesium stearate and compressed to tablet form using conventional equipment. An example of an aerosol formulation can be prepared by dissolving the compound, for example 0.1 to 1000 mg, of the invention in a suitable buffer solution, e.g. a phosphate buffer, adding a tonicifier, e.g. a salt such sodium chloride, if desired. The solution may be filtered, e.g., using a 0.2 micron filter, to remove impurities and contaminants.

An embodiment, therefore, includes a pharmaceutical composition comprising a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof. In a further embodiment includes a pharmaceutical composition comprising a compound of Formula I, or a stereoisomer or pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or excipient.

The following example A and B illustrate typical compositions of the present invention, but serve merely as representative thereof.

Example A

A compound of formula I can be used in a manner known per se as the active ingredient for the production of tablets of the following composition:

Per tablet

Active ingredient 200 mg

Microcrystalline cellulose 155 mg

Corn starch 25 mg

Talc 25 mg Hydroxypropylmethylcellulose 20 mg

425 mg

Example B

A compound of formula I can be used in a manner known per se as the active ingredient for the production of capsules of the following composition:

Per capsule

Active ingredient 100.0 mg

Corn starch 20.0 mg

Lactose 95.0 mg

Talc 4.5 mg

Magnesium stearate 0.5 mg

220.0 mg INDICATIONS AND METHODS OF TREATMENT

The compounds of the invention can inhibit HBsAg production or secretion and inhibit HBV gene expression. Accordingly, the compounds of the invention are useful for the treatment or prophylaxis of HBV infection.

The invention relates to the use of a compound of formula I for the inhibition of HBsAg production or secretion.

The invention relates to the use of a compound of formula I for the inhibition of HBV DNA production.

The invention relates to the use of a compound of formula I for the inhibition of HBV gene expression.

The invention relates to the use of a compound of formula I for the treatment or prophylaxis of HBV infection.

The use of a compound of formula I for the preparation of medicaments useful in the treatment or prophylaxis diseases that are related to HBV infection is an object of the invention.

The invention relates in particular to the use of a compound of formula I for the preparation of a medicament for the treatment or prophylaxis of HBV infection.

Another embodiment includes a method for the treatment or prophylaxis of HBV infection, which method comprises administering an effective amount of a compound of Formula I, a stereoisomer, tautomer, prodrug, conjugates or pharmaceutically acceptable salt thereof. EXAMPLES

The invention will be more fully understood by reference to the following examples. They should not, however, be construed as limiting the scope of the invention.

Abbreviations used herein are as follows:

μί: microliter

μιη: micrometer

μΜ: micromoles per liter

(Boc)₂0: di-ie/t-butyl dicarbonate

BSA: bovine serum albumin

DMF: dimethylformamide

IC₅₀: the half maximal inhibitory concentration

LC/MS: liquid chromatography/mass spectrometry

M: molarity

MHz: megahertz

min: minute

hr(s): hour(s)

mM: millimoles per liter

DCM: dichloromethane

EA: ethyl acetate

PE: petroleum ether

Me₃SiCl: chlorotnmethy!silane

MS (ESI): mass spectroscopy (electron spray ionization)

NaBH₃CN: sodium cyanotrihydroborate

nM: nanomoles per liter

NMR: nuclear magnetic resonance

obsd. observed

rt: room temperature

Pd/C: palladium on activated carbon

Pd(PPh₃)₄: tetrakis(triphenylphosphine)palladium(0)

Pd(PPh₃)₂Cl₂: bis(triphenylphosphine)palladium(II) chloride

Pd(dppf)Cl₂: [l,l'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) Pd₂(dba)₃: Tris(dibenzylideneacetone)dipalladium(0)

TFA: trifluoroacetic acid

δ: chemical shift

Xantphos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene

XPhos: 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl

RuPhos: 2-Dicyclohexylphosphino-2',6'-diisopropoxybiphenyl

BINAP: (2,2'-bis(diphenylphosphino)- l, l'-binaphthyl)

Sphos: 2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl

DMFDMA: N,N-Dimethylformamide dimethyl acetal

i-BuONa: Sodium iert-butoxide

HATU: N-[(Dimethylamino)- 1H- l,2,3-triazolo-[4,5-b]pyridin- 1-ylmethylene]- N-methylmethanaminium hexafluorophosphate N-oxide

GENERAL EXPERIMENTAL CONDITIONS

Intermediates and final compounds were purified by flash chromatography using one of the following instruments: i) Biotage SP l system and the Quad 12/25 Cartridge module, ii) ISCO combi -flash chromatography instrument. Silica gel B and and pore size: i) KP-SIL 60 A, particle size: 40-60 μ m; ii) CAS registry NO: Silica Gel: 63231-67-4, particle size: 47-60 micron silica gel; iii) ZCX from Qingdao Haiyang Chemical Co., Ltd, pore: 200-300 or 300-400.

Intermediates and final compounds were purified by preparative 11 PLC on reversed phase column using X Bridge™ Perp C_{! 8} (5 μ πι. OBD™ 30 x 100 mm) column or SunFire™ Perp Ci₈ (5 μπι, OBD™ 30 x 100 mm) column.

LC/MS spectra were obtained using an Acquity Ultra Performance LC - 3100 Mass Detector or Acquity Ultra Performance LC - SQ Detector. Standard LC/MS conditions were as follows (running time 3 minutes):

Acidic condition: A: 0.1% formic acid in H₂O; B: 0.1% formic acid in acetonitrile;

Basic condition: A: 0.05% NH₃ H₂O in H₂O; B: acetonitrile;

Neutral condition: A: I LO; B: acetonitrile.

Mass spectra (MS): generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion ( M+H f .

The microwave assisted reactions were carried out in a Biotage Initiator Sixty or CEM Discover.

NMR Spectra ere obtained using Bruker Avance 400MHz. All reactions involving air-sensitive reagents were performed under an argon atmosphere. Reagents were used as received from commercial suppliers without further purification unless otherwise noted. PREPARATIVE EXAMPLES

Example 1 : 6-(4-methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

Step 1: Preparation of 8-(4-meth lsulfonylphenyl)-l,4-dioxa-8-azaspiro[4.5]decane

To a flask containing l-bromo-4-methylsulfonyl-benzene (1.9 g, 8.12 mmol) and 1,4- dioxa-8-azaspiro[4.5]decane (1.39 g, 9.74 mmol) in dioxane (40 mL) was added i-BuONa (1.56 g, 16.24 mmol), Pd₂(dba)3 (147 mg, 0.16 mmol) and Sphos (131 mg, 0.32 mmol) successively under N₂, then the reaction mixture was heated to 100 °C and stirred at 100 °C overnight. After being cooled to rt, the reaction mixture was diluted with H₂0 (20 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to afford crude 8-(4-methylsulfonylphenyl)-l,4- dioxa-8-azaspiro[4.5]decane (2.2 g), which was used in the next step without further purification.

Step 2: Preparation of l-(4-meth lsulfonylphenyl)piperidin-4-one

A mixture of crude 8-(4-methylsulfonylphenyl)-l,4-dioxa-8-azaspiro[4.5]decane (2.2 g, 7.48 mmol) and 44% formic acid (20 mL) was heated at 90 °C for 8 hrs. The resulting mixture was concentrated in vacuo. The residue was diluted with sat. NaHC0₃ (20 mL), and then extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(4- methylsulfonylphenyl)piperidin-4-one (1.64 g) as brown solid, which was used in the next step without further purification.

Step 3: Preparation of 6-(4-methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

l-(4-Methylsulfonylphenyl)piperidin-4-one (1.64 g, 6.75 mmol) was heated with

DMFDMA (10 mL) at 90 °C for 3 hrs. The resulting mixture was concentrated in vacuo. The residue was dissolved in EtOH (20 mL). To the solution was added pyridine-2-carboxamidine hydrochloride (1.06 g, 6.75 mmol) and K₂CO₃ (1.86 g, 13.5 mmol) successively. After being heated to 80 °C and stirred overnight, the resulting reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(4-methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine (1.0 g). 1H NMR (400 MHz, CDC1₃) δ: 8.88-8.93 (m, 1H), 8.77 (s, 1H), 8.51-8.58 (m, 1H), 7.90-7.98 (m, 1H), 7.86 (d, 2H), 7.44-7.51 (m, 1H), 7.06 (d, 2H), 4.65 (s, 2H), 3.87 (t, 2H), 3.33 (t, 2H), 3.05 (s, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 367. Example 2: 2-(5-fluoro-2-pyridyl)-6-(4-methylsulfonylphenyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

To a solution of 5-fluoropyridine-2-carbonitrile (1.0 g, 8.26 mmol) in methanol (20 mL) was added NaOCH₃ (89 mg, 1.65 mmol). The resulting mixture was stirred at rt. for 12 hrs. Then to the reaction mixture was added NH₄C1 (440 mg, 8.26 mmol). After being heated under reflux for 3 hrs, the resulting mixture was concentrated in vacuo. The residue was suspended in ethanol (30 mL) and the suspension was heated under reflux for 1 hr. The resulting mixture was filtered and the filtrate was concentrated in vacuo to afford 5-fluoropyridine-2-carboxamidine

hydrochloride (1.4 g), which was used in the next step without further purification.

Step 2: Preparation of 2-(5-fluoro-2-pyridyl)-6-(4-methylsulfonylphenyl)-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine

A solution of l-(4-methylsulfonylphenyl)piperidin-4-one (100 mg, 0.39 mmol) and

DMFDMA (1 ml) in acetonitrile (8 mL) was heated with stirring at 90 °C for 2 hrs. The resulting mixture was concentrated in vacuo and the residue was dissolved in EtOH (10 mL). To the solution was added 5-fluoropyridine-2-carboxamidine hydrochloride (55 mg, 0.39 mmol) and potassium carbonate (107 mg, 0.78 mmol) successively. After being heated at 90 °C overnight, the reaction mixture was cooled to rt, diluted with water (20 mL) and extracted with EA (20 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to give 2-(5-fluoro- 2-pyridyl)-6-(4-methylsulfonylphenyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (13 mg). 1H

NMR (400MHz, CDC1₃): δ 8.74 (s, 1H), 8.70 (d, 1H), 8.59 (dd, 1H), 7.87 (d, 2H), 7.70 - 7.48 (m, 1H), 7.06 (d, 2H), 4.64 (s, 2H), 3.87 (t, 2H), 3.31 (t, 2H), 3.05 (s, 3H). MS obsd. (ESI⁺)

[(M+H)⁺] : 385.

Example 3: 2-(5-methyl-2-pyridyl)-6-(4-methylsulfonylphenyl)-7,8-dihyd]

pyrido[4,3-d]pyrimidine

Step 1: Preparation of 5-methylpyridine-2-carboxamidine hydrochloride

To a solution of 5-methylpyridine-2-carbonitrile (1.0 g, 8.55 mmol) in methanol (20 mL) was added NaOCH₃ (92 mg, 1.71 mmol). The resulting mixture was stirred at rt for 12 hrs. Then to the reaction mixture was added NH₄C1 (460 mg, 8.55 mmol). After being heated under reflux for 3 hrs, the resulting reaction mixture was then concentrated in vacuo. The residue was suspended in ethanol (30 mL) and the suspension was heated under reflux for 1 hr. The resulting mixture was filtered and the filtrate was concentrated in vacuo to afford crude 5-metylpyridine- 2-carboxamidine hydrochloride ( 1 .4 g), which was used in the next step without further purification.

Step 2: Preparation of 2-(5-methyl-2-pyridyl)-6-(4-methylsulfonylphenyl)-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine

A mixture of l-(4-methylsulfonylphenyl)piperidin-4-one (100 mg, 0.39 mmol) and

DMFDMA (1 mL) in acetonitrile (8 mL) was heated with stirring at 90 °C for 2 hrs. The resulting mixture was concentrated in vacuo and the residue was dissolved in EtOH (10 mL). To the solution was added 5-methylpyridine-2-carboxamidine hydrochloride (54 mg, 0.39 mmol) and potassium carbonate ( 88 mg, 0.64 mmol ) successively. After being heated at 90 "C overnight, the reaction mixture was cooled to rt, diluted with water (20 mL) and extracted with EA (20 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep- 11 PLC to give 2-(5-methyl- 2-pyridyl)-6-(4-methylsulfonylphenyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (9 mg). Ή NMR (400MHz, CDC1₃): δ 8.73 (s, 1H), 8.69 (s, 1H), 8.43 (d, 1H), 7.88 - 7.83 (m, 2H), 7.69 (dd, 1H), 7.09 - 6.98 (m, 2H), 4.63 (s, 2H), 3.87 (t, 2H), 3.31 (t, 2H), 3.05 (s, 3H), 2.45 (s, 3H). MS obsd. (ESf) [(M+H)⁺]: 381.

Example 4: 2-(3-methyl-2-pyridyl)-6-(4-methylsulfonylphenyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

Step 1: Preparation of 3-methylpyridine-2-carboxamidine hydrochloride

To a solution of 3-methylpyridine-2-carbonitrile (1.0 g, 8.55 mmol) in methanol (20 mL) was added NaOCH₃ (92 mg, 1.71 mmol). The resulting mixture was stirred at rt for 12 hrs. Then to the reaction mixture was added NH₄C1 (460 mg, 8.55 mmol). After being heated under reflux for 3 hrs, the resulting mixture was concentrated in vacuo. The residue was suspended in ethanol (30 mL) and the suspension was heated under reflux for 1 hr. The mixture was filtered and the filtrate was concentrated in vacuo to afford 3-metylpyridine-2-carboxamidine hydrochloride ( 1 .4 g), which was used in the next step without further purification.

Step 2: Preparation of 2-(3-methyl-2-pyridyl)-6-(4-methylsulfonylphenyl)-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine

A mixture of l-(4-methylsulfonylphenyl)piperidin-4-one (100 mg, 0.39 mmol) and

DMFDMA (1 mL) in acetonitrile (8 mL) was heated with stirring at 90 °C for 2 hrs. The resulting mixture was concentrated in vacuo and the residue was dissolved in EtOH (lOmL). To the solution was added 3-methylpyridine-2-carboxamidine hydrochloride (53 mg, 0.39 mmol) and potassium carbonate ( 88 mg, 0.64 mmol ) successively. After being heated at 90 "C overnight, the reaction mixture was cooled to rt. diluted with water (20 mL) and extracted with EA (20 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous

Na₂S0₄ and concentrated in vacuo. The residue was purified by prep- 11 PLC to give 2-(3-methyl- 2-pyridyl)-6-(4-methylsulfonylphenyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (20 mg). Ή NMR (400MHz, CDC1₃): δ 8.75 (s, 1H), 8.64 (dd, 1H), 7.87(d, 2H), 7.67 (d, 1H), 7.34 - 7.28 (m, 1H), 7.06 (d, 2H), 4.65 (s, 2H), 3.88 (t, 2H), 3.29 (t, 2H), 3.05 (s, 3H), 2.54 (s, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 381.

Example 5: 2-(5-niethoxy-2-pyridyl)-6-(4-methylsulfonylp eiiyl)-7,8-dihydro-5//- pyrido[4,3-d]pyriiiiidine

Step 1: Preparation of 5-methoxypyridine-2-carboxamidine hydrochloride

To a solution of 5-methyoxypyridine-2-carbonitrile (1.0 g, 7.46 mmol) in methanol (20 mL) was added NaOCH₃ (80 mg, 1.49 mmol). The mixture was stirred at rt for 12 hrs. Then to the reaction mixture was added NH₄C1 (399 mg, 7.46 mmol). After being heated under reflux for 3 hrs, the reaction mixture was then concentrated in vacuo. The residue was suspended in ethanol (30 mL) and the suspension was heated under reflux for 1 hr. The resulting mixture was filtered and the filtrate was concentrated in vacuo to afford 5-metyoxypyridine-2-carboxamidine hydrochloride ( 1 .3 g), which was used in the next step without further purification.

Step 2: Preparation of 2-(5-metIioxy-2-pyrldyI)-6-(4-methyIsulfonyIphenyI)-7,8- dihydro-5//-pyrido[4,3-d]pyrimidine

A mixture of l-(4-methylsulfonylphenyl)piperidin-4-one (100 mg, 0.39 mmol) and

DMFDMA (1 mL) in acetonitrile (8 mL) was heated with stirring at 90 °C for 2 hrs. The resulting mixture was concentrated in vacuo and the residue was dissolved in EtOH (lOmL). To the solution was added 5-methoxypyridine-2-carboxamidine hydrochloride (59 mg, 0.39 mmol) and potassium carbonate ( 88 mg, 0.64 mmol ) successively. After being heated at 90 "C overnight, the reaction mixture was cooled to rt, diluted with water (20 mL) and extracted with EA (20 mL) for three times. The combined organic layer was washed with brine, d ied over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep- H PLC to give 6-(4- methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine ( 42 mg ). Ή NMR (400MHz, DMSO- ): δ 8.78 (s, 1H), 8.55 - 8.32 (m, 2H), 7.74 (d, 2H), 7.54 (dd, 1H), 7.22 (d, 2H), 5.77 (s, 2H), 4.69 (s, 2H), 3.97 - 3.83 (m, 4H), 3.11 (s, 3H). MS obsd. (ESf) [(M+H)⁺] : 397. Example 6: 2-(5-cMoro-2-pyrMyI)-6-(4-methyIsuIfonylphenyI)-7,8-cIlhyclro-5H- pyrido[4,3-d]pyrimidiiie

Step 1 : Preparation of 5-ch!oropyridine-2-carboxainidiiie hydrochloride

To a solution of 5-chloropyridine-2-carbonitrile (1.0 g, 7.25 mmol) in methanol (20 mL) was added NaOCH₃ (80 mg, 1.45 mmol). The mixture was stirred at rt for 12 hrs. To the resulting reaction mixture was added NH₄C1 (390 mg, 7.25 mmol). After being heated under reflux for 3 hrs, the reaction mixture was then concentrated in vacuo. The residue was suspended in ethanol (30 mL) and heated under reflux for 1 hr. The resulting mixture was filtered and the filtrate was concentrated in vacuo to afford 5-chloropyridine-2-carboxamidine hydroc loride (1.3 g), which was used in the next step without further purification.

Step 2: Preparation of 2-(5-chloro-2-pyridyl)-6-(4-niethylsiilfonylphenyl)-7,8-dihydro- 5//-pyrido[4,3-d]pyrimidine

A mixture of l-(4-methylsulfonylphenyl)piperidin-4-one (100 mg, 0.39 mmol) and

DMFDMA (1 mL) in acetonitrile (5 mL) was heated with stirring at 90 °C for 2 hrs. The resulting mixture was concentrated in vacuo and the residue was dissolved in EtOH (10 mL). To the solution was added 5-chloropyridine-2-carboxamidine hydrochloride (74 mg, 0.39 mmol) and potassium carbonate (88 mg, 0.64 mmol ) successively. After being heated at 90 "C overnight, the reaction mixture was cooled to rt, diluted with water (20 mL) and extracted with EA (20 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep- H PLC to afford 2- (5- chloro-2-pyridyl )-6-(4-methylsulfonylphenyl )-7,8-dihydro-5//-pyndo[4,3-d]pyrimidine (10 mg). 1H NMR (400 MHz, CDC1₃): δ 3.05 (s, 3 H), 3.32 (t, 2 H), 3.88 (t, 2 H), 4.65 (s, 2 H), 7.00 - 7.11 (m, 2 H), 7.83 - 7.92 (m, 3 H), 8.48 - 8.57 (m, 1 H), 8.73 - 8.86 (m, 2 H). MS obsd. (ESI⁺)

[(M+H)⁺]: 401.

Example 7: 8-ethyl-6-(4-methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihyd]

pyrido[4,3-d]pyrimidine

Step 1: Preparation of 3-ethyl- 1 -(4-niethylsulfonylphenyl )piperidin-4-one

To a solution of 1 -(4-methylsulfonylphenyl )piperidin-4-one (1.0 g, 3.93 mmol) in Ti IF ( 15 mL) was added sodium hydride (104 mg, 4.43 mmol) at 0 °C under N₂ atmosphere. The mixture was stirred for 0.5 hr at 0 "C. To the resulting mixture was added ethyl iodide (3.5 ml, 4.33 mmol) and the reaction mi ture was heated under reflux overnight. Then the reaction was quenched with H₂0 and the resulting mixture was extracted with EA (40 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by column chromatography (eluting with 20% EA in PE) to give 3-ethyl-l-(4-methylsulfonylphenyi)-piperidin-4-one (1.0 g), which was used in the next step without further purification.

Step 2: Preparation of 8-ethyl-6-(4-methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine

A mixture of 3-ethyl-l-(4-methylsulfonylphenyl)piperidin-4-one (1.0 g, 3.54 mmol) and

DMFDMA (2 mL) in acetonitrile (8 mL) was heated with stirring at 90 °C for 2 hrs. The resulting mixture was concentrated in vacuo and the residue was dissolved in EtOH (20 mL). To the solution was added pyridine-2-carboxamidine hydrochloride (560 mg, 3.54 mmol) and potassium carbonate (980 mg, 7.08 mmol ) successively. After being heated with stirring at 90 "C overnight, the reaction mixture was cooled to rt, diluted with water (20 mL) and extracted with EA (50 mL) for three times. The combined organic layers were washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was puri ied by prep- H PL to give 8- ethyl-6-(4-methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (6 mg). 1H NMR (400MHz, CDC1₃): δ 8.92-8.83 (m, IH), 8.78 (s, IH), 8.56 (d, IH), 7.99 - 7.83 (m, 3H), 7.44 (ddd, IH), 7.08 - 6.98 (m, 2H), 4.68 (d, IH), 4.54 (d, IH), 3.89 (dd, IH), 3.72 (dd, IH), 3.17 (dd, IH), 3.06 (s, 3H), 2.16 (m, IH), 1.78 (m, IH), 1.19 (t, 3H). MS obsd. (ESI+) [(M+H)⁺]: 395.

Example 8: N-methyl-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl] benzenesulf onamide

Step 1: Preparation of 4-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-N-methyl- benzenesulfonamide

A mixture of 4-fluoro-N-methyl-benzenesulfonamide (0.50 g, 2.64 mmol), l,4-dioxa-8- azaspiro[4.5]decane (0.76 g, 5.28 mmol ) and potassium carbonate (0.73 g, 5.28 mmol ) in a mixed solvent of acetonitrile (10 mL) and l,3-dimethylhexahydropyrimidin-2-one (20 mL) was heated with stirring at 65 °C for 3 hrs. The resulting reaction mixture was cooled to rt, diluted with water (50 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo to give crude 4- (l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-N-methyl-benzenesulfonamide (0.60 g), which was used in the next step without further purification.

Step 2: Preparation of N-meth l-4-(4-oxo-l-piperidyl)benzenesulfonamide

A solution of 4-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-N-methyl-benzenesulfonamide (0.60 g, 1.91 mmol) in a mixture of H₂0 (5 mL) and formic acid (5 mL) was heated with stirring at 90 °C overnight. The resulting reaction mixture was cooled to rt and concentrated in vacuo. The residue was diluted with sat. aqueous solution of NaHCO; and extracted ith EA (30 mL) for three times. The combined organic layers were washed ith brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by column chromatography (2.5% MeOH in DCM) to give N-methyl-4-(4-oxo-l-piperidyl)benzenesulfonamide (0.45 g).

Step 3: Preparation of N-methyl-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]benzenesulfonamide

A mixture of N-methyl-4-(4-oxo-l-piperidyl)benzenesulfonamide (0.45 g, 1.67 mmol) and DMFDMA (2 mL) in acetonitrile (8 mL) was heated with stirring at 90 °C for 2 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (10 mL). To the solution was added pyridine-2-carboxamidine (0.15 g, 1.23 mmol) and potassium carbonate (0.34 g, 2.46 mmol ) successively. After being heated with stirring at 90 "C overnight, the resulting reaction mixture was cooled to rt, diluted with water (20 mL) and extracted with EA (20 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na^SC and concentrated in vacuo. The residue was purified by prep- LC to give N- methyl-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzenesulfonamide (7 mg). 1H NMR (400MHz, CDC1₃): δ 8.87 (d, 1H), 8.80 - 8.70 (m, 1H), 8.53 (d, 1H), 7.89 (dt, 1H), 7.80 (d, 2H), 7.44 (ddd, 1H), 7.06 - 6.97 (m, 2H), 4.63 (s, 2H), 3.86 (t, 2H), 3.32 (t, 2H), 2.67 (s, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 382.

Example 9: N,N-dimethyl-4-[2-(2^yridyl)-7,8-dihydro-5H^yrido[4,3-d]pyrimidin-6- yl] benzenesulf onamide

A mixture of N-methyl-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl]benzenesulfonamide (44 mg,0.12 mmol), sodium hydride (6 mg,0.24 mmol) and methyl iodide (34 mg,0.24 mmol) in anhydrous DMF (5 mL) was stirred at rt for 2 hrs under N₂ atmosphere. Then the reaction was quenched with water. The resulting mixture was extracted with EA (30 mL). The organic layer was washed w ith brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep- Η PL to give A',A'-dimethyl-4-[2-(2- pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzenesulfonamide (3 mg). 1H NMR (400MHz, CDC1₃): δ 8.88 (d, 1H), 8.76 (s, 1H), 8.54 (d, 1H), 7.90 (dt, 1H), 7.73 (d, 2H), 7.44 (ddd, 1H), 7.06 (d, 2H), 4.64 (s, 2H), 3.96 - 3.67 (m, 2H), 3.52 (s, 3H), 3.45 - 3.24 (m, 2H), 2.71 (s, 3H). MS obsd. (ESI⁺) [(M+H)⁺]: 396. Example 10: 6-(3,4-difluorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

Step 1: preparation of 8-(3,4-difluorophenyl)-l,4-dioxa-8-azaspiro[4.5]decane

To a flask containing a mixture of 4-bromo-l,2-difluoro-benzene (580 mg, 3.0 mmol) and l,4-dioxa-8-azaspiro[4.5]decane (515 mg, 3.6 mmol) in dioxane (20 mL) was added i-BuONa (580 mg, 6.0 mmol) followed by Pd₂(dba)₃ (137 mg, 0.15 mmol) and Sphos (123 mg, 0.30 mmol) successively under N₂. After being heated to 100 °C and stirred overnight, the resulting reaction mixture was cooled to rt, diluted with H₂0 (20 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to afford crude 8-(3,4-difluorophenyl)-l,4-dioxa-8- azaspiro[4.5]decane (800 mg), which was used in the next step without further purification.

Step 2: preparation of l-(3,4-difluorophenyl)piperidin-4-one

A mixture of crude 8-(3,4-difluorophenyl)-l,4-dioxa-8-azaspiro[4.5]decane (800 mg, 3.13 mmol) and 44% formic acid (10 mL) was heated with stirring at 90 °C for 8 hrs. The resulting mixture was concentrated in vacuo. The residue was diluted with sat. aqueous solution of

NaHC0₃ (20 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(3,4-difluorophenyl)piperidin-4-one (600 mg) as brown oil, which was used in the next step without further purification.

Step 3: Preparation of 6-(3,4-difluorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

l-(3,4-difluorophenyl)piperidin-4-one (600 mg, 2.84mmol) was heated with DMFDMA (5 mL) at 90 °C for 3 hrs. The resulting mixture was concentrated in vacuo and the residue was dissolved in EtOH (lOmL). To the resulting solution was added pyridine-2-carboxamidine hydrochloride (450 mg, 2.84 mmol) and K₂CO₃ (784 mg, 5.68 mmol) successively. After being heated to 80 °C and stirred overnight, the resulting reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(3,4-difluorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine (50 mg) as yellow solid. 1H NMR (400 MHz, CDC1₃): δ 8.86 (d, 1 H), 8.70 (s, 1 H), 8.48 - 8.56 (m, 1 H), 7.83 -7.92 (m 1 H), 7.37 - 7.45 (m, 1 H), 7.05 - 7.18 (m, 1 H), 6.77 - 6.92 (m, 1 H), 6.67 - 6.75 (m, 1 H), 4.41 (s, 2 H), 3.64 (t, 2 H), 3.21 - 3.35 (m, 2 H). MS obsd. (ESf) [(M+H)⁺]: 325.

Example ll:6-(3-methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

Step 1: Preparation 8-(3-methylsulfonylphenyl)-l,4-dioxa-8-azaspiro[4.5]decane

To a flask containing a mixture of l-bromo-3-methylsulfonyl-benzene (525 mg, 2.2 mmol) and l,4-dioxa-8-azaspiro[4.5]decane (372 mg, 2.6 mmol) in dioxane (10 mL) was added t- BuONa (317 mg, 3.3 mmol), Pd₂(dba)₃ (37 mg, 0.04 mmol) and Sphos (33 mg, 0.08 mmol) successively under N₂. The resulting mixture was heated to 100 °C and stirred overnight. After being cooled to rt, the reaction mixture was diluted with H₂0 (20 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give crude 8-(3-methylsulfonylphenyl)-l,4- dioxa-8-azaspiro[4.5]decane (280 mg), which was used in the next step without further purification.

Step 2: Preparation of l-(3-methylsulfonylphenyl)piperidin-4-one £ Q⁼°

o=s

/ ' * o

Crude 8-(3-methylsulfonylphenyl)-l,4-dioxa-8-azaspiro[4.5]decane (280 mg, 0.94 mmol) was heated with 44% formic acid (10 mL) at 90 °C for 8 hrs. The mixture was concentrated in vacuo and the residue was diluted with sat. aqueous solution of NaHC0₃ (20 mL). The resulting mixture was extracted with EA (30 mL) three times. The combined organic layer was washed with brine (30 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(3- methylsulfonylphenyl)piperidin-4-one (220 mg) as brown oil, which was used in the next step without further purification .

Step 3: Preparation of 6-(3-methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

Crude l-(3-methylsulfonylphenyl)piperidin-4-one (220 mg, 0.87 mmol) was heated with DMFDMA (5 mL) at 90 °C for 3 hrs. The resulting mixture was concentrated in vacuo and the residue was dissolved in EtOH (lOmL). To the solution was added pyridine-2-carboxamidine hydrochloride (137 mg, 0.87 mmol) and K₂C0₃ (240 mg, 1.74 mmol) successively. After being heated to 80 °C and stirred overnight, the reaction mixture was cooled to rt and purified by prep- HPLC to give 6-(3-methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine (20 mg) as pale yellow solid. 1H NMR (400 MHz, CDC1₃) : δ 8.83 - 8.90 (m, 1 H), 8.75 (s, 1 H), 8.53 (d, 1 H), 7.89 (td, 1 H), 7.48 - 7.57 (m, 2 H), 7.39 - 7.46 (m, 2 H), 7.23 - 7.28 (m, 1 H), 4.50 - 4.62 (m, 2 H), 3.76 - 3.86 (m, 2 H), 3.28 - 3.38 (m, 2 H), 3.09 (s, 3 H). MS obsd. (ESI⁺) [(M+H)⁺] : 367.

Example 12:2-(2-pyridyl)-6-[4-(trifluoromethylsulfonyl)phenyl]-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

Step 1: Preparation of 8-[4-(trifluoromethylsulfonyl)phenyl]-l,4-dioxa-8- azaspiro[4.5]decane

To a flask containing a mixture of l-bromo-4-(trifluoromethyl-sulfonyl)benzene (600 mg,

2.08 mmol) and l,4-dioxa-8-azaspiro[4.5]decane (358 mg, 2.5 mmol) in dioxane (20 mL) was added Cs₂C0₃ (1350 mg, 4.16 mmol), Pd₂(dba)₃ (37 mg, 0.04 mmol) and Sphos (33 mg, 0.08 mmol) successively under N₂. The resulting mixture was heated to 100 °C and stirred overnight. After being cooled to rt, the reaction mixture was diluted with H₂0 (20 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give crude 8-[4-

(trifluoromethylsulfonyl)phenyl]-l,4-dioxa-8-azaspiro[4.5]decane (200 mg), which was used in the next step without further purification.

Step 2: Preparation of l-[4-(trifluorometh lsulfonyl)phenyl]piperidin-4-one

To a flask containing crude 8-[4-(trifluoromethylsulfonyl)phenyl]-l,4-dioxa-8- azaspiro[4.5]decane (200 mg, 0.57 mmol) was added 44% formic acid (10 mL). After being heated with stirring at 90 °C for 8 hrs, the resulting mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (30 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-[4-(trifluoromethyl-sulfonyl)phenyl]piperidin-4-one (160 mg) as brown oil, which was used in the next step without further purification.

Step 3: Preparation of 2-(2-pyridyl)-6-[4-(trifluoromethylsulfonyl)phenyl]-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine

Crude l-[4-(trifluoromethylsulfonyl)phenyl]piperidin-4-one (160 mg, 0.52 mmol) was heated with DMFDMA (5 mL) at 90 °C for 3 hrs. The mixture was concentrated in vacuo and the residue was dissolved in EtOH (lOmL). To the solution was added pyridine-2-carboxamidine hydrochloride (82 mg, 0.52 mmol) and K₂CO₃ (144 mg, 1.04 mmol) successively. The resulting mixture was heated to 80 °C and stirred overnight. Then the reaction mixture was cooled to rt and purified by prep-HPLC to give 2-(2-pyridyl)-6-[4-(trifluoromethylsulfonyl)phenyl]-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine (5 mg). 1H NMR (400 MHz, MeOH-d₄): δ 8.73 - 8.80 (s, 1 H), 8.45 - 8.53 (m, 1 H), 7.99 - 8.07 (m, 1 H), 7.93 (m, 1 H), 7.83 - 7.89 (m, 2 H), 7.64 - 7.71 (m, 1 H), 7.10 - 7.17 (m, 2 H), 4.72 - 4.78 (m, 2 H), 3.90 - 3.99 (m, 2 H), 3.26 - 3.31 (m, 2 H). MS obsd. (ESf) [(M+H)⁺]: 421.

Example 13: 6-(3,5-difluorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

Step 1: Preparation of 8-(3,5-difluoro henyl)-l,4-dioxa-8-azaspiro[4.5]decane

To a flask containing a mixture of l,3-difluoro-5-iodo-benzene(900 mg, 3.75 mmol) and l,4-dioxa-8-azaspiro[4.5]decane (644 mg, 4.5 mmol) in dioxane (20 mL) was added i-BuONa (720 mg, 7.5 mmol), Pd₂(dba)₃ (174 mg, 0.19 mmol) and Sphos (156 mg, 0.38 mmol) successively under N₂. Then the resulting mixture was heated to 100 °C and stirred overnight. After being cooled to rt, the resulting reaction mixture was diluted with H₂0 (20 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give crude 8-(3,5- difluorophenyl)- l,4-dioxa-8-azaspiro[4.5]decane (900 mg), which was used in the next step without further purification.

Step 2: Preparation of l-(3,5-difluorophenyl)piperidin-4-one

To a flask containing crude 8-(3,5-difluorophenyl)- l,4-dioxa-8-azaspiro[4.5]decane (900 mg, 3.53 mmol) was added 44% formic acid (10 mL). After being heated with stirring at 90 °C for 8 hrs, the reaction mixture was concentrated in vacuo and the residue was diluted with sat. aqueous solution of NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (30 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(3,5-difluorophenyl)piperidin-4-one (750 mg) as brown oil, which was used in the next step without further purification.

Step 3: 6-(3,5-difluorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine

Crude l-(3,5-difluorophenyl)piperidin-4-one (750 mg, 3.55 mmol) was heated with DMFDMA (5 mL) at 90 °C for 3 hrs. The resulting mixture was concentrated in vacuo. The residue was dissolved in EtOH (lOmL). To the solution was added pyridine-2-carboxamidine hydrochloride (560 mg, 3.55 mmol) and K₂C0₃ (980 mg, 7.1 mmol) successively. The resulting mixture was heated to 80 °C and stirred overnight. The reaction mixture was then cooled to rt and purified by prep-HPLC to give 6-(3,5-difluorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine (50 mg).1H NMR (400 MHz, CDC1₃): δ 8.86 (d, 1 H), 8.72 (s, 1 H), 8.52 (d, 1 H), 7.88 (td, 1 H), 7.38 - 7.46 (m, 1 H), 6.44 - 6.51 (m, 2 H), 6.28 - 6.36 (m, 1 H), 4.48 (s, 2 H), 3.69 - 3.73 (m, 2 H), 3.24 - 3.32 (m, 2 H). MS obsd. (ESI^1") [(M+H)⁺] : 325.

Example 14: 6-(2,4-difluorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

Step 1: Preparation of 8-(2,4-difluorophenyl)-l,4-dioxa-8-azaspiro[4.5]decane

To a flask containing a mixture of 2,4-difluoro-l-iodo-benzene (440 mg, 1.83 mmol) and l,4-dioxa-8-azaspiro[4.5]decane (315 mg, 2.2 mmol) in dioxane (10 mL) was added i-BuONa (350 mg, 7.5 mmol), Pd₂(dba)₃ (83 mg, 0.09 mmol) and Sphos (74 mg, 0.18 mmol) successively under N₂. The resulting mixture was heated to 100 °C and stirred overnight. After being cooled to rt, the reaction mixture was diluted with H₂0 (20 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to afford crude 8-(2,4-difluorophenyl)-l,4-dioxa-8- azaspiro[4.5]decane (450 mg), which was used in the next step without further purification.

Step 2: Preparation of 1 -(2,4-difluorophenyl )piperidin-4-one

A mixture of crude 8-(2,4-difluorophenyl)-l,4-dioxa-8-azaspiro[4.5]decane (0.3 g, 1.18 mmol ) H₂0 (5 mL) and formic acid (5 mL) was heated with stirring at 90 "C overnight. The reaction mixture was then concentrated in vacuo, diluted with sat. aqueous solution of NaHCO and extracted with EA (20 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by column chromatography (eluting with 2% MeOH in dichloromethane) to give l-(2,4- difluorophenyl)piperidin-4-one (0.24 g).

Step 3: Preparation of 6-(2,4-difluorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

A solution of l-(2,4-difluorophenyl)piperidin-4-one (0.24 g, 1.14 mmol) and DMFDMA (0.5 mL) in acetonitrile (5 ml) was heated with stirring at 90 °C for 2 hrs. The mixture was concentrated in vacuo and the residue was dissolved in EtOH (lOmL). To the solution was added pyridine-2-carboxamidine (91 mg, 0.75 mmol ) and potassium carbonate (210 mg, 1 .50 mmol ) successively. After being heated at 90 "C overnight, the resulting mixture was cooled to rt, diluted with water (20 mL) and extracted with EA (20 mL) for three times. The organic layers were washed with brine, dried over anhydrous Na_^SC and concentrated in vacuo. The residue was purified by prep- H PLC to give 6-(2,4-difluorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine (6 mg). 1H NMR (400MHz, DMSO-J₆): δ 8.77 (s, 1H), 8.74 (d, 1H), 8.36 (d, 1H), 7.97 (dt, 1H), 7.52 (ddd, 1H), 7.34 - 7.16 (m, 2H), 7.14 - 6.97 (m, 1H), 4.33 (s, 2H), 3.48 (t, 2H), 3.10 (t, 2H). MS obsd. (ESI⁺) [(M+H)⁺]: 325.

Example 15 and 16:methyl 2-fluoro-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]benzoate and methyl 5-bromo-2-[2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl]benzoate

Example 15 Example 16

Step 1: Preparation of methyl 4-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-fluoro- benzoate and methyl 5-bromo-2-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)benzoate

To a flask containing a mixture of methyl 4-bromo-2-fluoro-benzoate (4.0 g, 17.2 mmol) and l,4-dioxa-8-azaspiro[4.5]decane (2.9 g, 20.6 mmol) in dioxane (50 mL) was added i-BuONa (3.3 g, 34.4 mmol), Pd₂(dba)₃ (312 mg, 0.34 mmol) and Sphos (279 mg, 0.68 mmol) successively under N₂. After being heated with stirring at 100 °C overnight, the reaction mixture was cooled to rt, diluted with H₂0 (40 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give methyl 4-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-fluoro-benzoate mixed with methyl 5-bromo-2-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)benzoate (total 4.5 g), which was used in the next step without further purification.

Step 2: Preparation of methyl 2-fluoro-4-(4-oxo-l-piperidyl)benzoate and methyl 5- bromo-2-(4-oxo-l-piperidyl)benzoate

A mixture of methyl 4-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-fluoro-benzoate and methyl 5-bromo-2-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)benzoate (4.5 g) was heated with 44% formic acid (20 mL) at 90 °C for 8 hrs. The reaction mixture was concentrated in vacuo, the residue was diluted with sat. aqueous solution of NaHC0₃ (40 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give a mixture of methyl 2-fluoro-4-(4-oxo-l- piperidyl)benzoate and methyl 5-bromo-2-(4-oxo-l-piperidyl)benzoate (total 3.5 g) as brown oil, which was used in the next step without further purification.

Step 3: Preparation of methyl 2-fluoro-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]benzoate and methyl 5-bromo-2-[2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]p rimidin-6-yl]benzoate

Example 15 Example 16

A mixture of methyl 2-fluoro-4-(4-oxo-l-piperidyl)benzoate and methyl 5-bromo-2-(4- oxo-l-piperidyl)benzoate (total 3.5 g, 13.9 mmol) was heated with DMFDMA (10 mL) at 90 °C for 3hrs. The reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20 mL). To the resulting solution was added pyridine-2-carboxamidine hydrochloride (2196 mg, 13.9 mmol) and K₂CO₃ (3836 mg, 27.8 mmol) successively. After being heated with stirring at 80 °C overnight, the reaction mixture was cooled to rt and purified by prep-HPLC to give methyl 2-fluoro-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzoate (Example 15, 5 mg) and methyl 5-bromo-2-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzoate (Example 16, 5 mg).

Example 15: methyl 2-fluoro-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl]benzoate: 1H NMR (400 MHz, CDC1₃): δ 8.83 - 8.93 (m, 1 H), 8.74 (s, 1 H), 8.47 - 8.60 (m, 1 H), 7.85 - 7.96 (m, 2 H), 7.40 - 7.51 (m, 1 H), 6.57 - 6.78 (m, 2 H), 4.55 - 4.63 (m, 2 H), 3.90 (s, 3 H), 3.77 - 3.85 (m, 2 H), 3.25 - 3.34 (m, 2 H). MS obsd. (ESf) [(M+H)⁺] : 365.

Example 16: methyl 5-bromo-2-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl]benzoate: 1H NMR (400 MHz, CDC1₃): δ 8.82 - 8.92 (m, 1 H), 8.67 (s, 1 H), 8.48 - 8.57 (m, 1 H), 7.83 - 7.93 (m, 1 H), 7.67 - 7.75 (m, 1 H), 7.38 - 7.45 (m, 1 H), 7.30 - 7.33 (m, 1 H), 7.19 - 7.24 (m, 1 H), 4.37 (s, 2 H), 3.90 (s, 3 H), 3.46 - 3.53 (m, 2 H), 3.29 - 3.38 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺] : 425.

Example 17 and 18: 6-(3,4-difluoro-5-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine and 2,3-difluoro-5-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]phenol

Step 1: Preparation of 5-(l,4-dioxa-8-azas iro[4.5]decan-8-yl)-2,3-difluoro-phenol

To a flask containing a mixture of 5-bromo-2,3-difluoro-phenol (2.5 g, 12 mmol) and 1,4- dioxa-8-azaspiro[4.5]decane (2.1 g, 14.4 mmol) in dioxane (40 mL) was added i-BuONa (2.3 g, 24 mmol), Pd₂(dba)₃ (220 mg, 0.24 mmol) and Sphos (197 mg, 0.48 mmol) successively under N₂. The resulting mixture was heated to 100 °C and stirred overnight. After being cooled to rt, the reaction mixture was diluted with H₂0 (40 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to afford 5-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2,3- difluoro-phenol (2000 mg), which was used in the next step without further purification.

Step 2: Preparation of l-(3,4-difluoro-5-hydroxy-phenyl)piperidin-4-one

Crude 5-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2,3-difluoro-phenol (2.0 g, 7.38 mmol) was heated with 44% formic acid (20 mL) at 90 °C for 8 hrs. The reaction mixture was concentrated in vacuo and the residue was diluted with sat. aqueous solution of NaHC0₃ (20 mL). The resulting mixture was extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(3,4-difluoro-5-hydroxy-phenyl)piperidin-4-one (1200 mg) as brown oil, which was used in the next step without further purification .

Step 3: Preparation of 6-(3,4-difluoro-5-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine and 2,3-difluoro-5-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]phenol

Example 17 Example 18

Crude l-(3,4-difluoro-5-hydroxy-phenyl)piperidin-4-one (1200 mg, 5.29 mmol) was heated with DMFDMA (10 mL) at 90 °C for 3 hrs. The reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20mL). To the solution was added pyridine-2- carboxamidine hydrochloride (840 mg, 5.29 mmol) and K₂C0₃ (1460 mg, 10.58 mmol) successively. After being heated with stirring at 80 °C overnight, the reaction mixture was cooled to rt and purified by prep-HPLC to give 2,3-difluoro-5-[2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl]phenol (Example 18, 5 mg) and 6-(3,4-difluoro-5-methoxy-phenyl)- 2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (Example 17, 5 mg). Example 17: 6-(3,4-difluoro-5-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine, 1H NMR (400 MHz, CDC1₃): δ 8.47 - 8.96(m, 3 H), 7.93 (t, 1 H), 7.40 - 7.52 (m, 1 H), 6.34 - 6.51 (m, 2 H), 4.35 - 4.45 (m, 2 H), 3.95 (s, 3 H), 3.59 - 3.69 (m, 2 H), 3.24 - 3.36 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺] : 354.

Example 18: 2,3-difluoro-5-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl]phenol, 1H NMR (400 MHz, MeOH-d₄): δ 8.73 - 8.79 (m, 1 H), 8.66 - 8.72 (m, 1 H), 8.70 (s, 1 H), 8.44 - 8.51 (m, 1 H), 7.87 - 8.00 (m, 1 H), 7.53 - 7.59 (m, 1 H), 7.43 - 7.52 (m, 1 H), 6.27 - 6.45 (m, 1 H), 4.36 - 4.41 (m, 2 H), 3.58 - 3.66 (m, 2 H), 3.16 - 3.24 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺] : 340.

Example 19: 6-[3,4-difluoro-5-(3-methoxypropoxy)phenyl]-2-(2-pyridyl)-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine

To a solution of 2,3-difluoro-5-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yfjphenol (200 mg, 0.59 mmol) in DMF (5 mL) was added l-bromo-3-methoxy-propane (0.2 mL) and K₂C0₃ (160 mg, 1.18 mmol). The mixture was heated with stirring at 90 °C. After the reaction finished, the reaction mixture was cooled to rt and filtered. The filtrate was purified by prep-HPLC to give 6-[3,4-difluoro-5-(3-methoxypropoxy)phenyl]-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine (2 mg). 1H NMR (400 MHz, CDC1₃): δ 8.82 - 8.97 (m, 1 H), 8.66 - 8.78 (m, 1 H), 8.48 - 8.61 (m, 1 H), 7.86 - 7.99 (m, 1 H), 7.38 - 7.52 (m, 1 H), 6.37 - 6.48 (m, 2 H), 4.36 - 4.44 (m, 2 H), 4.14 - 4.23 (m, 2 H), 3.55 - 3.67 (m, 4 H), 3.40 (s, 3 H), 3.25 - 3.33 (m, 2 H), 2.05 - 2.19 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺] : 354.

Example 20: 6-(3-benzyloxy-4,5-difluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

Step 1: Preparation of l-benzyloxy-5-bromo-2,3-difluoro-benzene

To a solution of 5-bromo-2,3-difluoro-phenol (3.4 g, 16.3 mmol) in acetone (40 mL) was added benzyl bromide (3.0 g, 17.9 mmol) and K₂CO₃ (4.5 g, 32.6 mmol). The reaction was heated under reflux for 5 hrs. After being cooled to rt, the resulting mixture was filtered and the filtrate was purified by flash column to give l-benzyloxy-5-bromo-2,3-difluoro-benzene (4.9 g).

Step 2: Preparation of 8-(3-benzyloxy-4,5-difluoro-phenyl)-l,4-dioxa-8- azaspiro[4.5]decane

To a flask containing a mixture of l-benzyloxy-5-bromo-2,3-difluoro-benzene (2.00 g, 6.71 mmol) and l,4-dioxa-8-azaspiro[4.5]decane (1.06 g, 7.38 mmol) in dioxane (40 mL) was added i-BuONa (1.29 g, 13.42 mmol), Pd₂(dba)₃ (119 mg, 0.13 mmol) and Sphos (106 mg, 0.26 mmol) successively under N₂. The reaction mixture was heated to 100 °C and stirred overnight. After being cooled to rt, the resulting mixture was diluted with H₂0 (40 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to afford 8-(3-benzyloxy-4,5-difluoro- phenyl)-l,4-dioxa-8-azaspiro[4.5]decane (1.00 g), which was used in the next step without further purification.

Step 3: Preparation of l-(3-benzyloxy-4,5-difluoro-phenyl)piperidin-4-one

To a flask containing crude 8-(3-benzyloxy-4,5-difluoro-phenyl)- l,4-dioxa-8- azaspiro[4.5]decane (1.00 g, 2.77 mmol) was added 44% formic acid (10 mL). The resulting mixture was heated with stirring at 90 °C for 8 hrs, and then concentrated in vacuo. The residue was diluted with sat. aqueous solution of NaHC0₃ (20 mL), and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(3-benzyloxy-4,5-difluoro-phenyl)piperidin-4-one (800 mg) as brown oil, which was used in the next step without further purification.

Step 4: Preparation of 6-(3-benzyloxy-4,5-difluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine

Crude l-(3-benzyloxy-4,5-difluoro-phenyl)piperidin-4-one (800 mg, 2.52 mmol) was heated with DMFDMA (10 mL) at 90 °C for 3 hrs. The reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20mL). To the solution was added pyridine-2- carboxamidine hydrochloride (398 mg, 2.52 mmol) and K₂C0₃ (696 mg, 5.04 mmol) successively. After being heated with stirring at 80 °C overnight, the reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(3-benzyloxy-4,5-difluoro-phenyl)-2-(2-pyridyl)-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine (900 mg). 1H NMR (400 MHz, CDC1₃): δ 8.91 - 9.08 (m, 1 H), 8.67 - 8.77 (m, 1 H), 8.55 - 8.66 (m, 1 H), 7.97 - 8.11 (m, 1 H), 7.51 - 7.64 (m, 1 H), 7.34 - 7.50 (m, 5 H), 6.38 - 6.49 (m, 2 H), 5.17 - 5.24 (m, 2 H), 4.32 - 4.39 (m, 2 H), 3.54 - 3.65 (m, 2 H), 3.23 - 3.35 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺] : 431.

Example 21:6-(3-ethoxy-4,5-difluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

To a solution of 2,3-dinuoro-5-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yfjphenol (80 mg, 0.24 mmol) in DMF (2 mL) was added ethyliodide (112 mg, 0.72 mmol) and K₂CO₃ (66 mg, 0.48 mmol). The mixture was heated with stirring at 90 °C. After the reaction finished, the reaction mixture was cooled to rt and filtered. The filtrate was purified by prep- HPLC to give 6-(3-ethoxy-4,5-difluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine (14 mg). 1H NMR (400 MHz, CDC1₃): δ 8.84 - 9.01 (m, 1 H), 8.65 - 8.80 (m, 1 H), 8.51 - 8.63 (m, 1 H), 7.90 - 8.00 (m, 1 H), 7.43 - 7.56 (m, 1 H), 6.36 - 6.48 (m, 2 H), 4.40 (s, 2 H), 4.16 (d, 2 H), 3.63 (t, 2 H), 3.30 (t, 2 H), 1.49 (t, 3 H). MS obsd. (ESI⁺) [(M+H)⁺] : 369.

Example 22:6-(3,4-difluoro-5-propoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

To a solution of 2,3-difluoro-5-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yfjphenol (80 mg, 0.24 mmol) in DMF (2 mL) was added 1-iodopropane (122 mg, 0.72 mmol) and K₂CO₃ (66 mg, 0.48 mmol). The mixture was heated with stirring at 90 °C. After the reaction finished, the reaction mixture was cooled to rt and filtered. The filtrate was purified by prep-HPLC to give 6-(3,4-difluoro-5-propoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine (5 mg).1H NMR (400 MHz, CDC1₃): δ 8.83 - 8.93 (m, 1 H), 8.68 - 8.75 (m, 1 H), 8.50 - 8.58 (m, 1 H), 7.85 - 7.95 (m, 1 H), 7.39 - 7.48 (m, 1 H), 6.37 - 6.46 (m, 2 H), 4.39 (s, 2 H), 4.04 (t, 2 H), 3.57 - 3.67 (m, 2 H), 3.29 (s, 2 H), 1.80 - 1.96 (m, 2 H), 1.09 (t, 3 H). MS obsd. (ESI⁺) [(M+H)⁺] : 383.

Example 23: 6-[3,4-difluoro-5-(2-methoxyethoxy)phenyl]-2-(2-pyridyl)-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine

To a solution of 2,3-diiluoro-5-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yfjphenol (80 mg, 0.24 mmol) in DMF (2 mL) was added l-bromo-2-methoxy-ethane (100 mg, 0.72 mmol) and K₂CO₃ (66 mg, 0.48 mmol). The mixture was heated with stirring at 90 °C.

After the reaction finished, the reaction mixture was cooled to rt and filtered. The filtrate was purified by prep-HPLC to give 6-[3,4-difluoro-5-(2-methoxyethoxy)phenyl]-2-(2-pyridyl)-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine (5 mg).1H NMR (400 MHz, CDC1₃): δ 8.84 - 8.96 (m, 1 H), 8.68 - 8.76 (m, 1 H), 8.50 - 8.59 (m, 1 H), 7.88 - 7.97 (m, 1 H), 7.40 - 7.51 (m, 1 H), 6.39 - 6.51 (m, 2 H), 4.36 - 4.42 (m, 2 H), 4.22 - 4.28 (m, 2 H), 3.77 - 3.83 (m, 2 H), 3.59 - 3.66 (m, 2 H), 3.49 (s, 3 H), 3.25 - 3.33 (m, 2 H). MS obsd. (ESf) [(M+H)⁺] : 399.

Example 24: 6-(3,4-difluoro-5-methoxy-phenyl)-2-(4-methoxy-2-pyridyl)-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine

Step 1: Preparation of 4-niet oxj pj ridiiie-2-carboxaniidiiie hydrochloride

To a solution of 4-methyoxypyridine-2-carbonitrile (1.0 g, 7.46 mmol) in methanol (20 mL) was added NaOCH₃ (80 mg, 1.49 mmol). The reaction mixture was stirred at rt for 12 hrs. To the resulting mixture was added NH₄CI (399 mg, 7.46 mmol). After being heated under reflux for 3 hrs, the reaction mixture was concentrated in vacuo. The residue was suspended in ethanol (30 mL) and the suspension was heated under reflux for lhr. The resulting mixture was cooled to rt and filtered. The filtrate was concentrated in vacuo to give 4-metyoxypyridine-2-carboxarnidine hydrochloride (1.2 g).

Step 2: Preparation of 6-(3-benzyloxy-4,5-difluoro-phenyl)-2-(4-methoxy-2-pyridyl)- 7,8-dihydro-5H-pyrido[4,3-d]pyrimidine

A solution of l-(3-benzyloxy-4,5-difluoro-phenyl)piperidin-4-one (314 mg, 0.99 mmol) and DMFDMA (1 mL) in acetonitrile (9 mL) was heated with stirring at 90 °C for 2 hrs. The reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (10 mL). To the solution was added 4-methoxypyridine-2-carboxamidine hydrochloride (185 mg, 0.99 mmol) and potassium carbonate (280 mg, 2.0 mmol) successively and the reaction was heated with stirring at 90 °C overnight. The reaction mixture was cooled to rt, diluted with water (20 mL) and extracted with EA (30 mL). The organic layer was separated and washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 6-(3-benzyloxy-4,5-difluoro-phenyl)-2-(4- methoxy-2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (0.48 g), which was used in the next step without purification.

Step 3: Preparation of 2,3-difluoro-5-[2-(4-methoxy-2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl]phenol

A mixture of 6-(3-benzyloxy-4,5-difluoro-phenyl)-2-(4-methoxy-2-pyridyl)-7,8-dihydro-

5H-pyrido[4,3-d]pyrimidine (0.48 g, 1.04 mmol), ammonium formate (0.66 g, 10.4 mmol) and Pd(OH)₂ (25 mg, 0.18 mmol) in methanol (10 mL) was heated with stirring at 90 °C overnight. The reaction mixture was cooled to rt and filtered. The filtrate was concentrated in vacuo to give crude 2,3-dinuoro-5-[2-(4-methoxy-2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl] phenol (0.9 g), which was used in the next step without purification.

Step 4: Preparation of 6-(3,4-difluoro-5-methoxy-phenyl)-2-(4-methoxy-2-pyridyl)- 7,8-dihydro-5H-pyrido[4,3-d]pyrimidine

A mixture of 2,3-difluoro-5-[2-(4-methoxy-2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]phenol (100 mg, 0.27 mmol), methyl iodide (120 mg, 0.81 mmol) and potassium carbonate ( 75 mg, 0.54 mmol) in DMF (2 mL) was heated with stirring at 60 "C for 5 hrs. The reaction was cooled to rt and puri fied by prep- H PLC to give 6-(3,4-difluoro-5-methoxy- phenyl)-2-(4-methoxy-2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (22 mg). Ή NMR (400MHz, DMSO-J₆): δ 8.78 (s, 1H), 8.54 (d, 1H), 7.89 (d, 1H), 7.11 (dd, 1H), 6.70 - 6.61 (m, 2H), 4.51 (s, 2H), 3.92 (s, 3H), 3.90 (s, 3H), 3.71 (t, 2H), 3.09 (t, 2H). MS obsd. (ESI⁺) [(M+H)⁺] 385.

Example 25: 6-(3,4-difluoro-5-methoxy-phenyl)-2-(6-methoxy-2-pyridyl)-7,8-dihyd] 5H-pyrido[4,3-d]pyrimidine

Step 1: Preparation of 6-metyoxypyridine-2-carboxainidine hydrochloride

To a solution of 6-methyoxypyridine-2-carbonitrile (1.0 g, 7.46 mmol) in methanol (20 mL) added NaOCH₃ (80 mg, 1.49 mmol). After the resulting mixture was stirred at rt for 12 hrs, to the mixture was added NH₄C1 (399 mg, 7.46 mmol). After being heated under reflux for 3 hrs, the reaction mixture was cooled to rt and concentrated in vacuo. The residue was suspended in ethanol (30 mL) and the suspension was heated under reflux for 1 hr. The mixture was filtered and the filtrate was concentrated in vacuo to give 6-metyoxypyridine-2-carboxamidine hydrochloride (1.2 g).

Step 2: Preparation of 6-(3-benzyIoxy-4,5-dlfluoro-plienyI)-2-(6-methoxy-2-pyriclyl)- 7,8-dihydro-5//-pyrido[4,3-d]pyrimidine

A solution of l-(3-benzyloxy-4,5-difluoro-phenyl)piperidin-4-one (314 mg, 0.99 mmol) and DMFDMA (1 mL) in acetonitrile (9 mL) was heated with stirring at 90 °C for 2 hrs. The reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (lOmL). To the solution was added 6-methoxypyridine-2-carboxamidine hydrochloride (185 mg, 0.99 mmol) and potassium carbonate (280 mg, 2.0 mmol). After being heated with stirring at 90 "C overnight, the reaction mixture was cooled to rt and diluted with water (20 mL). The resulting mixture was extracted with EA (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na_^SC and concentrated in vacuo to give 6-i3-benzyloxy-4,5-difluoro~ phenyi)-2-(6-methoxy-2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (0.52 g), which was used in the next step without purification.

Step 3: Preparation of 2,3-difluoro-5-[2-(6-methoxy-2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl]phenol

A mixture of 6-(3-benzyloxy-4,5-difluoro-phenyl)-2-(6-methoxy-2-pyridyl)-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine (0.52 g, 1.13 mmol), ammonium formate (0.71 g, 11.3 mmol) and Pd(OH)₂ (25 mg, 0. 18 mmol ) in methanol (10 ml ) was sti red at 90 "C overnight. The reaction mixture was cooled to rt and filtered. The filtrate was concentrated in vacuo to give 2,3-difluoro- 5-[2-(6-methoxy-2-pyridyl )-7,8-dihydro-5H-pyndo[4,3-d]pynmidin-6-yl] phenol (0.55 g), which was used in the next step without purification.

Step 4: Preparation of 6-(3,4-difluoro-5-methoxy-phenyl)-2-(6-methoxy-2-pyridyl)- 7,8-dihydro-5H-pyrido[4,3-d]pyrimidine

A mixture of 2,3-difluoro-5-[2-(6-methoxy-2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]phenol (100 mg, 0.27 mmol), methyl iodide (120 mg, 0.81 mmol) and potassium carbonate ( 75 mg, 0.54 mmol ) in DMF (2 mL) was heated with stirring at 60 "C for 5 hrs. The reaction mixture was cooled to rt and purified by prep- 1 1 PLC to give 6-(3,4-difluoro-5- methoxy-phenyl)-2-(6-methoxy-2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (40 m h ' H

NMR (400MHz, DMSO-J₆): δ 8.78 (s, 1H), 7.98 (d, 1H), 7.91 - 7.82 (m, 1H), 6.95 (d, 1H), 6.72 - 6.61 (m, 2H), 4.49 (s, 2H), 3.97 (s, 3H), 3.91 (s, 3H), 3.70 (t, 2H), 3.15 - 3.05 (m, 2H). MS obsd. (ESf) [(M+H)⁺] : 385.

Example 26: 6-(3,4-difluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihyd] pyrido[4,3-d]pyrimidine

Step 1: Preparation of 8-(3,4-difluoro-5-methoxy-phenyl)-l,4-dioxa-8- azaspiro[4.5]decane

To a flask containing a mixture of 5-bromo-l,2-difluoro-3-methoxy-benzene (1.1 g, 4.93 mmol) and l,4-dioxa-8-azaspiro[4.5]decane (0.85 g, 5.92 mmol) in 1,4-dioxane (10 mL) was added ί-BuONa (0.95 g, 9.86 mmol), Pd₂(dba)₃ (92 mg, 0.10 mmol) and Ru-Phos (92 mg, 0.20 mmol ) under N₂. After being heated with stirring at 100 "C overnight, the reaction mixture was cooled to rt and diluted with water (20 mL). The resulting mixture was extracted with EA (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 8-(3,4-difluoro-5-methoxy-phenyl)-l,4-dioxa-8- azaspiro[4.5]decane (1.57 g), which was used in the next step without further purification.

Step 3: Preparation of l-(3,4-difluoro-5-methoxy-phenyl)piperidin-4-one

A mixture of 8-(3,4-difluoro-5-methoxy-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane (1.57 g, 5.5 1 mmol ), H₂0 (5 mL) and formic acid (5 mL) was heated with stirring at 90 "C overnight. The reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(3,4-difluoro-5- methoxy-phenyl)piperidin-4-one (1.06 g), which was used in the next step without further purification.

Step 4: Preparation of 6-(3,4-difluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine

A solution of l-(3,4-difluoro-5-methoxy-phenyl)piperidin-4-one (0.39 g, 1.64 mmol) and DMFDMA (1 mL) in acetonitrile (9 mL) was heated with stirring at 90 °C for 2 hrs. The reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (10 mL). To the solution was added pyrimidine-2-carboxamidine (200 mg, 1.64 mmol) and potassium carbonate (453 mg, 3.28 mmol ) successively. After being heated with stirring at 90 "C overnight, the reaction mixture was cooled to rt and purified by prep- H PLC to give 6-(3,4-difluoro-5-methoxy- phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (10 mg).¹H NMR (400MHz, DMSO-J₆): δ 9.00 (d, 7=4.8 Hz, 2H), 8.82 (s, 1H), 7.64 (t, 7=4.8 Hz, 1H), 6.75 - 6.63 (m, 2H), 4.55 (s, 2H), 3.91 (s, 3H), 3.72 (t, 7=5.9 Hz, 2H), 3.10 (t, 7=5.8 Hz, 2H). MS obsd. (ESf) [(M+H)⁺]: 356.

Example 27: 6-(4,5-dinuoro-2-niet oxj -phenyl )-2-(2-pyridyl )-7,8-dihydro-5//- pyrido[4,3-d]pyriinidine

Step 1: Preparation of l-bromo-4,5-difluoro-2-methoxy-benzene

A mixture of 2-bromo-4,5-dif uoro-phenol (1.0 g, 4.78 mmol), methyl iodide (1.36 g, 9.57 mmol ) and potassium carbonate (1.32 g, 9.57 mmol) in DMF (5 mL) was heated with stirring at 90 "C for 4 hrs. The reaction mixture was cooled to rt. diluted with water ( 15 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-bromo-4,5-dif uoro-2-methoxy-benzene (1.16 g), which was used in the next step without further purification.

Step 2: Preparation of 8-(4,5-difluoro-2-methoxy-phenyl)-l,4-dioxa-8- azaspiro[4.5]decane

To a flask containing l-bromo-4,5-difluoro-2-methoxy-benzene (1.1 g, 4.93 mmol) and l,4-dioxa-8-azaspiro[4.5]decane (0.78 g, 5.43 mmol) in 1,4-dioxane (10 mL) was added t- BuONa (1.18 g, 12.33 mmol), Pd₂(dba)₃ (92 mg, 0.10 mmol) and Ru-Phos (92 mg, 0.20 mmol) under N₂. After being heated with stirring at 100 "C overnight, the reaction mixture was cooled to rt. diluted with water (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 8-(4,5-difluoro-2-methoxy-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane (1.31 g), which was used in the next step without further purification.

Step 3: Preparation of l-(4,5-difluoro-2-methoxy-phenyl)piperidin-4-one

A solution of 8-(4,5-difluoro-2-methoxy-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane (1.31 g, 4.59 mmol ) in H₂0 (5 mL) and formic acid (5 mL) was heated with sti ring at 90 "C overnight. The reaction mi ture was concentrated in vacuo. The residue was diluted with sat. aqueous solution of NaHCO; and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 1 -(4,5- dif uoro-2-methoxy-phenyl)piperidin-4-one (0.62 g), which was used in the next step without further purification.

Step 4: Preparation of 6-(4,5-difluoro-2-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine

A solution of l-(4,5-difluoro-2-methoxy-phenyl)piperidin-4-one (0.62 g, 2.57 mmol) and

DMFDMA (1 mL) in acetonitrile (9 mL) was heated with stirring at 90 °C for 2 hrs. The reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (lOmL). To the solution was added pyridine-2-carboxamidine (0.27 g, 2.19 mmol) and potassium carbonate (0.60 g, 4.38 mmol) successively. After being heated with stirring at 90 "C overnight, the reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(4,5-difluoro-2-methoxy- phenyl )-2-(2-pyndyl )-7,8-dihydiO-5H-pyrido[4,3-d]pyrimidine (30 mgi. ' H NMR (400MHz,

DMSO-J₆): δ 8.76 - 8.71 (m, 2H), 8.36 (d, 1H), 7.97 (t, 1H), 7.52 (ddd, 1H), 7.20 - 7.06 (m, 2H), 4.27 (s, 2H), 3.84 (s, 3H), 3.42 (t, 2H), 3.08 (t, 2H). MS obsd. (ESI⁺) [(M+H)⁺]: 355.

Example 28:6-(3,4-difluoro-5-methoxy-phenyl)-2-pyrazin-2-yl-7,8-dihyd]

pyrido[4,3-d]pyrimidine

Step 1 : Preparation of pyrazine-2-carboxaniidine hydrochloride

To a solution of pyrazine-2-carbonitrile (1.0 g, 9.52 mmol) in methanol (20 mL) was added NaOCH₃ (0.10 g, 1.90 mmol). The resulting mixture was heated with stirring at rt for 12 hrs. To the reaction mixture was added NH₄C1 (0.51 g, 9.52 mmol). After being heated under reflux for 3 hrs, the resulting reaction mixture was concentrated in vacuo. The residue was suspended in ethanol (30 mL). The suspension was heated under reflux for 1 hr, then cooled to rt and filtered. The filtrate was concentrated in vacuo to give pyrazine-2-carboxamidine hydrochloride (1.2 g), which was used in the next step without further purification.

Step 2: Preparation of 6-(3,4-difluoro-5-methoxy-phenyl)-2-pyrazin-2-yl-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine

A solution of l-(4,5-difluoro-2-methoxy-phenyl)piperidin-4-one (250 mg, 1.03 mmol) and DMFDMA (1 mL) in acetonitrile (9 mL) was heated with stirring at 90 °C for 2 hrs. The reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (lOmL). To the solution was added pyrazine-2-carboxamidine hydrochloride (160 mg, 1.01 mmol) and potassium carbonate (279 mg, 2.02 mmol). After being heated with stirring at 90 "C overnight, the reaction mixture was cooled to rt and purified by piep-HPLC to give 6-(3,4-difluoro-5- methoxy-phenyl)-2-pyrazin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (30 mg). 1H NMR

(400MHz, CDC1₃): δ 9.75 (s, 1H), 8.81 (s, 1H), 8.78-8.70 (m, 2H), 6.50-6.38 (m, 2H), 4.42 (s, 2H), 3.95 (s, 3H), 3.65 (t, 2H), 3.31 (t, 2H). MS obsd. (ESf) [(M+H)⁺]: 356. Example 29:6-(3 -difIuoro-5-niet oxj -phenyl )-2-pj riniidiii-4-j 1-7,8-dihj dro-5//- pyrido[4,3-d]pyriinidine

Step 1 : Preparation of pyriniidine-4-carboxamidine hydrochloride

To a solution of 4-cyanopyrimidine (500 mg, 4.8 mmol) in MeOH (5 mL) was added NaOMe (30 mg, 0.48 mmol). The mixture was heated with stirring at 20 °C for 16 hrs. To the resulting mixture was added NH₄C1 (333 mg, 5.8 mmol). After being heated under reflux for 3 hrs, the reaction mixture was concentrated in vacuo to give crude pyrimidine-4-carboxamidine hydrochloride (680 mg), which was used directly in the next step without further purification.

Step 2: Preparation of 6-(3,4-difluoro-5-methoxy-phenyD-2-pyriniidin-4-yl-7,8- dihydro-5//-pyrido[4 -d]pyriinidine

A solution of l-(4,5-difluoro-2-methoxy-phenyl)piperidin-4-one (630 mg, 2.65 mmol) and

DMFDMA (2 mL) in acetonitrile (9 mL) was heated with stirring at 90 °C for 2 hrs. The reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20 mL). To the solution was added p yri m id i ne-4-carbox am i d i ne hydrochloride (420 mg, 2.65 mmol ) and potassium carbonate (730 mg, 5.3 mmol). After being heated with sti ring at 90 "C overnight, the reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(3,4-difiuoro-5-methoxy- phenyl)-2-pyrimidin-4-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (6 mg). Ή NMR (400MHz, CDCI3): δ 9.56 (br. s., 1 H), 8.46 - 9.10 (m, 3 H), 6.44 (d, 2 H), 4.45 (br. s., 2 H), 3.96 (s, 3 H), 3.66 (t, 2 H), 3.31 (br. s., 2 H). MS obsd. (ESf) [(M+H)⁺]: 356. Example 30: 6-(3,4-dinuoro-2-niet oxj -phenyl )-2-pj riniidiii-2-j 1-7,8-dihj dro-5//- pyrido[4,3-d]pyriinidiiie

Step 1: Preparation of 6-bromo-2,3-difluoro-phenol

To a solution of 2,3-difluorophenol (1.0 g, 7.69 mmol) and isopropyl amine (0.45 g, 7.69 mmol) in dry DCM (20 mL) was added NBS (5.48 g, 30.76 mmol) portion- wise at -10 °C . After being stirred at - 10 "C for 30 minutes, the resulting mixture was allowed to warm naturally to rt, then diluted with 1.0 N HQ (40 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 6-bromo-2,3-difluoro-phenol (2.6 g), which was used in the next step without purification.

Step 2: Preparation of l-bromo-3,4-difluoro-2-methoxy-benzene

A mixture of 6-bromo-2,3-difluoro-phenol (2.6 g, 12.4 mmol), methyl iodide (1.0 mL, 15.38 mmol ) and potassium carbonate (2.12 g, 15.38 mmol ) in DMF (10 mL) was heated with stirring at 90 "C for 4 hrs. The reaction mixture was cooled to rt, diluted with water (15 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated // vacuo to give l-bromo-3,4-difluoro-2- methoxy-benzene (1.0 g), which was used in the next step without further purification.

Step 3: Preparation of 8-(3,4-difluoro-2-methoxy-phenyl)-l,4-dioxa-8- azaspiro[4.5]decane

To a flask containing l-bromo-3,4-difluoro-2-methoxy-benzene (1.0 g, 4.48 mmol) and l,4-dioxa-8-azaspiro[4.5]decane (0.71 g, 4.93 mmol) in 1,4-dioxane (10 ml) was added t- BuONa (1.3 g, 13.44 mmol), Pd₂(dba)₃ (82 mg, 0.09 mmol) and Ru-Phos (84 mg, 0.18 mmol) under N₂. After being heated with stirring at 100 "C overnight, the reaction mixture was cooled to rt, diluted with water (20 ml.) and extracted with EA (30 mL) for three times. The combined organic layer was washed w ith brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 8-(3,4-difluoro-2-methoxy-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane (0.74 g), which was used in the next step without further purification.

Step 4: Preparation of l-(3,4-difluoro-2-methoxy-phenyl)piperidin-4-one

A solution of 8-(3,4-difluoro-2-methoxy-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane (0.74 g, 2.59 mmol ) in H₂0 (5 mL) and formic acid (5 mL) was heated with stirring at 90 "C overnight. The reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHCCh, and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(3,4-difluoro-2- methoxy-phenyl)piperidin-4-one (0.65 g), which was used in the next step without further purification.

Step 5: Preparation of 6-(3.4-difluoro-2-niethoxj -phenyl )-2-pyriinidin-2-yl-7.8- dihydro-5//-pyrido[4 -d]pyrimidine

A solution of l-(3,4-difluoro-2-methoxy-phenyl)piperidin-4-one (0.40 g, 1.64 mmol) and DMFDMA (1 mL) in acetonitrile (5 mL) was heated with stirring at 90 °C for 2 hrs. The reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (lOmL). To the solution was added pyridine-2-carboxamidine hydrochloride (260 mg, 1.64 mmol) and potassium carbonate (0.45 g, 3.24 mmol ) successively. After being heated with sti ring at 90 "C overnight, the reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(3,4- difluoro-2-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (6 mg). Ή NMR (400MHz, CDC1₃): δ 9.04 (d, 2H), 8.75 (s, 1 H), 7.45 (t, 1 H), 6.94 - 6.80 (m, 1 H), 6.71 (ddd, 1 H), 4.35 (s, 2H), 3.96 (d, 3 H), 3.54 (t, 2 H), 3.35 (t, 2 H). MS obsd. (ESf) [(M+H)⁺] : 356.

Example 31: ethyl 4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl]benzoate

Step 1: fert-butyl (3Z)-3-(dimethylaminomethylene)-4-oxo-piperidine-l-carboxylate

A solution of iert-butyl 4-oxopiperidine- l-carboxylate (20 g, 100 mmol) and DMFDMA (13.15 g, 110.5 mmol) in DMF (150 mL) was heated with stirring at 90 °C overnight. After being cooled to rt, the reaction mixture was poured into H₂0 (100 mL) and extracted with EA (100 mL) for three times. The combined organic layer was dried over anhydrous Na₂S0₄ and concentrated in vacuo to give iert-butyl (3Z)-3-(dimethylaminomethylene)-4-oxo-piperidine-l- carboxylate (28 g) as an oil, which was used in the next step without further purification.

Step 2: fert-butyl 2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6- carboxylate

To a solution of iert-butyl (3Z)-3-(dimethylaminomethylene)-4-oxo-piperidine-l- carboxylate (5g, 19.7 mmol) and pyridine-2-carboxamidine hydrochloride (2.38 g, 19.7 mmol) in EtOH (100 mL) was added NaH (3.0 g, 60% in mineral oil, 39.4 mmol). After being heated with stirring at 100 °C for 8 hrs, the reaction mixture was poured into H₂0 (100 mL) and extracted with EA (100 mL) for three times. The combined organic layer was dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column (eluting with 2% MeOH in DCM) to give iert-butyl 2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6- carboxylate (3.7 g).

Step 3: Preparation of 2-(2-pyridyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine

ie/t-Butyl 2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylate (3.7 g, 11.86 mmol) was heated with 1.0 N HCl in EA (50 mL) at rt. After the reaction was completed, the resulting mixture was concentrated in vacuo to give 2-(2-pyridyl)-5,6,7,8- tetrahydropyrido[4,3-d]pyrimidine, which was used in the next step without further purification.

Step 4: Preparation of ethyl 4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin- 6-yl]benzoate

To a mixture of 2-(2-pyridyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine (200 mg, 0.94 mmol) and ethyl 4-fluorobenzoate (316 mg, 1.88 mmol) in DMF (5 mL) was added Cs₂C0₃ (611 mg, 1.88 mmol). After being heated with stirring at 150 °C for 3 hrs, the resulting reaction mixture was purified by prep-HPLC to give ethyl 4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]benzoate (4 mg). 1H NMR (400 MHz, CDC1₃): δ 8.80 - 8.89 (m, 1 H), 8.70 - 8.76 (m, 1 H), 8.48 - 8.55 (m, 1 H), 8.00 (d, 2 H), 7.82 - 7.91 (m, 1 H), 7.37 - 7.45 (m, 1 H), 6.97 (d, 2 H), 4.60 (s, 2 H), 4.35 (q, 2 H), 3.76 - 3.87 (m, 2 H), 3.24 - 3.34 (m, 2 H), 1.39 (t, 3 H). MS obsd. (ESf) [(M+H)⁺] : 361.

Example 32: 4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzoic

To a solution of ethyl 4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl]benzoate (10 mg, 0.03 mmol) in THF (2 mL) was added LiOH (1.0 M in H₂0, 1.0 mL). The resulting mixture was heated with stirring at rt. After the reaction was complete, the resulting reaction mixture was purified by prep-HPLC to give 4-[2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl]benzoic acid (4 mg). 1H NMR (400 MHz, MeOH-d₄): δ 8.84 - 8.89 (m, 1 H), 8.74 - 8.84 (m, 2 H), 8.31 - 8.41 (m, 1 H), 7.93 - 8.01 (m, 2 H), 7.79 - 7.88 (m, 1 H), 7.04 - 7.13 (m, 2 H), 4.66 - 4.73 (m, 2 H), 3.86 - 3.95 (m, 2 H), 3.25 - 3.30 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺] : 357.

Example 33: 6-(2-nitrophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine

To a mixture of 2-(2-pyridyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine (50 mg, 0.24 mmol) and l-fluoro-2-nitro-benzene (68 mg, 0.48 mmol) in DMF (5 mL) was added CS₂CO₃ (156 mg, 0.48 mmol). After being heated with stirring at 80 °C for 5 hrs, the resulting mixture was purified by prep-HPLC to give 6-(2-nitrophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine (2 mg). 1H NMR (400 MHz, CDC1₃): δ 8.82 - 8.91 (m, 1 H), 8.66 (s, 1 H), 8.48 - 8.57 (m, 1 H), 7.83 - 7.93 (m, 2 H), 7.52 - 7.61 (m, 1 H), 7.38 - 7.46 (m, 1 H), 7.29 - 7.33 (m, 1 H), 7.10 - 7.20 (m, 1 H), 4.40 (s, 2 H), 3.53 (s, 2 H), 3.23 - 3.39 (m, 2 H). MS obsd. (ESf) [(M+H)⁺] : 334.

To a mixture of 2-(2-pyridyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine (200

mmol) and l-fluoro-2-methoxy-4-nitro-benzene (245 mg, 1.43 mmol) in DMSO (5 mL) was added K₂CO₃ (260 mg, 1.88 mmol). After being heated with stirring at 80 °C for 3 hrs, the reaction mixture was purified by prep-HPLC to give 6-(2-methoxy-4-nitro-phenyl)-2-(2- pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (30 mg). 1H NMR (400 MHz, CDC1₃): δ 8.82 - 8.90 (m, 1 H), 8.69 (s, 1 H), 8.47 - 8.57 (m, 1 H), 7.83 - 7.96 (m, 2 H), 7.80 (d, 1 H), 7.38 - 7.47 (m, 1 H), 7.02 (d, 1 H), 4.48 - 4.56 (m, 2 H), 4.02 (s, 3 H), 3.68 - 3.75 (m, 2 H), 3.29 - 3.37 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺] : 364.

Example 35: 2,6-bis(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine

To a mixture of 2-(2-pyridyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine (50 mg, 0.24 mmol) and 2-fluoropyridine (2 mL) was added K₂CO₃ (65 mg, 0.48 mmol). After being heated with stirring at 150 °C for 5 hrs in a microwave reactor, the resulting reaction mixture was purified by prep-HPLC to give 2,6-bis(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (2 mg). 1H NMR (400 MHz, CDC1₃): δ 8.83 - 8.89 (m, 1 H), 8.70 - 8.78 (m, 1 H), 8.48 - 8.55 (m, 1 H), 8.23 - 8.30 (m, 1 H), 7.83 - 7.91 (m, 1 H), 7.53 - 7.62 (m, 1 H), 7.37 - 7.45 (m, 1 H), 6.78 - 6.85 (m, 1 H), 6.67 - 6.75 (m, 1 H), 4.85 (s, 2 H), 3.97 - 4.05 (m, 2 H), 3.21 - 3.31 (m, 2 H). MS obsd. (ESf) [(M+H)⁺] : 290. Example 36: 6-(5-chloro-2-pyridyl)-2-(2-pyridyD-7,8-dihydro-5//-pyrido[4,3- d]pyriniidine

A mixture of 2-(2-pyridyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine hydrogen chloride (200 mg, 0.806 mmol), 5-chloro-2-fluoro-pyridine (1.06 g, 8.06 mmol) and Et₃N (1.63 g, 16.13 mmol) in DMF (0.2 mL) was heated with stirring at 150 °C for 20 minutes. Then the mixture was concentrated in vacuo and the residue was purified by Prep-HPLC to give 6-(5-chloro-2- pyridyl )-2-( 2-pyridyl )-7.8 lihydro-5H-pyrido[4,3-d jpyrimidine (8 mg). Ή NMR (400 MHz, CDC1₃): δ 8.86 (dd, 1 H), 8.74 (s, 1 H), 8.52 (d, 1 H), 8.19 (d, 1 H), 7.88 (dt, 1 H), 7.52 (dd, 1 H), 7.42 (ddd, 1 H), 6.74 (d, 1 H), 4.81 (s, 2 H), 3.98 (t, 2 H), 3.27 (t, 2 H). MS obsd. (ESf)

[(M+H)⁺]: 324.

Example 37: 2-(2-pyridyl)-6-pyrimidiii-2-yl-7,8-dihydro-5//-pyr!do[4 -d]pyriinidine

A mixture of 2-(2-pyridyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine trifluoroacetic acid

(500 mg, 1.53 mmol), 2-chloropyrimidine (350 mg, 3.07 mmol) and sodium i-butoxide (442 mg, 4.6 mmol) in DMF (10 mL) was heated with stirring at 140 °C for 1 hr. The resulting reaction mixture was diluted with water (20 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was dried and concentrated in vacuo. The residue was purified by prep- HPLC to give 2-(2-pyridyl)-6-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine as a light yellow solid (107 mg). 1H NMR (400 MHz, CDC1₃): δ 8.86 (d, 1 H), 8.74 (s, 1 H), 8.52 (d, 1 H), 8.40 (d, 2H), 7.88 (dt, 1 H), 7.36-7.46 (m, 1 H), 6.60 (s, 1 H), 5.05 (s, 2 H), 4.18-4.31 (m, 2 H), 3.24 (s, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 291. Example 38: 6-(2-beiizyloxy-4-fluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5//- pyrido[4,3-d]pyrimidiiie

Step 1 : Preparation of 2-( l,4-dioxa-8-azaspiro[4.5]decaii-8-yl)-5-fluoro-p enol

A mixture of l,4-dioxa-8-azaspiro[4.5]decane hydrochloride (9.02 g, 0.05 mol), 2-bromo-

5-f uoro-phenol (8 g, 0.042 mol), Cul (1.6 g, 0.0084 mol), L-proline (4.8 g, 0.042 mmol) and K₂C0₃ (23.12 g, 0.168 mmol) in DMSO (100 mL) was heated with stirring at 110 °C overnight. The resulting reaction mixture was diluted with water (50 mL), acidified to pH=5-6 with 2 N hydrochloric acid and extracted with EA (30 mL) for three times. The combined organic layer was dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column to give 2-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-5-fluoro-phenol as a yellow oil (1.2 g).

Step 2: Preparation of 8-(2-benzyloxy-4-fluoro-phen l )- 1 ,4-dioxa-8- azaspiro[4.5]decane

A mixture of 2-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-5-fluoro-phenol (460 mg, 1.818 mmol), bromomethylbenzene (311 mg, 1.818 mmol) and K₂C0₃ (502 mg, 3.64 mmol) in DMF (5 mL) was heated with stirring at rt overnight. The resulting reaction mixture was diluted with water (5 mL) and extracted with EA (30 mL) for three times. The combined organic layer was dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column to give 8-(2-benzyloxy-4-fluoro-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane as an oil (440 mg).

Step 3: Preparation of l-(2-benzy!oxy-4-fluoro-phenyl)piperidin-4-one

A mixture of 8-(2-benzyloxy-4-fluoro-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane (400 mg, 1.17 mmol), formic acid (3 mL) and H₂0 (3 mL) was heated with stirring at 90 °C overnight. The resulting reaction mixture was concentrated in vacuo. The residue was diluted with sat.

aqueous solution of NaHC0₃ and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column to give l-(2-benzyloxy-4-fluoro-phenyl)piperidin-4- one as an oil (130 mg).

Step 4: 6-(2-beiizyloxy-4-fluoro-p eiiyl)-2-(2-pyridyl)-7,8-dihydro-5//-pyrido[4,3- djpyrimidine

A mixture of l-(2-benzyloxy-4-fluoro-phenyl)piperidin-4-one (130 mg, 0.44 mmol) and DMFDMA (5 mL) was heated with stirring at 90 °C overnight. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (5 mL). To the solution was added pyridine-2-carboxamidine hydrochloride (68 mg, 0.44) and CH₃ONa (47 mg, 0.87 mmol). After being heated with stirring at 90 °C overnight, the resulting reaction mixture was

concentrated in vacuo. The residue was purified by prep-HPLC to give 6-(2-benzyloxy-4-fluoro- phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (2 mg). 1H NMR (400 MHz, CDC1₃): δ 8.83-8.91 (m, 1 H), 8.60 (s, 1 H), 8.52 (d, 1 H), 7.84-7.91 (m, 1 H), 7.33-7.50 (m, 6 H), 7.01 (dd, 1 H), 6.79 (dd, 1 H), 6.70 (dt, 1 H), 5.13 (s, 2 H), 4.33 (s, 2 H), 3.51 (t, 2 H), 3.23 (t, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 413.

Example 39: 2-(2-pyndyl )-6-(3-pyridyl)-7,8-di iydro-5//-pyrido[4 -d]pyri

Step 1 : Preparation of 8-(3-pyrid l)-l,4-dioxa-8-azaspiro[4.5]decaiie

A mixture of l,4-dioxa-8-azaspiro[4.5]decane hydrochloride (3 g, 16.7 mmol), 3- bromopyridine (2.9 g, 18.4 mmol), Pd(OAc)₂ (0.187 g, 0.83 mmol), Xphos (0.398 g, 0.83 mmol) and sodium iert-butoxide (3.2 g, 33.4 mmol) in a mixed solution of toluene (50 mL) and tert- butyl alcohol (10 mL) was heated with stirring at 120 °C overnight. The reaction mixture was diluted with water (50 mL) and extracted with EA (30 mL) for three times. The combined organic layer was dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column to give 8-(3-pyridyl)-l,4-dioxa-8-azaspiro[4.5]decane (590 mg).

Step 2: Preparation of l-(3-pyridyl) iperidin-4-one

A mixture of 8-(3-pyridyl)-l,4-dioxa-8-azaspiro[4.5]decane (590 mg, 1.17 mmol), formic acid (5 mL) and H₂0 (5 mL) was heated with stirring at 90 °C overnight. The reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ and extracted with EA (30 mL) for three times. The combined organic layer was dried over anhydrous Na₂S0₄ and concentrated in vacuo to give crude 1 -( 3-pyridyl )piperidin-4-one, which was used for next step without further purification.

Step 3: Preparation of 2-(2-pyridyl)-6-(3-pyridyI)-7,8-di ydro-5//-pyrido[4,3- djpyriinidiiie

A mixture of l-(3-pyridyl)piperidin-4-one (470 mg, 2.67 mmol) and DMFDMA (1.14 g, 9.6 mmol) in DMF (5 mL) was heated with stirring at 90 °C for 2 hrs. The reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20 mL). To the solution was added pyridine-2-carboxamidine (262 mg, 2.16 mmol) and CH₃ONa (234 mg, 4.33 mmol). After being heated with stirring at 90 °C overnight, the resulting mixture was concentrated in vacuo and the residue was dissolved in EA (50 mL). The organic phase was washed with water, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to give 2-(2-pyridyl)-6-(3-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (25 mg). 1H NMR (400 MHz, CDC1₃): δ 8.87 (dd, 1 H), 8.74 (s, 1 H), 8.53 (d, 1 H), 8.46 (d, 1 H), 8.18 (dd, 1 H), 7.89 (dt, 1 H), 7.43 (ddd, 1 H), 7.31-7.37 (m, 1 H), 7.25-7.28 (m, 1 H), 4.53 (s, 2 H), 3.76 (t, 2 H), 3.28-3.36 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 290.

Example 40: 6-(3-fluoro-5-niethyl-p enyl)-2-(2-pyridyl)-7,8-dihydro-5//-pyrido[4,3- d]pyriniidine

Step 1 : Preparation of 8-(3-fluoro-5-methyl-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane

A mixture of l,4-dioxa-8-azaspiro[4.5]decane hydrochloride (2.85 g, 15.86 mmol), 1- bromo-3-fluoro-5-methyl-benzene (6 g, 31.7 mmol), Pd₂(dba)₃ (0.29 g, 3.17 mmol), Ruphos (0.296 g, 6.3 mmol) and Cs₂C0₃ (20.6 g, 63.4 mmol) in toluene (50 mL) was heated with stirring at 120 °C overnight. The resulting reaction mixture was filtered. The filtrate was concentrated in vacuo to give crude 8-(3-fluoro-5-methyl-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane (3.5 g), which was used in the next step without further purification.

Step 2: Preparation of l-(3-fluoro-5-niet yl-p enyl)piperidin-4-one

A mixture of 8-(3-fluoro-5-methyl-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane (3.5 g, 13.94 mmol), formic acid (24 mL) and H₂0 (24 mL) was heated with stirring at 90 °C overnight. The resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ and extracted with EA (30 ml) for three times. The combined organic layer was dried over anhydrous Na₂S0₄ and concentrated in vacuo to give crude l-(3-fluoro-5-methyl- phenyl)piperidin-4-one as a black oil (2.8 g), which was used in the next step without further purification.

Step 3: Preparation of 6-(3-fluoro-5 nethyl-p eiiyl)-2-(2-pyridyl)-7,8-dihydro-5//- pyrido[4,3-d]pyrimidine

A mixture of l-(3-fluoro-5-methyl-phenyl)piperidin-4-one (2.8 g, 13.5 mmol) and

DMFDMA (1.93 g, 16.23 mmol) in DMF (20 mL) was heated with stirring at 90 °C overnight. The reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20 mL). To the solution was added pyridine-2-carboxamidine hydrochloride (2.89 g, 18.3 mmol) and CH₃ONa (1.32 g, 24.4 mmol). After being heated with stirring at 90 °C overnight, the resulting reaction mixture was concentrated in vacuo and the residue was purified by Prep-HPLC to give 6-(3-fluoro-5-methyl-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (155 mg). 1H NMR (400 MHz, CDC1₃): δ 8.83-8.90 (m, 1 H), 8.72 (s, 1 H), 8.52 (d, 1 H), 7.88 (d, 1 H), 7.42 (s, 1 H), 6.61 (s, 1 H), 6.53 (d, 1 H), 6.44 (d, 1 H), 4.46 (s, 2 H), 3.70 (t, 2 H), 3.28 (t, 2 H), 2.35 (s, 3 H). MS obsd. (ESI⁺) [(M+H)⁺]: 321.

Example 41 : 6-(3-bronio-5-nuoro-plienyl)-2-pyriinidin-2-yl-7,8-dihydro-5//- py rido[ 4,3-d 1 py r i mid i ne

Step 1 : Preparation of 8-(3-bromo-5-fluoro-phenyi )- 1 ,4-dioxa-8-a/aspiro[4.5]decane

A mixture of l,4-dioxa-8-azaspiro[4.5]decane hydrochloride (2.0 g, 11.1 mmol), 1,3- dibromo-5-fluoro-benzene (3.39 g, 13.4 mmol), Cul (0.423 g, 2.23 mmol), L-proline (1.28 g, 11.1 mmol) and K₂C0₃ (4.61 g, 33.4 mmol) in DMF (20 mL) was heated with stirring at 90 °C overnight. The resulting reaction mixture was diluted with water (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column to give 8-(3-bromo-5-fluoro- phenyl)-l,4-dioxa-8-azaspiro[4.5]decane as an oil (1.79 g).

Step 2: Preparation of 1 -(3-broiiio-5-fluoro-phenyl )piperidin-4-one

A mixture of 8-(3-bromo-5-fluoro-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane (1.7 g, 5.4 mmol), formic acid (20 mL) and H₂0 (20 mL) was heated with stirring 90 °C for 6 hrs. The reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ and extracted with EA(30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(3-bromo-5-fluoro- phenyl)piperidin-4-one as an oil (1.4 g), which was used in the next step without further purification.

Step 3: Preparation of 6-(3-bron )-5-fluoro-pheiiyl)-2-pyriniidiii-2-yl-7,8-dilivdro-5//- pyrido[4,3-d]pyrimidine

A mixture of l-(3-bromo-5-fluoro-phenyl)piperidin-4-one (1.4 g, 5.17 mmol) and

DMFDMA (0.74 g, 6.2 mmol) in DMF (10 mL) was heated with stirring at 90 °C for 3 hrs. The reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20 mL). To the solution was added pyrimidine-2-carboxamidine hydrochloride (1.23 g, 7.75 mmol) and CH₃ONa (0.56 g, 10.34 mmol). After being heated with stirring at 80 °C overnight, the resulting reaction mixture was concentrated in vacuo and the residue was purified by Prep-HPLC to give 6-(3-bromo-5-fluoro-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (20 mg). 1H NMR (400 MHz, CDC1₃): δ 9.06 (d, 2 H), 8.85 (s, 1 H), 7.47 (t, 1 H), 6.90-6.96 (m, 1 H), 6.77 (td, 1H), 6.64 (td, 1 H), 4.45-4.60 (m, 2 H), 3.68-3.83 (m, 2H), 3.30-3.44 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 386.

Example 42: 6-(3-cyclopropyl-5-fluoro-p eiiyl)-2-pyriniidin-2-yl-7,8-dihydro-5//- pyrido[4,3-d]pyrimidine

A mixture of 6-(3-bromo-5-fluoro-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine (150 mg, 0.39 mmol), potassium cyclopropyltrifluoroborate (86 mg, 0.58 mmol), PdCl₂(dppf)₂-CH₂Cl₂ (6.35 mg, 0.01 mmol) and K₂C0₃ (161 mg, 1.17 mmol) in toluene (3 mL) and H₂0 (1 mL) was heated with stirring at 90 °C for 2 days. The resulting mixture was concentrated in vacuo and the residue was purified by Prep-HPLC to give 6-(3-cyclopropyl-5- fluoro-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (12 mg). 1H NMR (400 MHz, CDC1₃) δ 9.05 (d, 2 H), 8.83 (s, 1 H), 7.43-7.49 (m, 1 H), 6.59 (s, 1 H), 6.52 (d, 1 H), 6.24-6.33 (m, 1 H), 4.51 (s, 2 H), 3.72 (t, 2 H), 3.35 (t, 2 H), 1.83-1.94 (m, 1 H), 0.93-1.03 (m, 2H), 0.63-0.77 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 348.

Example 43: 2-pyrimidin-2-yl-6-[3-(lrifluorometlioxy)plH iyl]-7,8-di iydro-5H- pyrido[4,3-d jpyrmiidiiie

Step 1: Preparation of 8-[3-(trifluoroniethoxy)phenyl]-l ,4-dioxa-8- azaspiro[4.5]decane

A mixture of l,4-dioxa-8-azaspiro[4.5]decane hydrochloride (2.0 g, 11.1 mmol), 1-bromo- 3-(trifluoromethoxy)benzene (5.72 g, 22.3 mmol), Pd₂(dba)₃ (0.204 g, 0.223 mmol), Ruphos (0.21 g, 0.445 mmol) and Cs₂C0₃ (14.5 g, 44.5 mmol) in toluene (50 mL) was heated with stirring at 120 °C overnight. The resulting reaction mixture cooled to rt and filtered. The filtrate was concentrated in vacuo and the residue was purified by flash column to give 8- [3- (trifluoromethoxy)-phenyl]-l,4-dioxa-8-azaspiro[4.5]decane as an oil (3.0 g).

Step 2: Preparation of l-[3-(trifluoroniethoxy)phenyl]piperidin-4-one

A mixture of 8-[3-(trifluoromethoxy)phenyl]-l,4-dioxa-8-azaspiro[4.5]decane (1.5 g, 4.95 mmol), formic acid (20 mL) and H₂0 (20 mL) was heated with stirring at 90 °C overnight. The resulting mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃, and extracted with EA (30 mL) for three times. The combined organic layer was dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-[3-(trifluoromethoxy)phenyl]piperidin-4- one as an oil (1.2 g), which was used in the next step without further purification.

Step 4: Preparation of 2-pyriniidin-2-y!-6-[3-(trifluoroniet oxy)phenyl]-7.8-dihydro- 5H-pyrido[4,3-d]pyriniidine

A mixture of l-[3-(trifluoromethoxy)phenyl]piperidin-4-one (0.685 g, 2.64 mmol) and DMFDMA (1.26 g, 10.6 mmol) in DMF (10 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20 mL). To this solution was added pyrimidine-2-carboxamidine hydrochloride (0.63 g, 3.97 mmol) and CH₃ONa (0.29 g, 5.285 mmol). After being heated with stirring at 90 °C overnight, the reaction mixture was filtered. The filtrate was concentrated in vacuo and the residue was dissolved in EA (50 mL). The solution was washed with water, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to give 2-pyrimidin-2-yl-6-[3- (trifluoromethoxy)-phenyl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (4 mg). 1H NMR (400 MHz, CDC1₃): δ 9.06 (d, 2 H), 8.85 (s, 1 H), 7.46 (t, 1 H), 7.31-7.36 (m, 1 H), 6.93-6.98 (m, 1 H), 6.86 (s, 1 H), 6.79 (s, 1 H), 4.54 (s, 2 H), 3.76 (s, 2 H), 3.38 (s, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 348.

Example 44: 6-f3-nielhoxy-4-(3-niel oxypropoxy)p eiiyl]-2-(2-pyridyl)-7,8-dihydro- 5//-pyrido[4.3-d]pyriniidine

Step 1: Preparation of 4-bromo-2-methox -l-(3-methoxypropoxy)benzene

A mixture of 4-bromo-2-methoxy-phenol (3.00 g, 14.78 mmol), l-bromo-3-methoxy- propane (2.71 g, 17.73 mmol) and K₂C0₃ (6.12 g, 44.33 mmol) in DMF (30 mL) was stirred at rt for 3 hrs. The mixture was concentrated in vacuo, diluted with water (30 mL) and extracted with DCM (30 mL) for three times. The combined organic layer was dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 4-bromo-2-methoxy-l-(3-methoxypropoxy)benzene (3.00 g), which was used in the next step without further purification.

Step 2: Preparation of 8-[3-met oxy-4-(3-metlioxypropoxy)phenyl]-l,4-dioxa-8- azaspiro|4.5]decane

A mixture of l,4-dioxa-8-azaspiro[4.5]decane hydrochloride (2.00 g, 11.1 mmol), 4- bromo-2-methoxy-l-(3-methoxypropoxy)benzene (4.58 g, 16.65 mmol), Cul (0.423 g, 2.23 mmol), L-proline (1.28 g, 11.1 mmol) and K₂C0₃ (4.61 g, 33.4 mmol) in DMF (20 mL) was heated with stirring at 90 °C overnight. The resulting mixture was diluted with water (30 mL) and extracted with EA (50 mL) for three times. The combined organic layer was dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column to give 8-[3-methoxy-4-(3-methoxypropoxy)phenyl]-l,4-dioxa-8-azaspiro[4.5]decane (1.5 g).

Step 3: Preparation of l-[3-niethoxy-4-(3-niethoxypropoxy)p enyl]piperidin-4-one

A mixture of 8-[3-methoxy-4-(3-methoxypropoxy)phenyl]-l,4-dioxa-8- azaspiro[4.5]decane (1.5 g, 8.89 mmol), formic acid (10 mL) and H₂0 (10 mL) was heated with stirring at 90 °C for 6 hrs. The resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ and extracted with EA (30 mL) for three times. The combined organic layer was washed with water, dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-[3-methoxy-4-(3-methoxypropoxy)phenyl]piperidin-4-one (1 g), which was used in the next step without further purification.

Step 4: Preparation of 6-[3-niethoxy-4-(3-nu^>tlioxypiOpoxy)phenyl]-2-(2-pyridyl)-7,8- dihydro-5iI-pyrido[4,3-d]pyriinidine

A mixture of l-[3-methoxy-4-(3-methoxypropoxy)phenyl]piperidin-4-one (1.0 g, 3.41 mmol) and l,l-dimethoxy-N,N-dimethyl-methanamine (0.49 g, 4.1 mmol) in DMF (10 mL) was heated with stirring at 90°C overnight. The reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20 mL). To this solution was added pyridine-2-carboxamidine hydrochloride (0.577 g, 3.66 mmol) and CH₃ONa (0.395 g, 9.32 mmol). After being heated with stirring at 80 °C overnight, the resulting mixture was concentrated in vacuo and the residue was purified by Prep-HPLC to give 6-[3-methoxy-4-(3-methoxypropoxy)phenyl]-2-(2-pyridyl)-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine (20 mg). 1H NMR (400 MHz, MeOH-<¾: δ 8.69-8.78 (m, 2H), 8.50 (d, 1 H), 8.43-8.55 (m, 1 H), 8.00 (d, 1 H), 7.55 (ddd, 1 H), 6.91 (d, 1 H), 6.82 (d, 1 H), 6.64 (dd, 1 H), 4.38 (s, 2 H), 4.03 (s, 2 H), 3.53-3.65 (m, 4 H), 3.37 (s, 3 H), 3.33 (t, 3 H), 3.20 (t, 2 H), 1.95-2.06 (m, 2 H). MS obsd. (ESf) [(M+H)⁺]: 374. Example 45: 6-(4-chlorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

Step 1: Preparation of 8-(4-chloro henyl)-l,4-dioxa-8-azaspiro[4.5]decane

To a flask containing l-chloro-4-iodo-benzene (1170 mg, 4.92 mmol) and l,4-dioxa-8- azaspiro[4.5]decane (774 mg, 5.41 mmol) in dioxane (20 mL) was added i-BuONa (945 mg, 9.84 mmol), Pd₂(dba)₃ (229 mg, 0.25 mmol) and Sphos (201 mg, 0.49 mmol) under N₂. After being heated with stirring at 100 °C overnight, the resulting mixture was cooled to rt, diluted with H₂0 (40 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 8-(4-chlorophenyl)-l,4-dioxa-8-azaspiro[4.5]decane (1100 mg), which was used in the next step without further purification.

Step 2: Preparation of l-(4-chlorophenyl)piperidin-4-one

A mixture of crude 8-(4-chlorophenyl)-l,4-dioxa-8-azaspiro[4.5]decane (1100 mg, 4.34 mmol) and 44% formic acid (10 mL) was heated with stirring at 90 °C for 8 hrs. The resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(4- chlorophenyl)piperidin-4-one (820 mg) as brown oil, which was used in the next step without further purification.

Step 3: Preparation of 6-(4-chlorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

A mixture of l-(4-chlorophenyl)piperidin-4-one (820 mg, 3.91 mmol) and DMFDMA (10 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20 mL). To this solution was added pyridine-2- carboxamidine hydrochloride (618 mg, 3.91 mmol) and K₂CO₃ (1079 mg, 7.82 mmol) successively. After being heated with stirring at 80 °C overnight, the resulting reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(4-chlorophenyl)-2-(2-pyridyl)-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine (20 mg). 1H NMR (400 MHz, CDC1₃): δ 8.82 - 8.90 (m, 1 H), 8.71 (s, 1 H), 8.52 (d, 1 H), 7.88 (d, 1 H), 7.40 - 7.45 (m, 1 H), 7.26 - 7.32 (m, 3 H), 6.91 - 7.01 (m, 2 H), 4.45 (s, 2 H), 3.69 (s, 2 H), 3.29 (s, 2 H). MS obsd. (ESf) [(M+H)⁺] : 323.

Example 46: 6-(4-benzyloxyphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

Step 1: Preparation of 8-(4-benz loxyphenyl)-l,4-dioxa-8-azaspiro[4.5]decane

To a flask containing l-benzyloxy-4-iodo-benzene (5000 mg, 16.1 mmol) and l,4-dioxa-8- azaspiro[4.5]decane (2500 mg, 17.7 mmol) in dioxane (20 mL) was added i-BuONa (12700 mg, 32.2 mmol), Pd₂(dba)3 (732 mg, 0.8 mmol) and Sphos (656 mg, 1.6 mmol) under N₂. After being heated with stirring at 100 °C overnight, the resulting mixture was cooled to rt, diluted with H₂0 (50 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL) and dried over anhydrous Na₂S0₄ and concentrate in vacuo to give 8-(4- benzyloxyphenyl)-l,4-dioxa-8-azaspiro[4.5]decane (5700 mg), which was used in the next step without further purification.

Step 2: Preparation of l-(4-benzyloxyphenyl)piperidin-4-one

A mixture of crude 8-(4-benzyloxyphenyl)-l,4-dioxa-8-azaspiro[4.5]decane (3200 mg, 9.85 mmol) in 44% formic acid (10 mL) was heated with stirring at 90 °C for 8 hrs. The resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(4- benzyloxyphenyl)piperidin-4-one (2500 mg) as brown oil, which was used in the next step without further purification.

Step 3: Preparation of 6-(4-benzyloxyphenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

A mixture of l-(4-benzyloxyphenyl)piperidin-4-one (700 mg, 2.49 mmol) and DMFDMA (10 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20 mL). To the solution was added pyridine-2-carboxamidine hydrochloride (393 mg, 2.49 mmol) and K₂C0₃ (677 mg, 4.98 mmol) successively. After being heated with stirring at 80 °C overnight, the resulting reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(4-benzyloxyphenyl)-2-(2- pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (850 mg). 1H NMR (400 MHz, CDC1₃): δ 8.80 - 8.91 (m, 1 H), 8.64 - 8.71 (m, 1 H), 8.49 - 8.57 (m, 1 H), 7.81 - 7.93 (m, 1 H), 7.30 - 7.51 (m, 6 H), 6.93 - 7.09 (m, 4 H), 5.06 (s, 2 H), 4.36 (s, 2 H), 3.59 (s, 2 H), 3.24 - 3.32 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 395.

Example 47: 6-^-tolyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine

Step 1: Preparation of 8-(p-tolyl -l,4-dioxa-8-azaspiro[4.5]decane

To a flask containing l-iodo-4-methyl -benzene (1500 mg, 6.88 mmol) and l,4-dioxa-8- azaspiro[4.5]decane (1080 mg, 7.57 mmol) in dioxane (20 mL) was added i-BuONa (1320 mg, 13.76 mmol), Pd₂(dba)₃ (311 mg, 0.34 mmol) and Sphos (283 mg, 0.68 mmol) under N₂. After being heated with stirring at 100 °C overnight, the resulting reaction mixture was cooled to rt, diluted with H₂0 (50 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL) and dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 8-(p-tolyl)-l,4-dioxa-8-azaspiro[4.5]decane (1450 mg), which was used in the next step without further purification.

Step 2: Preparation of l-(p-tolyl)piperidin-4-one

To a flask containing crude 8-(p-tolyl)-l,4-dioxa-8-azaspiro[4.5]decane (1.45 g, 6.22 mmol) was added 44% formic acid (10 mL). After being heated with stirring at 90 °C for 8 hrs, the resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(p-tolyl)piperidin-4-one (1.0 g) as brown oil, which was used in the next step without further purification.

Step 3: Preparation of 6-(p-tolyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

A mixture of l-(p-tolyl)piperidin-4-one (500 mg, 2.65 mmol) and DMFDMA (10 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20mL). To the solution was added pyridine-2- carboxamidine hydrochloride (418 mg, 2.65 mmol) and K₂C0₃ (731 mg, 5.3 mmol) successively. After being heated with stirring at 80 °C overnight, the resulting reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(p-tolyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine (15 mg). 1H NMR (400 MHz, CDC1₃): δ 8.83 - 8.90 (m, 1 H), 8.70 (s, 1 H), 8.49 - 8.56 (m, 1 H), 7.83 - 7.92 (m, 1 H), 7.37 - 7.46 (m, 1 H), 7.11 - 7.20 (m, 2 H), 6.95 - 7.02 (m, 2 H), 4.42 (s, 2 H), 3.66 (t, 2 H), 3.29 (t, 2 H), 2.32 (s, 3 H). MS obsd. (ESI⁺) [(M+H)⁺]: 303.

Example 48: 8-methyl-6-(4-nitrophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

Step 1: Preparation of l-benzyl-3-methyl-piperidin-4-one

To a solution of l-benzylpiperidin-4-one (5.50 g, 29.1 mmol) in THF (100 mL) was added NaH (1700 mg, 60% in mineral oil, 43.7 mmol) at 0 °C. The resulting mixture was stirred at 0 °C for 30 minutes. To the resulting mixture was added Mel (6200 mg, 43.7 mmol) at 0 °C. After being heated with stirring at 60 °C overnight, the resulting reaction mixture was cooled to rt, diluted with sat. aqueous solution of NH₄C1 (50 mL) and extracted with EA (50 mL) for three times. The combined organic layer was dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column (eluting with 1% MeOH in DCM) to give l-benzyl-3- methyl-piperidin-4-one (2.50 g).

Step 2: Preparation of 6-benzyl-8-methyl-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

A mixture of l-benzyl-3-methyl-piperidin-4-one (2.50 g, 12.32 mmol) and DMFDMA (10 mL) was heated with stirring at 120 °C for 8 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20mL). To the solution was added pyridine-2- carboxamidine hydrochloride (1.95 g, 12.32 mmol) and K₂CO₃ (3.4 g, 24.64 mmol) successively. After being heated with stirring at 80 °C overnight, the resulting reaction mixture was cooled to rt, diluted with H₂0 (40 mL) and extracted with EA (50 mL) for three times. The combined organic layer was dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column to give 6-benzyl-8-methyl-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine (500 mg).

Step 3: Preparation of 8-methyl-2-(2-pyridyl)-5,6,7,8-tetrahydropyrido[4,3- d]pyrimidine

To a solution of 6-benzyl-8-methyl-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine

(500 mg, 1.58 mmol) in MeOH (15 mL) was added ammonium formate (995 mg, 15.8 mmol) and 5% Pd on charcoal (100 mg). After being degassed and heated with stirring at 80 °C overnight, the reaction was cooled to rt and filtered. The filtrate was concentrated in vacuo to give 8-methyl-2-(2-pyridyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine (200 mg), which was used directly in the next step without further purification.

Step 4: Preparation of 8-methyl-6-(4-nitrophenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

To a mixture of 8-methyl-2-(2-pyridyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine (100 mg, 0.44 mmol) and l-fluoro-4-nitro-benzene (186 mg, 1.32 mmol) in DMSO (5 mL) was added K₂CO₃ (120 mg, 0.88 mmol). After being heated with stirring at 80 °C for 3 hrs, The resulting reaction mixture was purified by prep-HPLC to give 8-methyl-6-(4-nitrophenyl)-2-(2-pyridyl)- 7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (10 mg). 1H NMR (400 MHz, CDC1₃): δ 8.84 - 8.91 (m, 1 H), 8.79 (s, 1 H), 8.51 - 8.60 (m, 1 H), 8.19 - 8.27 (m, 2 H), 7.85 - 7.94 (m, 1 H), 7.41 - 7.47 (m, 1 H), 6.93 - 6.99 (m, 2 H), 4.61 - 4.78 (m, 2 H), 3.84 - 3.96 (m, 1 H), 3.63 - 3.74 (m, 1 H), 3.37 - 3.50 (m, 1 H), 1.58 (s, 3 H). MS obsd. (ESI⁺) [(M+H)⁺]: 348. Example 49: 6-(3,4-dichlorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

Step 1: Preparation of 8-(3,4-dichlorophenyl)-l,4-dioxa-8-azaspiro[4.5]decane

To a flask containing l,2-dichloro-4-iodo-benzene (1700 mg, 6.23 mmol) and l,4-dioxa-8- azaspiro[4.5]decane (1070 mg, 7.48 mmol) in dioxane (20 mL) was added i-BuONa (1200 mg, 12.46 mmol), Pd₂(dba)₃ (284 mg, 0.31 mmol) and Sphos (254 mg, 0.62 mmol) under N₂. After being heated with stirring at 100 °C overnight, the resulting mixture was cooled to rt, diluted with H₂0 (50 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 8-(3,4-dichlorophenyl)-l,4-dioxa-8-azaspiro[4.5]decane (700 mg), which was used in the next step without further purification.

Step 2: Preparation of l-(3,4-dichlorophenyl)piperidin-4-one

A mixture of 8-(3,4-dichlorophenyl)-l,4-dioxa-8-azaspiro[4.5]decane (700 mg, 2.43 mmol) and 44% formic acid (10 mL) was heated with stirring at 90 °C for 8 hrs. The reaction mixture was concentrated in vacuo and the residue was diluted with sat. aqueous solution of NaHC0₃ (20 mL). The resulting mixture was extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(3,4-dichlorophenyl)piperidin-4-one (590 mg) as brown oil, which was used in the next step without further purification.

Step 3: Preparation of 6-(3,4-dichlorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

A mixture of l-(3,4-dichlorophenyl)piperidin-4-one (590 mg, 2.42 mmol) and DMFDMA (10 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20mL). To the solution was added pyridine-2-carboxamidine hydrochloride (382 mg, 2.42 mmol) and K₂CO₃ (668 mg, 4.84 mmol) successively. After being heated with stirring at 80 °C overnight, the resulting reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(3,4-dichlorophenyl)-2-(2-pyridyl)-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine (15 mg). 1H NMR (400 MHz, CDC1₃): δ 8.83 - 8.91 (m, 1 H), 8.69 - 8.77 (m, 1 H), 8.50 - 8.56 (m, 1 H), 7.85 - 7.93 (m, 1 H), 7.40 - 7.46 (m, 1 H), 7.34 - 7.38 (m, 1 H), 7.08 - 7.11 (m, 1 H), 6.85 - 6.90 (m, 1 H), 4.43 - 4.51 (m, 2 H), 3.66 - 3.74 (m, 2 H), 3.24 - 3.34 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 357.

Example 50: 6-(4-methoxyphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

Step 1: Preparation of 8-(4-methox henyl)-l,4-dioxa-8-azaspiro[4.5]decane

To a flask containing l-iodo-4-methoxy-benzene(2.0 g, 8.5 mmol) and l,4-dioxa-8- azaspiro[4.5]decane (1.5 g, 10.2 mmol) in dioxane (30 mL) was added i-BuONa (1.60 g, 17 mmol), Pd₂(dba)₃ (366 mg, 0.4 mmol) and Sphos (328 mg, 0.8 mmol) under N₂. After being heated with stirring at 100 °C overnight, the resulting mixture was cooled to rt, diluted with H₂0 (50 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL) and dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 8-(4- methoxyphenyl)-l,4-dioxa-8-azaspiro[4.5]decane (1.5 g), which was used in the next step without further purification.

Step 2: Preparation of l-(4-methoxyphenyl)piperidin-4-one

A mixture of 8-(4-methoxyphenyl)-l,4-dioxa-8-azaspiro[4.5]decane (1.5 g, 6.02 mmol) and 44% formic acid (10 mL) was heated with stirring at 90 °C for 8 hrs. The resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(4- methoxyphenyl)piperidin-4-one (1.2 g) as brown oil, which was used in the next step without further purification.

Step 3: Preparation of 6-(4-methoxyphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

A mixture of l-(4-methoxyphenyl)piperidin-4-one (1.2 g, 5.85 mmol) and DMFDMA (10 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20 mL). To the solution was added pyridine-2- carboxamidine hydrochloride (924 mg, 5.85 mmol) and K₂C0₃ (1615 mg, 11.7 mmol) successively. After being heated with stirring at 80 °C overnight, the reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(4-methoxyphenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine (10 mg). 1H NMR (400 MHz, MeOH-d₄): δ 8.69 - 8.77 (m, 1 H), 8.62 - 8.68 (m, 1 H), 8.45 - 8.54 (m, 1 H), 7.88 - 7.99 (m, 1 H), 7.44 - 7.51 (m, 1 H), 7.00 - 7.07 (m, 2 H), 6.84 - 6.92 (m, 2 H), 4.31 - 4.37 (m, 2 H), 3.78 (s, 3 H), 3.52 - 3.61 (m, 2 H), 3.19 - 3.28 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 319.

Example 51:6-(3-bromo-4-fluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

Step 1: Preparation of 8-(3-bromo-4-fluoro-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane

To a flask containing 2-bromo-l-fluoro-4-iodo-benzene (4.0 g, 13.3 mmol) and 1,4-dioxa- 8-azaspiro[4.5]decane (2.09 g, 14.6 mmol) in N-methyl-2-pyrrolidone (50 mL) was added

K₂C0₃(3.67 g, 26.6 mmol), Cul (128 mg, 0.67 mmol) and L-proline (77 mg, 0.67 mmol) under N₂. After being heated with stirring at 120 °C overnight, the resulting mixture was cooled to rt, diluted with H₂0 (50 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash chromatography to give 8-(3-bromo-4-fluoro-phenyl)-l,4- dioxa-8-azaspiro[4.5]decane (1.4 g).

Step 2: Preparation of l-(3-bromo-4-fluoro-phenyl)piperidin

A mixture of 8-(3-bromo-4-fluoro-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane (1.4 g, 4.43 mmol) and 44% formic acid (10 mL) was heated with stirring at 90 °C for 8 hrs. The resulting reaction mixture was concentrated in vacuo, diluted with sat. NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(3-bromo-4-fluoro- phenyl)piperidin-4-one (1.2 mg) as brown oil, which was used in the next step without further purification.

Step 3: Preparation of 6-(3-bromo-4-fluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

A mixture of l-(3-bromo-4-fluoro-phenyl)piperidin-4-one (1.2 mg, 4.43 mmol) and DMFDMA (10 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20 mL). To the solution was added pyridine-2-carboxamidine hydrochloride (700 mg, 4.43 mmol) and K₂CO₃ (1220 mg, 8.86 mmol) successively. After being heated with stirring at 80 °C overnight, the resulting reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(3-bromo-4-fluoro-phenyl)-2-(2- pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (600 mg). 1H NMR (400 MHz, CDC1₃): δ 8.90 - 9.00 (m, 1 H), 8.73 (s, 1 H), 8.54 - 8.65 (m, 1 H), 7.90 - 8.04 (m, 1 H), 7.44 - 7.57 (m, 1 H), 7.19 - 7.23 (m, 1 H), 7.06 - 7.15 (m, 1 H), 6.92 - 7.00 (m, 1 H), 4.42 (s, 2 H), 3.62 - 3.70 (m, 2 H), 3.26 - 3.36 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 385.

Example 52:6-(4-bromo-3-fluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

Step 1: Preparation of 8-(4-bromo-3-fluoro- henyl)-l,4-dioxa-8-azaspiro[4.5]decane

A mixture of l-bromo-2-fluoro-4-iodo-benzene (100 mg, 0.33 mmol), l,4-dioxa-8- azaspiro[4.5]decane (53 mg, 0.37 mmol), K₂CO₃ (91 mg, 0.66 mmol), Cul (4 mg, 0.02 mmol) and L-Proline (2 mg, 0.02 mmol) in DMSO (1 mL) was heated with stirring under N₂ atmosphere at 120 "C overnight. The resulting reaction mixture was cooled to rt, diluted with water (5 ml) and extracted with EA (50 mL). The organic layer was washed w ith brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by column chromatography (eluting with 2.5% EA in PE) to give 8-(4-bromo-3-fluoro-phenyl)-l,4-dioxa-8- azaspiro[4.5]decane (50 mg).

Step 2: Preparation of l-(4-bromo-3-fluoro-phenyl)piperidin-4-one

A mixture of 8-(4-bromo-3-f uoro-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane (2.6 g, 8.2 mmol ), H₂0 ( 15 mL) and formic acid ( 15 mL) was heated with stirring at 90 "C overnight. The resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by column chromatography (eluting with 2.5% MeOH in DCM) to give l-(4-bromo-3- fluoro-phenyl)piperidin-4-one (1.9 g).

Step 3: Preparation of 6-(4-bromo-3-fluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

A mixture of l-(4-bromo-3-f uoro-phenyl)piperidin-4-one (0.35 g, 1.29 mmol) and DMFDMA (2 mL) in acetonitrile (8 mL) was heated with stirring at 90 °C for 2 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20mL). To the solution was added pyridine-2-carboxamidine hydrochloride (0.21 g, 1.35 mmol) and potassium carbonate (0.37 g, 2.70 mmol ) successively. After being heated with stirring at 90 "C overnight, the reaction mixture was cooled to rt, diluted with water (20 ml) and extracted with EA (20 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep- f I PLC to give 6- (4-bromo-3-fluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (10 mg). Ή

NMR (400MHz, CDC1₃): δ 8.96 - 8.81 (m, 1 H), 8.73 (s, 1 H), 8.53 (d, 1 H), 7.90 (dt, 1 H), 7.51 - 7.41 (m, 2 H), 6.79 (d, 1 H), 6.71 (d, 1 H), 4.47 (s, 2 H), 3.71 (t, 2 H), 3.29 (t, 7=5.8 Hz, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 385.

Example 53: 6-(4-benzyloxy-3-fluoro-phenyl)-2-(2-pyridyl)-7,8-dihydi

pyrido[4,3-d]pyrimidine

Step 1: Preparation of l-benzyloxy-4-bromo-2-fluoro-benzene

A mixture of 4-bromo-2-f uoro-phenol (3.0 g, 15.7 mmol), bromomethylbenzene (4.0 g, 23.6 mmol ) and potassium carbonate (4.3 g, 1 .4 mmol ) in acetonitrile (30 mL) was heated with stirring at 100 "C overnight. The resulting reaction mixture was cooled to rt, diluted with water (50 ml . ) and extracted w ith EA (30 mL) for three times. The combined organic layer was washed w ith brine, dried over anhydrous Na_^SC and concentrated in vacuo. The residue was purified by column chromatography (eluting with 2% EA in PE) to give l-benzyloxy-4-bromo-2-f uoro- benzene (3.89 g).

Step 2: Preparation of 8-(4-benzyloxy-3-fluoro-phenyl)-l,4-dioxa-8- azaspiro[4.5]decane

To a flask containing l-benzyloxy-4-bromo-2-fluoro-benzene (5.85 g, 20.82 mmol), 1,4- dioxa-8-azaspiro[4.5]decane (3.58 g, 24.98 mmol) in 1,4-dioxane (50 mL) was added i-BuONa (4.0g, 41 .64 mmol ) under N₂. After being heated with stirring at 100 "C overnight, the reaction mixture was cooled to rt. diluted w ith water (60 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 8-(4-benzyloxy-3-fluoro-phenyl)- l,4-dioxa-8-azaspiro[4.5]decane (7.85 g), which was used in the next step without purification.

Step 3: Preparation of l-(4-benzyloxy-3-fluoro-phenyl)piperidin-4-one

A mixture of 8-(4-benzyloxy-3-fluoro-phenyl)- l,4-dioxa-8-azaspiro[4.5]decane (7.85 g, 22.87 mmol ), H₂0 ( 15 mL ) and formic acid ( 15 mL) was heated with stirring at 90 "C overnight. The resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHCO ; and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by column chromatography (eluting with 2.5% MeOH in DCM) to give l-(4-benzyloxy- 3-f uoro-phenyl)piperidin-4-one (4.17 g).

Step 4: Preparation of 6-(4-benzyloxy-3-fluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

A mixture of l-(4-benzyloxy-3-fluoro-phenyl)piperidin-4-one (4.17 g, 13.94 mmol) and DMFDMA (20 mL) in acetonitrile (10 mL) was heated with stirring at 90 °C for 2 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (40 mL). To the solution was added pyridine-2-carboxamidine (1.8 g, 14.96 mmol) and potassium carbonate (4.1 g, 29.92 mmol ) successively. After being heated with stirring at 90 "C overnight, the resulting reaction mixture was cooled to rt, diluted with water (60 ml.) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by column

chromatography (eluting with 5% MeOH in DCM) to give 6-(4-benzyloxy-3-fluoro-phenyl)-2- (2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (2.33 g). 1H NMR (400MHz, CDC1₃): δ 8.96 - 8.85 (m, 1 H), 8.69 (s, 1 H), 8.53 (d, 1 H), 7.89 (t, 1 H), 7.52 - 7.32 (m, 6 H), 6.98 (t, 1 H), 6.85 (dd, 1 H), 6.77 - 6.63 (m, 1 H), 5.12 (s, 2 H), 4.38 (s, 2 H), 3.61 (t, 2 H), 3.28 (t, 2 H). MS obsd. (ESf) [(M+H)⁺] : 413.

Example 54: 6-(4-ethoxy-3-fluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

Step 1: Preparation of 2-fluoro-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]phenol

A mixture of 6-(4-benzyloxy-3-fluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine (2.33 g, 5.65 mmol), ammonium formate (3.56 g, 56.5 mmol) and Pd(OH)₂ (50 mg 0.36 mmol) in methanol (30 mL) was heated with stirring at 90 °C overnight. The resulting reaction mixture was cooled to rt and filtered. The filtrate was concentrated in vacuo to give 2- fluoro-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]phenol (4.0 g), which was used in the next step without further purification.

Step 2: Preparation of 6-(4-ethoxy-3-fluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

A mixture of 2-fluoro-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl] phenol (50 mg, 0.16 mmol), ethyl iodide (50 mg, 0.32 mmol) and potassium carbonate (44 mg, 0.32 mmol) in acetone (5 mL) was heated with sti ring at 85 "C for 5 hrs. The resulting reaction mixture was cooled to rt. diluted with water (10 mL) and extracted with EA (20 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to give 6-(4-ethoxy-3-fluoro- phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (10 mg). Ή NMR (400MHz, CDC1₃) δ: 8.87 (d, 1 H), 8.69 (s, 1H), 8.52 (d, 1 H), 7.88 (dt, 1 H), 7.42 (ddd, 1 H), 6.96 (t, 1 H), 6.85 (dd, 1 H), 6.79 - 6.65 (m, 1 H), 4.38 (s, 2H), 4.09 (q, 2 H), 3.61 (t, 2 H), 3.28 (t, 2 H), 1.44 (t, 3 H). MS obsd. (ESI⁺) [(M+H)⁺] : 351.

Example 55: 6-(3-fluoro-4-propoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

A mixture of 2-fluoro-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl] phenol (200 mg, 0.62 mmol ), iodopropane (320 mg, 1 .86 mmol ) and potassium carbonate (171 mg, 1.24 mmol ) in acetone (5 mL) was heated with stirring at 85 "C for 5 hrs. The reaction mixture was cooled to rt, diluted with water (10 ml. ) and extracted with EA (30 mL) for three times. The combined organic layer was washed ith brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to gi ve 6-(3-fluoro-4-propoxy- phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (6 mg ). Ή NMR (400MHz, CDC1₃): δ 8.87 (d, 1 H), 8.70 (s, 1 H), 8.52 (d, 1 H), 7.88 (dt, 1 H), 7.42 (t, 1 H), 6.96 (t, 1 H), 6.85 (dd, 1 H), 6.73 (ddd, 1 H), 4.37 (s, 2 H), 3.98 (t, 2 H), 3.61 (t, 2 H), 3.28 (t, 2 H), 1.84 (sxt, 2 H), 1.06 (t, 3 H). MS obsd. (ESI⁺) [(M+H)⁺] : 365.

Example 56 :6- [3-fluoro-4-(3-methoxypropoxy)phenyl] -2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

A mixture of 2-fluoro-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl]phenol (200 mg, 0.62 mmol), l-bromo-3-methoxy-propane (280 mg, 1.86 mmol) and potassium carbonate (257 mg, 1 .86 mmol ) in acetone (5 mL) was heated with stirring at 85 "C for 5 hrs. The resulting reaction mixture was cooled to rt. diluted with water (10 ml .) and extracted ith EA (30 mL) for three times. The combined organic layer was washed with bri e dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep- HPLC to give 6-[3-fluoro-4-(3-methoxypropoxy)phenyl]-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine (6 mg). Ή NMR (400MHz, CDCl : δ 8.87 (d, 1 H), 8.70 (s, 1 H), 8.53 (d, 1 H), 7.88 (dt, 1 H), 7.42 (ddd, 1 H), 6.98 (t, 1 H), 6.85 (dd, 1 H), 6.79 - 6.51 (m, 1 H), 4.38 (s, 2 H), 4.12 (t, 2 H), 3.60 (q, 4 H), 3.38 (s, 3 H), 3.29 (t, 2 H), 2.08 (q, 2 H). MS obsd. (ESf)

[(M+H)⁺]: 395.

Example 57: 6-[3-methoxy-4-(2-methoxyethoxy)phenyl]-2-(2-pyridyl)-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine

Step 1: Preparation of 4-bromo-2-methox -l-(2-methoxyethoxy)benzene

A mixture of 4-bromo-2-methoxy-phenol (1.0 g, 4.93 mmol), l-bromo-2-methoxy-ethane ( 1 .4 mL, 14.78 mmol ) and potassium carbonate (2.0 g, 14.78 mmol ) in DMF ( 15 mL) was heated with stirring at 120 "C for 4 hrs. The resulting reaction mixture was cooled to rt, diluted with water (30 mL) and extracted ith EA (20 mL) for three times. The combined organic layer was washed w ith brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 4-bromo-2- methoxy-l-(2-methoxyethoxy)benzene (1.3 g), which was used in the next step without purification.

Step 2: Preparation of 8-[3-methoxy-4-(2-methoxyethoxy)phenyl]-l,4-dioxa-8- azaspiro[4.5]decane

To a flask containing 4-bromo-2-methoxy-l-(2-methoxyethoxy)benzene (1.30 g, 4.98 mmol) and l,4-dioxa-8-azaspiro[4.5]decane (0.86 g, 5.98 mmol) in 1,4-dioxane (15 ml) was added i-BuONa (0.96 g, 9.96 mmol), Pd₂(dba)₃ (92 mg, 0.10 mmol) and Ru-Phos (93 mg, 0.20 mmol under N₂. After being heated with stirring at 100 "C overnight, the resulting reaction mixture was cooled to rt, diluted w ith water (20 mL) and e tracted w ith EA (20 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na_^SC and concentrated in vacuo to give 8-[3-methoxy-4-(2-methoxyethoxy)phenyl]-l,4-dioxa-8- azaspiro[4.5]decane (2.1 g), which was used in the next step without purification.

Step 3: Preparation of l-[3-methoxy-4-(2-methoxyethoxy)phenyl]piperidin-4-one

To a flask containing 8-[3-methoxy-4-(2-methoxyethoxy)phenyl]-l,4-dioxa-8- azaspiro[4.5]decane (2.10 g, 6.50 mmol) was added H₂0 (15 mL) and formic acid (15 mL).

After being heated with stirring at 90 °C overnight, the resulting reaction mixture was

concentrated in vacuo, diluted with sat. aqueous solution of NaHCO . and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-[3-methoxy-4-(2-methoxyethoxy)phenyl]piperidin- 4-one (1.0 g), which was used in the next step without purification.

Step 4: Preparation of 6-[3-methoxy-4-(2-methoxyethoxy)phenyl]-2-(2-pyridyl)-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine

A mixture of l-[3-methoxy-4-(2-methoxyethoxy)phenyl]piperidin-4-one (1.0 g, 3.58 mmol) and DMFDMA (2 mL) in acetonitrile (8 mL) was heated with stirring at 90 °C for 2 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20 mL). To the solution was added pyridine-2-carboxamidine hydrochloride (0.56 g, 3.57 mmol) and potassium carbonate (0.98 g, 7. 13 mmol) successively. After being heated with stirring at 90 "C overnight, the resulting reaction mixture was cooled to rt, diluted with water (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep- HP LC to give 6-[3-methoxy-4-(2-methoxyethoxy)phenyl]-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine. 1H NMR (400MHz, CDC1₃): δ 8.87 (d, 1 H), 8.69 (s, 1 H), 8.53 (d,

7=8.0 Hz, 1 H), 7.88 (dt, 1 H), 7.42 (t, 1 H), 6.92 (d, 1 H), 6.69 (d, 1 H), 6.56 (dd, 1 H), 4.38 (s, 2 H), 4.16 (dd, 2 H), 3.91 (s, 3 H), 3.78 (dd, 2 H), 3.61 (t, 2 H), 3.47 (s, 3 H), 3.30 (t, 2 H). MS obsd. (ESf) [(M+H)⁺]: 393.

Example 58: 6-[4-methoxy-3-(2-methoxyethoxy)phenyl]-2-(2-pyridyl)-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine

Step 1: Preparation of 4-bromo-l-methox -2-(2-methoxyethoxy)benzene

A mixture of 5-bromo-2-methoxy-phenol (0.50 g, 2.46 mmol), l-bromo-3-methoxy- propane (1.03 g, 7.39 mmol ) and potassium carbonate (1.02 g, 7.39 mmol ) in DMF (5 mL) was heated with stirring at 120 "C for 4 hrs. The resulting reaction mi ture was cooled to rt, diluted with water (15 mL) and extracted with EA (20 mL) for three times. The combined organic layer was washed ith brine, dried over anhydrous Na_^SC and concentrated in vacuo to give 4- bromo-l-methoxy-2-(2-methoxyethoxy)benzene (0.65 g), which was used in the next step without further purification.

Step 2: Preparation of 8-[4-methoxy-3-(2-methoxyethoxy)phenyl]-l,4-dioxa-8- azaspiro[4.5]decane

To a flask containing 4-bromo-l-methoxy-2-(2-methoxyethoxy)benzene (0.65 g, 2.48 mmol) and l,4-dioxa-8-azaspiro[4.5]decane (0.43 g, 2.98 mmol) in 1,4-dioxane (10 ml) was added i-BuONa (0.48 g, 4.96 mmol), Pd₂(dba)₃ (46 mg, 0.05 mmol) and Ru-Phos (46 mg, 0.10 mmol ) under N₂. After being heated with stirring at 100 "C overnight, the resulting reaction mixture was cooled to rt, diluted w ith water (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed w ith brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 8-[4-methoxy-3-(2-methoxyethoxy)phenyl]-l,4-dioxa-8- azaspiro[4.5]decane (0.78 g), which was used in the next step without further purification. Step 3: Preparation of l-[4-methoxy-3-(2-methoxyethoxy)phenyl]piperidin-4-one

\

O

To a flask containing 8-[4-methoxy-3-(2-methoxyethoxy)phenyl]-l,4-dioxa-8- azaspiro[4.5]decane (0.78 g, 2.41 mmol) was added H₂0 (2 mL) and formic acid (2 mL). After being heated with stirring at 90 "C overnight, the resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-[4-methoxy-3-(2-methoxyethoxy)phenyl]piperidin-4-one (0.7 g), which was used in the next step without further purification.

Step 4: Preparation of 6-[4-methoxy-3-(2-methoxyethoxy)phenyl]-2-(2-pyridyl)-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine

A mixture of l-[4-methoxy-3-(2-methoxyethoxy)phenyl]piperidin-4-one (0.7 g, 2.50 mmol) and DMFDMA (2 mL) in acetonitrile (8 mL) was heated with stirring at 90 °C for 2 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (lOmL). To the solution was added pyridine-2-carboxamidine hydrochloride (0.34 g, 2.15 mmol) and potassium carbonate (0.59 g. 4.30 mmol ) successively. After being heated with stirring at 90 "C overnight, the reaction mixture was cooled to rt, diluted with water (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep- H PLC to give 6- [4-methoxy-3-(2-methoxyethoxy)phenyl]-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (44 mg). 1H NMR (400MHz, DMSO-J₆): δ 8.79 (s, 1 H), 8.74 (td, 1 H), 8.36 (d, 1 H), 7.96 (dt, 1 H), 7.52 (ddd, 1 H), 6.87 (d, 1 H), 6.80 (d, 1 H), 6.57 (dd, 1 H), 4.38 (s, 2 H), 4.12 (dd, 2 H), 3.71 - 3.64 (m, 5 H), 3.59 (t, 2 H), 3.33 (s, 3 H), 3.09 (t, 2 H). MS obsd. (ESf) [(M+H)⁺]: 393.

Example 59: 6-(3,4-dimethoxyphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

Step 1: Preparation of 8-(3,4-dimethoxyphenyl)-l,4-dioxa-8-azaspiro[4.5]decane

To a flask containing 4-bromo-l,2-dimethoxy-benzene (1.1 g, 5.1 mmol) and l,4-dioxa-8- azaspiro[4.5]decane (800 mg, 5.6 mmol) in dioxane (20 mL) was added i-BuONa (980 mg, 10.2 mmol), Pd₂(dba)₃ (239 mg, 0.26 mmol) and Sphos (209 mg, 0.51 mmol) under N₂. After being heated with stirring at 100 °C overnight, the resulting mixture was cooled to rt, diluted with H₂0 (50 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 8-(3,4- dimethoxyphenyl)-l,4-dioxa-8-azaspiro[4.5]decane (1.3 g), which was used in the next step without further purification.

Step 2: Preparation of l-(3,4-dimethoxyphenyl)piperidin-4-one

A mixture of 8-(3,4-dimethoxyphenyl)-l,4-dioxa-8-azaspiro[4.5]decane (1.3 g, 4.66 mmol) and 44% formic acid (10 mL) was heated with stirring at 90 °C for 8 hrs. The resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(3,4- dimethoxyphenyl)piperidin-4-one (1.1 g) as brown oil, which was used in the next step without further purification.

Step 3: Preparation of 6-(3,4-dimethoxyphenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

A mixture of l-(3,4-dimethoxyphenyl)piperidin-4-one (1.1 g, 4.68 mmol) and DMFDMA (10 mL) was heated with stirring at 90 °C for 3 hrs. The reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20 mL). To the solution was added pyridine-2- carboxamidine hydrochloride (739 mg, 4.68 mmol) and K₂CO₃ (1.29 g, 9.36 mmol) successively. After being heated with stirring at 80 °C overnight, the resulting reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(3,4-dimethoxyphenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine (800 mg). 1H NMR (400 MHz, CDC1₃) δ: 8.81 - 8.89 (m, 1 H), 8.68 (s, 1 H), 8.48 - 8.55 (m, 1 H), 7.82 - 7.91 (m, 1 H), 7.36 - 7.44 (m, 1 H), 6.81 - 6.88 (m, 1 H), 6.67 - 6.72 (m, 1 H), 6.54 - 6.62 (m, 1 H), 4.36 (s, 2 H), 3.80 - 3.98 (m, 6 H), 3.54 - 3.62 (m, 2 H), 3.25 - 3.32 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 349.

Example 60: 2-methoxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl]benzonitrile

Step 1: Preparation of 4-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-methoxy-benzonitrile

To a flask containing 4-bromo-2-methoxy-benzonitrile (500 mg, 2.37 mmol) and 1,4- dioxa-8-azaspiro[4.5]decane (374 mg, 2.61 mmol) in dioxane (10 mL) was added i-BuONa (455 mg, 4.74 mmol), Pd₂(dba)₃ (174 mg, 0.19 mmol) and Sphos (156 mg, 0.38 mmol) under N₂. After being heated with stirring at 100 °C overnight, the resulting reaction mixture was cooled to rt, diluted with H₂0 (50 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 4-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-methoxy-benzonitrile (650 mg), which was used in the next step without further purification.

Step 2: Preparation of 2-methox -4-(4-oxo-l-piperidyl)benzonitrile

A mixture of 4-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-methoxy-benzonitrile (650 mg,

2.37 mmol) and 44% formic acid (10 mL) was heated with stirring at 90 °C for 8 hrs. The resulting reaction mi ture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 2-methoxy-4-(4-oxo-l-piperidyl)benzonitrile (540 mg) as brown oil, which was used in the next step without further purification.

Step 3: Preparation of 2-methoxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]benzonitrile

A mixture of 2-methoxy-4-(4-oxo-l-piperidyl)benzonitrile (540 mg, 2.37 mmol) and

DMFDMA (10 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20mL). To the solution was added pyridine-2-carboxamidine hydrochloride (374 mg, 2.37 mmol) and K₂C0₃ (654 mg, 4.74 mmol) successively. After being heated with stirring at 80 °C overnight, the resulting reaction mixture was cooled to rt and purified by prep-HPLC to give 2-methoxy-4-[2-(2-pyridyl)-7,8- dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzonitrile (160 mg).¹H NMR (400 MHz, CDC1₃): δ 8.86 - 8.97 (m, 1 H), 8.73 - 8.82 (m, 1 H), 8.52 - 8.61 (m, 1 H), 7.88 - 7.99 (m, 1 H), 7.42 - 7.54 (m, 2 H), 6.52 - 6.61 (m, 1 H), 6.40 - 6.47 (m, 1 H), 4.62 (s, 2 H), 3.98 (s, 3 H), 3.80 - 3.87 (m, 2 H), 3.29 - 3.37 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 344.

Example 61 : 6-(2,3-difluoro-4-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihyd]

pyrido[4,3-d]pyrimidine

Step 1: Preparation of 8-(2,3-difluoro-4-methoxy-phenyl)-l,4-dioxa-8- azaspiro[4.5]decane

To a flask containing l-bromo-2,3-difluoro-4-methoxy-benzene (500 mg, 2.25 mmol) and l,4-dioxa-8-azaspiro[4.5]decane (355 mg, 2.48 mmol) in dioxane (10 mL) was added i-BuONa (432 mg, 4.5 mmol) under N₂. After being heated with stirring at 100 °C overnight, the resulting reaction mixture was cooled to rt, diluted with H₂0 (30 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (30 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to afford 8-(2,3-difluoro-4-methoxy-phenyl)-l,4-dioxa-8- azaspiro[4.5]decane (600 mg), which was used in the next step without further purification.

Step 2: Preparation of l-(2,3-difluoro-4-methoxy-phenyl)piperidin-4-one

A mixture of 8-(2,3-difluoro-4-methoxy-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane (600 mg, 2.1 mmol) and 44% formic acid (10 mL) was heated with stirring at 90 °C for 8 hrs. The reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(2,3-difluoro-4- methoxy-phenyl)piperidin-4-one (500 mg) as brown oil, which was used in the next step without further purification.

Step 3: Preparation of 6-(2,3-difluoro-4-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine

A mixture of l-(2,3-difluoro-4-methoxy-phenyl)piperidin-4-one (500 mg, 2.1 mmol) and DMFDMA (10 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (10 mL). To the solution was added pyridine-2-carboxamidine hydrochloride (330 mg, 2.1 mmol) and K₂CO₃ (580 mg, 4.2 mmol) successively. After being heated with stirring at 80 °C overnight, the reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(2,3-difluoro-4-methoxy-phenyl)-2-(2- pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (30 mg). 1H NMR (400 MHz, CDC1₃): δ 8.80 - 8.93 (m, 1 H), 8.62 - 8.70 (m, 1 H), 8.47 - 8.57 (m, 1 H), 7.83 - 7.93 (m, 1 H), 7.37 - 7.47 (m, 1 H), 6.62 - 6.82 (m, 2 H), 4.31 (s, 2 H), 3.90 (s, 3 H), 3.46 - 3.57 (m, 2 H), 3.24 - 3.34 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 356.

Example 62: 6-(4-chloro-3-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

Step 1: Preparation of 8-(4-chloro-3-methoxy-phenyl)-l,4-dioxa-8- azaspiro[4.5]decane

To a flask containing 4-bromo-l-chloro-2-methoxy-benzene (550 mg, 2.5 mmol) and 1,4- dioxa-8-azaspiro[4.5]decane (393 mg, 2.75 mmol) in dioxane (10 mL) was added i-BuONa (720 mg, 7.5 mmol), Pd₂(dba)₃ (119 mg, 0.13 mmol) and Sphos (103 mg, 0.26 mmol) under N₂. After being heated with stirring at 100 °C overnight, the resulting reaction mixture was cooled to rt, diluted with H₂0 (30 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (30 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 8-(4-chloro-3-methoxy-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane (710 mg), which was used in the next step without further purification.

Step 2: Preparation of l-(4-chloro-3-methoxy-phenyl)piperidin-4-one

A mixture of 8-(4-chloro-3-methoxy-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane (710 mg, 2.5 mmol) and 44% formic acid (10 mL) was heated with stirring at 90 °C for 8 hrs. The resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(4-chloro-3-methoxy-phenyl)piperidin-4-one (600 mg) as brown oil, which was used in the next step without further purification.

Step 3: Preparation of 6-(4-chloro-3-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

A mixture of l-(4-chloro-3-methoxy-phenyl)piperidin-4-one (600 mg, 2.5 mmol) and DMFDMA (10 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (10 mL). To the solution was added pyridine-2-carboxamidine hydrochloride (395 mg, 2.5 mmol) and K₂C0₃ (690 mg, 5.0 mmol) successively. After being heated with stirring at 80 °C overnight, the resulting reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(4-chloro-3-methoxy-phenyl)-2-

(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (15 mg). 1H NMR (400 MHz, CDC1₃): δ 8.84 - 8.92 (m, 1 H), 8.72 (s, 1 H), 8.48 - 8.59 (m, 1 H), 7.84 - 7.94 (m, 1 H), 7.39 - 7.48 (m, 1 H), 7.24 - 7.32 (m, 1 H), 6.52 - 6.66 (m, 2 H), 4.45 (s, 2 H), 3.95 (s, 3 H), 3.64 - 3.75 (m, 2 H), 3.23 - 3.35 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 353.

Example 63: 6-[3-(difluoromethoxy)phenyl]-2-pyrimidin-2-yl-7,8-dihyd]

pyrido[4,3-d]pyrimidine

Step 1: Preparation of 8-[3-(difluoromethoxy)phenyl]-l,4-dioxa-8-azaspiro[4.5]decane

To a flask containing l-bromo-3-(difluoromethoxy)benzene (350 mg, 1.58 mmol) and 1,4- dioxa-8-azaspiro[4.5]decane (249 mg, 1.74 mmol) in dioxane (10 mL) was added i-BuONa (303 mg, 3.16 mmol), under N₂ After being heated with stirring at 100 °C overnight, the resulting reaction mixture was cooled to rt, diluted with H₂0 (30 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (30 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 8-[3-(difluoromethoxy)phenyl]-l,4-dioxa-8- azaspiro[4.5]decane (450 mg), which was used in the next step without further purification.

Step 2: Preparation of l-[3-(difluoromethoxy)phenyl]piperidin-4-one

F

A mixture of 8-[3-(difluoromethox ^Fy)ph tenylx]-l,4-dioxa-8-azaspiro[4.5]decane (450 mg, 1.58 mmol) and 44% formic acid (10 mL) was heated with stirring at 90 °C for 8 hrs. The resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-[3-(difluoromethoxy)phenyl]piperidin-4-one (380 mg) as brown oil, which was used in the next step without further purification.

Step 3: Preparation of 6-[3-(difluoromethoxy)phenyl]-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

A mixture of l-[3-(difluoromethoxy)phenyl]piperidin-4-one (380 mg, 1.58 mmol) and DMFDMA (10 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (10 mL). To the solution was added pyrimidine-2-carboxamidine hydrochloride (250 mg, 1.58 mmol) and K₂CO₃ (436 mg, 3.16 mmol) successively. After being heated with stirring at 80 °C overnight, the resulting reaction mixture was cooled to rt and purified by prep-HPLC to give 6- [3- (difluoromethoxy)phenyl]-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (20 mg). 1H NMR (400 MHz, DMSO-J₆): δ 3.09 (t, 2 H), 3.76 (s, 2 H), 4.58 (s, 2 H), 6.59 (dd, 1 H), 6.80 - 6.88 (m, 1 H), 6.92 - 7.00 (m, 1 H), 7.21 - 7.34 (m, 2 H), 7.64 (t, 1 H), 8.85 (s, 1 H), 9.00 (d, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 356.

Example 64: 6-(4-benzyloxy-3,5-difluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

Step 1: Preparation of 8-(4-benzyloxy-3,5-difluoro-phenyl)-l,4-dioxa-8- azaspiro[4.5]decane

To a flask containing 2-benzyloxy-5-bromo-l,3-difluoro-benzene (500 mg, 1.67 mmol) and l,4-dioxa-8-azaspiro[4.5]decane (263 mg, 1.84 mmol) in dioxane (10 mL) was added t- BuONa (320 mg, 3.34 mmol), Pd₂(dba)₃ (73 mg, 0.08 mmol) and Ruphos (74 mg, 0.16 mmol) under N₂. After being heated with stirring at 100 °C overnight, the resulting reaction mixture was cooled to rt, diluted with H₂0 (30 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (30 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 8-(4-benzyloxy-3,5-difluoro-phenyl)-l,4-dioxa-8- azaspiro[4.5]decane (600 mg), which was used in the next step without further purification.

Step 2: Preparation of l-(4-benzyloxy-3,5-difluoro-phenyl)piperidin-4-one

A mixture of 8-(4-benzyloxy-3,5-difluoro-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane (600 mg, 1.67 mmol) and 44% formic acid (10 mL) was heated with stirring at 90 °C for 8 hrs. The resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(4-benzyloxy-3,5-difluoro-phenyl)piperidin-4-one (530 mg) as brown oil, which was used in the next step without further purification.

Step 3: Preparation of 6-(4-benzyloxy-3,5-difluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine

A mixture of l-(4-benzyloxy-3,5-difluoro-phenyl)piperidin-4-one (530 mg, 1.67 mmol) and DMFDMA (10 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (10 mL). To the solution was added pyridine-2-carboxamidine hydrochloride (250 mg, 1.67 mmol) and K₂C0₃ (460 mg, 3.34 mmol) successively. After being heated with stirring at 80 °C overnight, the resulting reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(4-benzyloxy- 3,5-difluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (50 mg). 1H NMR (400 MHz, MeOH-d₄): δ 8.72 - 8.80 (m, 2 H), 8.48 - 8.58 (m, 1 H), 7.97 - 8.05 (m, 1 H), 7.51 - 7.60 (m, 1 H), 7.39 - 7.46 (m, 2 H), 7.29 - 7.39 (m, 3 H), 6.67 - 6.78 (m, 2 H), 5.05 (s, 2 H), 4.46 (s, 2 H), 3.63 - 3.75 (m, 2 H), 3.16 - 3.25 (m, 2 H). MS obsd. (ESf) [(M+H)⁺]: 431.

Example 65: 2-methoxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl] benzoic acid

Step 1: Preparation of methyl 4-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-methoxy- benzoate

To a flask containing methyl 4-bromo-2-methoxy-benzoate (500 mg, 2.0 mmol) and 1,4- dioxa-8-azaspiro[4.5]decane (340 mg, 2.4 mmol) in dioxane (10 mL) was added i-BuONa (384 mg, 4.0 mmol), Pd₂(dba)₃ (37 mg, 0.04 mmol) and Sphos (33 mg, 0.08 mmol) under N₂. After being heated with stirring at 100 °C overnight, the resulting reaction mixture was cooled to rt, diluted with H₂0 (30 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (30 mL) and dried over anhydrous Na₂S0₄ and concentrated in vacuo to give methyl 4-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-methoxy-benzoate (600 mg), which was used in the next step without further purification.

Step 2: Preparation of methyl 2-methox -4-(4-oxo-l-piperidyl)benzoate

A mixture of methyl 4-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-methoxy-benzoate (600 mg 2.0 mmol) and 44% formic acid (10 mL) was heated with stirring at 90 °C for 8 hrs. The resulting reaction mixture was concentrated in vacuo, diluted with sat. NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give methyl 2-methoxy-4- (4-oxo- l-piperidyl)benzoate (530 mg) as brown oil, which was used in the next step without further purification.

Step 3: Preparation of 2-methoxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]benzoic acid

A mixture of methyl 2-methoxy-4-(4-oxo-l-piperidyl)benzoate (530 mg, 2.0 mmol) and DMFDMA (10 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (10 mL). To the solution was added pyridine-2-carboxamidine hydrochloride (320 mg, 2.0 mmol) and K₂CO₃ (552 mg, 4.0 mmol) successively. After being heated with stirring at 80 °C overnight, the resulting reaction mixture was cooled to rt and purified by prep-HPLC to give 2-methoxy-4-[2-(2-pyridyl)-7,8- dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzoic acid (10 mg). 1H NMR (400 MHz, MeOH-d₄): δ 8.82 (s, 1 H), 8.71 - 8.78 (m, 1 H), 8.51 - 8.58 (m, 1 H), 7.97 - 8.06 (m, 1 H), 7.83 - 7.90 (m, 1 H), 7.51 - 7.59 (m, 1 H), 6.65 - 6.79 (m, 2 H), 4.71 (s, 2 H), 3.98 - 4.05 (m, 3 H), 3.87 - 3.95 (m, 2 H), 3.20 - 3.28 (m, 2 H). MS obsd. (ESI^1") [(M+H)⁺] : 363.

Example 66: 2-ethoxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl] benzoic acid

Step 1: Preparation of methyl 4-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-hydroxy- benzoate

H O A mixture of methyl 4-bromo-2-hydroxy-benzoate (100 mg, 0.43 mmol), l,4-dioxa-8- azaspiro[4.5]decane (74 mg, 0.52 mmol), Cs₂C0₃ (280 mg, 0.86 mmol), Pd₂(dba)₃ (8 mg, 0.009 mmol) and Ru-Phos (8 mg, 0.018 mmol) in toluene (10 mL) was heated with stirring at 100 °C overnight. The reaction mixture was cooled to rt, diluted with water (20 mL) and extracted with EA (20 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo to give methyl 4-(l,4-dioxa-8-azaspiro[4.5]decan- 8-yl)-2-hydroxy-benzoate (95 mg), which was used in the next step directly without further purification.

Step 2: Preparation of methyl 2-h droxy-4-(4-oxo-l-piperidyl)benzoate

To a flask containing methyl 4-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-hydroxy-benzoate (5.0 g, 17.0 mmol) was added to H₂0 (20 mL) and formic acid (20 mL). After being heated with stirring at 90 °C overnight, the resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ and extracted with EA (40 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by column chromatography (eluting with 2.5% MeOH in DCM) to give methyl 2-hydroxy-4-(4-oxo-l-piperidyl)benzoate (1.9 g).

Step 3: Preparation of ethyl 2-hydroxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]benzoate

A solution of methyl 2-hydroxy-4-(4-oxo-l-piperidyl)benzoate (1.9 g, 7.6 mmol) and DMFDMA (10 mL) in acetonitrile (10 mL) was heated with stirring at 90 °C for 2 hrs. The reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (10 mL). To the solution was added pyridine-2-carboxamidine hydrochloride (1.24 g, 7.86 mmol) and potassium carbonate (2.2 g, 15.72 mmol) successively. After being heated with stirring at 90 °C overnight, the resulting reaction mixture was cooled to rt, diluted with water (30mL) and extracted with EA (20 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by column chromatography (eluting with 2.5% MeOH in DCM) to give ethyl 2-hydroxy-4-[2-(2-pyridyl)- 7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzoate (1.2 g).

Step 4: Preparation of 2-hydroxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]benzoic acid

A mixture of ethyl 2-hydroxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yfjbenzoate (100 mg, 0.27 mmol) and LiOH (62 mg, 2.7 mmol) in a mixed solvent of THF (5 mL) and H₂0 (5 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was cooled to rt, diluted with 1.0 N HCl solution and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and

concentrated in vacuo to give crude 2-hydroxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]benzoic acid (100 mg), which was used in the next step without further purification.

Step 5: Preparation of ethyl 2-ethoxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]benzoate

A mixture of ethyl 2-hydroxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yfjbenzoate (100 mg, 0.26 mmol), ethyl bromide (142 mg, 1.30 mmol) and potassium carbonate ( 72 mg. 0.52 mmol) in DMF (3 mL) was heated with sti ring at 90 "C for 3 hrs. The resulting reaction mixture was cooled to rt. diluted with water (10 mL) and extracted with EA (20 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo to give ethyl 2-ethoxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]benzoate (100 mg), which was used in the next step without further purification.

Step 6: Preparation of 2-ethoxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]benzoic acid

A mixture of ethyl 2-ethoxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl]benzoate (100 mg, 0.25 mmol) and LiOH (119 mg, 4.94 mmol) in a mi ed solvent of THF (5 mL) and H₂0 (5 mL) was heated with stirring at 90 "C for 3 hrs. The resulting reaction mixture was cooled to rt, diluted with 1.0 N MCI solution and extracted with EA (20 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep- M PEC to give 2-ethoxy-4-[2-(2- pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzoic acid (13 mg). Ή NMR (400MHz, CDC1₃): δ 8.88 (d, 1 H), 8.77 (s, 1H), 8.55 (d, 1 H), 8.12 (d, 1 H), 7.91 (dt, 1 H), 7.45 (ddd, 1 H), 6.72 (dd, 1 H), 6.47 (d, 1H), 4.64 (s, 2 H), 4.38 (q, 2 H), 3.85 (t, 2 H), 3.33 (t, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 377.

Example 67: 2-butoxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl] benzoic acid

Step 1: Preparation of ethyl 2-butoxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]benzoate

A mixture of ethyl 2-hydroxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl]benzoate (100 mg, 0.26 mmol), butyl bromide (190 mg, 1.30 mmol) and potassium carbonate (72 mg, 0.52 mmol ) in DMF (3 mL) was heated with sti ring at 90 "C for 3 hrs. The resulting reaction mixture was cooled to rt, diluted with water (10 mL) and extracted with EA (20 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na_^SC and concentrated in vacuo to give ethyl 2-butoxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]benzoate (95 mg), which was used in the next step without further purification.

Step 2: Preparation of 2-butoxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]benzoic acid

A mixture of ethyl 2-butoxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yfjbenzoate (110 mg, 0.25 mmol ) and LiOH (119 mg. 4.94 mmol) in a mixed solvent of THF (5 mL) and H₂0 (5 mL) was heated with stirring at 90 "C for 3 hrs. The resulting reaction mixture was cooled to rt. diluted with 1.0 N MCI solution and extracted with EA (20 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to give 2-butoxy-4-[2-(2- pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzoic acid (8 mg). Ή NMR (400MHz, CDC1₃): δ 8.93 (d, 1 H), 8.78 (s, 1H), 8.60 (d, 1 H), 8.13 (d, 1 H), 8.00 (d, 1 H), 7.53 (dd, 1 H), 6.71 (dd, 1 H), 6.48 (d, 1 H), 4.65 (s, 2H), 4.30 (t, 2 H), 3.86 (t, 2 H), 3.33 (t, 2H), 1.93 (m, 2 H), 1.59 (m, 2 H), 1.06 (t, 3 H). MS obsd. (ESI⁺) [(M+H)⁺]: 405.

Example 68 and 69: 6-(5-chloro-4-methoxy-pyrimidin-2-yl)-2-(2-pyridyl)-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine and 6-(5-chloro-2-methoxy-pyrimidin-4-yl)-2-(2-pyridyl)-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine

Example 68 Example 69

Step 1: Preparation of 2,5-dichloro-4-methoxy-pyrimidine and 4,5-dichloro-2- methoxy-pyrimidine

To a solution of 2,4,5-trichloropyrimidine (5.0 g, 27.26 mmol) in MeOH (30 mL) was added MeONa (1.47 g, 27.26 mmol). The resulting mixture was stirred at rt overnight. The resulting reaction mixture was purified by flash column to give a mixture of 2,5-dichloro-4- methoxy-pyrimidine and 4,5-dichloro-2-methoxy-pyrimidine (total 3.1 g).

Step 2: Preparation of 8-(5-chloro-4-methoxy-pyrimidin-2-yl)-l,4-dioxa-8- azaspiro[4.5]decane and 8-(5-chloro-2-methoxy-pyrimidin-4-yl)-l,4-dioxa-8- azaspiro[4.5]decane

To a solution of a mixture of 2,5-dichloro-4-methoxy-pyrimidine and 4,5-dichloro-2- methoxy-pyrimidine (totall.2 g, 6.74 mmol), and l,4-dioxa-8-azaspiro[4.5]decane (1.06 g, 7.41 mmol) in dioxane (40 mL) was added CS₂CO₃ (4.38 g, 13.48 mmol) under N₂. After being heated with stirring at 100 °C overnight, the resulting reaction mixture was cooled to rt, diluted with H₂0 (30 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (30 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give a mixture of 8-(5-chloro-4-methoxy-pyrimidin-2-yl)-l,4-dioxa-8-azaspiro[4.5]decane and 8-(5- chloro-2-methoxy-pyrimidin-4-yl)-l,4-dioxa-8-azaspiro[4.5]decane (totall.4 g), which was used in the next step without further purification.

Step 3: Preparation of l-(5-chloro-4-methoxy-pyrimidin-2-yl)piperidin-4-one and 1- (5-chloro-2-methoxy-pyrimidin-4-yl)piperidin-4-one

A mixture of 8-(5-chloro-4-methoxy-pyrimidin-2-yl)-l,4-dioxa-8-azaspiro[4.5]decane and 8-(5-chloro-2-methoxy-pyrimidin-4-yl)-l,4-dioxa-8-azaspiro[4.5]decane (totall.4 g, 4.9 mmol) and 44% formic acid (10 mL) was heated with stirring at 90 °C for 8 hrs. The resulting reaction mixture was cooled to rt, diluted with sat. aqueous solution of NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give a mixture of l-(5-chloro-4- methoxy-pyrimidin-2-yl)piperidin-4-one and l-(5-chloro-2-methoxy-pyrimidin-4-yl)piperidin-4- one (total 1.2 g) as brown oil, which was used in the next step without further purification.

Step 4: Preparation of 6-(5-chloro-4-methoxy-pyrimidin-2-yl)-2-(2-pyridyl)-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine and 6-(5-chloro-2-methoxy-pyrimidin-4-yl)-2-(2- pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine

Example 68 Example 69

A mixture of l-(5-chloro-4-methoxy-pyrimidin-2-yl)piperidin-4-one and l-(5-chloro-2- methoxy-pyrimidin-4-yl)piperidin-4-one (totall.2 g, 4.9 mmol) and DMFDMA (20 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20 mL). To the solution was added pyridine-2- carboxamidine hydrochloride (774 mg, 4.9 mmol) and K₂C0₃ (1350 mg, 9.8 mmol) successively. After being heated with stirring at 80 °C overnight, the resulting reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(5-chloro-4-methoxy-pyrimidin-2-yl)-2-(2-pyridyl)-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine (Example 68, 200 mg) and 6-(5-chloro-2-methoxy- pyrimidin-4-yl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (Example 69, 40 mg).

Example 68: 6-(5-chloro-4-methoxy-pyrimidin-2-yl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine, 1H NMR (400 MHz, CDC1₃): δ 8.79 - 8.89 (m, 1 H), 8.73 (s, 1 H), 8.47 - 8.55 (m, 1 H), 8.24 - 8.33 (m, 1 H), 8.11 (s, 1 H), 7.86 - 7.96 (m, 1 H), 7.40 - 7.49 (m, 1 H), 4.99 (s, 2 H), 4.14 - 4.23 (m, 2 H), 4.05 (s, 3 H), 3.14 - 3.24 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺] : 355.

Example 69: 6-(5-chloro-2-methoxy-pyrimidin-4-yl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine, 1H NMR (400 MHz, CDC1₃): δ 8.81 - 8.90 (m, 1 H), 8.71 (s, 1 H), 8.51 (d, 1 H), 8.13 - 8.20 (m, 1 H), 7.88 (t, 1 H), 7.39 - 7.47 (m, 1 H), 4.92 (s, 2 H), 4.12 (t, 2 H), 3.98 (s, 3 H), 3.29 - 3.38 (m, 2 H). MS obsd. (ESf) [(M+H)⁺] : 355.

Example 70 and 71: 6-(5-fluoro-4-methoxy-2-pyridyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine and 6-(3-fluoro-4-methoxy-2-pyridyl)-2-(2-pyridyl)-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine

xampk' 70 Example 71

Step 1: Preparation of 2-chloro-5-fluoro-4-methoxy-pyridine and 2-chloro-3-fluoro-4- methoxy-pyridine

A mixture of 3-fluoro-4-methoxy-pyridine (3.0 g, 23.62 mmol) and H₂0₂ (35 wt. % in H₂0,

2.0 mL, 23.6 mmol) was refluxed overnight. The resulting reaction mixture was concentrated in vacuo to give pyridine oxide. A mixture of the above pyridine oxide and POCl₃ (10 mL) was heated with stirring for 5 hrs. The resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHCO₃(10 mL) and extracted with EA (50 mL) for three times. The combined organic layer was dried and concentrated in vacuo. The residue was purified by flash column to give a mixture of 2-chloro-5-fluoro-4-methoxy-pyridine and 2-chloro-3-fluoro- 4-methoxy-pyridine (500 mg).

Step 2: Preparation of 8-(5-fluoro-4-methoxy-2-pyridyl)-l,4-dioxa-8- azaspiro[4.5]decane and 8-(3-fluoro-4-methoxy-2-pyridyl)-l,4-dioxa-8-azaspiro[4.5]decane

To a flask containing 2-chloro-5-fluoro-4-methoxy-pyridine and 2-chloro-3-fluoro-4- methoxy-pyridine (total 500 mg, 3.11 mmol) and l,4-dioxa-8-azaspiro[4.5]decane (489 mg, 3.42 mmol) in dioxane (15 mL) was added i-BuONa (896 mg, 9.33 mmol), Pd₂(dba)₃ (147 mg, 0.16 mmol) and Ruphos (144 mg, 0.32 mmol) under N₂. After being heated with stirring at 100 °C overnight, the resulting reaction mixture was cooled to rt, diluted with H₂0 (30 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (30 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give a mixture of 8-(5- fluoro-4-methoxy-2-pyridyl)-l,4-dioxa-8-azaspiro[4.5]decane and 8-(3-fluoro-4-methoxy-2- pyridyl)-l,4-dioxa-8-azaspiro[4.5]decane (total 800 mg), which was used in the next step without further purification.

Step 3: Preparation of l-(5-fluoro-4-methoxy-2-pyridyl)piperidin-4-one and l-(3- fluoro-4-methoxy-2-pyridyl) iperidin-4-one

A mixture of 8-(5-fluoro-4-methoxy-2-pyridyl)-l,4-dioxa-8-azaspiro[4.5]decane and 8-(3- fluoro-4-methoxy-2-pyridyl)-l,4-dioxa-8-azaspiro[4.5]decane (total 800 mg, 3.1 mmol) and 44% formic acid (10 mL) was heated with stirring at 90 °C for 8 hrs. The resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give a mixture of l-(5-fluoro-4- methoxy-2-pyridyl)piperidin-4-one and l-(3-fluoro-4-methoxy-2-pyridyl)piperidin-4-one (total 690 mg) as brown oil, which was used in the next step without further purification.

Step 4: 6-(5-fluoro-4-methoxy-2-pyridyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine and 6-(3-fluoro-4-methoxy-2-pyridyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

xampk' 70 Example 71

A mixture of l-(5-fluoro-4-methoxy-2-pyridyl)piperidin-4-one and l-(3-fluoro-4-methoxy- 2-pyridyl)piperidin-4-one (total 690 mg, 3.1 mmol) and DMFDMA (10 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20 mL). To the solution was added pyridine-2-carboxamidine hydrochloride (490 mg, 3.1 mmol) and K₂CO₃ (850 mg, 6.2 mmol) successively. After being heated with stirring at 80 °C overnight, the resulting reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(5-fluoro-4-methoxy-2-pyridyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine (Example 71, 5 mg) and 6-(3-fluoro-4-methoxy-2-pyridyl)-2-(2- pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (Example 70, 5 mg).

Example 71 : 6-(5-fluoro-4-methoxy-2-pyridyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine, 1H NMR (400 MHz, CDC1₃): δ 8.82 - 8.92 (m, 1 H), 8.75 (s, 1 H), 8.49 - 8.59 (m, 1 H), 7.96 - 8.03 (m, 1 H), 7.85 - 7.93 (m, 1 H), 7.38 - 7.48 (m, 1 H), 6.29 - 6.38 (m, 1 H), 4.78 (s, 2 H), 3.93 - 4.02 (m, 5 H), 3.24 - 3.32 (m, 2 H). MS obsd. (ESf ) [(M+H)⁺]: 338.

Example 70: 6-(3-fluoro-4-methoxy-2-pyridyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine, 1H NMR (400 MHz, CDC1₃): δ 8.84 - 8.95 (m, 1 H), 8.71 (s, 1 H), 8.49 - 8.58 (m, 1 H), 7.86 - 7.99 (m, 2 H), 7.40 - 7.50 (m, 1 H), 6.52 - 6.62 (m, 1 H), 4.78 (s, 2 H), 3.90 -4.00 (m, 5 H), 3.26 - 3.34 (m, 2 H). MS obsd. (ESf) [(M+H)⁺]: 338. Example 72: 6-(5-fluoro-6-methoxy-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

Step 1: Preparation of 3,6-difluoro-2-methoxy-pyridine

To a solution of 2,3,6-trifluoropyridine (3.0 g, 22.54 mmol) in MeOH (30 mL) was added NaH (1.08 g, 27.05 mmol, 60%wt) at 0 °C. After being heated with stirring at 70 °C for 2 hrs, the resulting reaction mixture was concentrated in vacuo and the residue was dissolved in H₂0 (30 mL). The solution was extracted by DCM (50 mL) twice. The combined organic layer was concentrated in vacuo to give 3,6-difluoro-2-methoxy-pyridine (1.6 g), which was used in next step directly without further purification.

Step 2: Preparation of 8-(5-fluoro-6-methoxy-2-pyridyl)-l,4-dioxa-8- azaspiro[4.5]decane

To a solution of 3,6-difluoro-2-methoxy-pyridine (2.0 g, 13.78 mmol) in DMF (20 mL) was added l,4-dioxa-8-azaspiro[4.5]decane (2.96 g, 20.64 mmol) and Cs₂C0₃ (13.5 g, 41.34 mmol). After being heated with stirring at 120 °C for 12 hrs, the resulting reaction mixture was diluted with DCM (50 mL) and then washed with brine (40 mL) for three times. The organic layer was dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by column chromatography (eluting with 1-10% EA in PE) to give 8-(5-fluoro-6-methoxy-2- pyridyl)-l,4-dioxa-8-azaspiro[4.5]decane (600 mg) as a pale yellow oil.

Step 3: Preparation of l-(5-fluoro-6-methoxy-2-pyridyl)piperidin-4-one

A mixture of 8-(5-fluoro-6-methoxy-2-pyridyl)-l,4-dioxa-8-azaspiro[4.5]decane (600 mg, 2.24 mmol) and 44% formic acid (10 mL) was heated with stirring at 90 °C for 2 hrs. The resulting reaction mixture was concentrated in vacuo, diluted with H₂0 (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by silica gel column to give l-(5-fluoro-6-methoxy-2-pyridyl)piperidin-4-one (300 mg) as a pale yellow oil.

Step 4: Preparation of 6-(5-fluoro-6-methoxy-2-pyridyl)-2-pyrimidin-2-yl-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine

A solution of l-(5-fluoro-6-methoxy-2-pyridyl)piperidin-4-one (300 mg, 1.34 mmol) in DMFDMA (10 mL) was heated with stirring at 120 °C for 4 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in MeOH (10 mL). To the solution was added pyridine-2-carboxamidine hydrochloride (285 mg, 1.8 mmol) and K₂CO₃ (745 mg, 5.4 mmol). After being heated with stirring at 60 °C for 1 hr, the resulting mixture was concentrated in vacuo. The residue was diluted with DCM (100 mL), washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-TLC and further purified by prep-HPLC to give 6-(5-fluoro-6-methoxy-2-pyridyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine (15 mg) as a white solid. 1H NMR (400 MHz, CDC1₃): δ 9.03 - 9.04 (d, 2 H), 8.83 (s, 1 H), 7.43 - 7.44 (t, 1 H), 7.27 - 7.30 (t, 1 H), 6.19 - 6.21 (d, 1 H), 4.76 (s, 2 H), 4.02 (s, 3 H), 3.95 - 3.98 (t, 2 H), 3.30 - 3.33 (t, 2 H). MS obsd. (ESf) [(M+H)⁺]: 339.

Example 73: 6-(3,5-dimethoxyphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

Step 1: Preparation of 8-(3,5-dimethoxyphenyl)-l,4-dioxa-8-azaspiro[4.5]decane

—

To a solution of l,4-dioxa-8-azaspiro[4.5]decane hydrochloride (1.0 g, 5.6 mmol) and 1- bromo-3,5-dimethoxybenzene (1.6 g, 7.3 mmol) in dioxane (15 mL) was added i-BuONa (1.0 g, 11.2 mmol), Pd₂(dba)₃ (100 mg, 0.11 mmol) and Ruphos (50 mg, 0.11 mmol) under N₂. After being heated with stirring at 100 °C for 12 hrs, the resulting mixture was filtered and the filtrate was concentrated in vacuo. The residue was diluted with DCM (100 mL), washed with water (30 mL) and brine (30 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 8-(3,5- dimethoxyphenyl)-l,4-dioxa-8-azaspiro[4.5]decane (2.0 g, crude) as a yellow oil, which was used in the next step without further purification.

Step 2: Preparation of l-(3,5-dimethoxyphenyl)piperidin-4-one

—

A mixture of 8-(3,5-dimethoxyphenyl)-l,4-dioxa-8-azaspiro[4.5]decane (1.0 g, 3.6 mmol) and 44% formic acid (10 mL) was heated with stirring at 90 °C for 2 hrs. The resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ and extracted with EA (30 mL) for three times. The combined organic layer was washed with water and brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(3,5- dimethoxyphenyl)piperidin-4-one (0.9 g, crude) as a yellow oil, which was used in the next step without further purification.

Step 4: Preparation of 6-(3,5-dimethoxyphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

A solution of l-(3,5-dimethoxyphenyl)piperidin-4-one (0.9 g, 3.8 mmol) in DMFDMA (10 mL) was heated with stirring at 120 °C for 4 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in MeOH (10 mL). To the solution was added K₂C0₃ (1.38 g, 10 mmol) and pyrimidine-2-carboxamidine hydrochloride (550 mg, 3.4 mmol). After being heated with stirring at 70 °C for 12 hrs, the resulting mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by prep-HPLC to give 6-(3,5- dimethoxyphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (6.8 mg) as a white solid.1H NMR (400 MHz, MeOH-J₄): δ 9.02-9.01 (d, 2H), 8.82 (s, 1H), 7.64 -7.61 (t, 1H), 6.24 - 6.24 (d, 2 H), 6.05 (s, 1 H), 4.48 (s, 2 H), 3.76 (s, 6 H), 3.70 - 3.68 (m, 2 H), 3.22 - 3.19 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 350.

Example 74: 6-(8-methoxy-3-isoquinolyl)-2-pyrimidin-2-yl-7,8-dihyd]

pyrido[4,3-d]pyrimidine

Step 1: Preparation of 8-(8-methoxy-3-isoquinolyl)-l,4-dioxa-8-azaspiro[4.5]decane

—

To a solution of 2-chloro-7-methoxyquinoline (500 mg, 2.6 mmol) in DMF (1.0 mL) was added l,4-dioxa-8-azaspiro[4.5]decane hydrochloride (1.40 g, 7.8 mmol) and K₂CO₃ (1.79 g, 13 mmol). After being heated with stirring at 90 °C for 16 hrs, the resulting reaction mixture was cooled to rt, diluted with water (30 mL) and extracted with EA (30 mL) for three times. The combined organic layer was brine (30 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by column to give 8-(8-methoxy-3-isoquinolyl)-l,4-dioxa-8- azaspiro[4.5]decane (400 mg) as a yellow oil.

Step 2: Preparation of l-(8-methoxy-3-isoquinolyl)piperidin-4-one

—

A mixture of 8-(8-methoxy-3-isoquinolyl)-l,4-dioxa-8-azaspiro[4.5]decane (380 mg, 1.27 mmol) and 44% formic acid (4 mL) was heated with stirring at 90 °C for 2 hrs. After being cooled to rt, the resulting mixture was concentrated in vacuo. The residue was diluted with EA (100 mL), washed with sat. aqueous solution of NaHC0₃ (30 mL) and brine (30 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(8-methoxy-3-isoquinolyl)piperidin-4- one (300 mg) as a yellow solid.

Step 3: Preparation of 6-(8-methoxy-3-isoquinolyl)-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

A solution of l-(8-methoxy-3-isoquinolyl)piperidin-4-one (270 mg, 1.05 mmol) in DMFDMA (3 mL) was heated with stirring at 100 °C for 4 hrs. After being cooled to rt, the resulting mixture was concentrated in vacuo and the residue was dissolved in MeOH (10 mL). To the solution was added pyrimidine-2-carboxamidine hydrochloride (249 mg, 1.58 mmol) and K₂CO₃ (362 mg, 2.63 mmol). After being heated with stirring at 60 °C for 1 hr, the resulting reaction mixture was cooled to rt and concentrated in vacuo. The residue was diluted with DCM (50 mL), washed with sat. NaHC0₃ (30 mL) and brine (30 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-TLC and further purified by prep- HPLC to give 6-(8-methoxy-3-isoquinolyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine (88 mg) as a yellow solid.1H NMR (400 MHz, MeOH-J₄): δ 8.90-9.12 (m, 2 H), 8.90 (s, 1 H), 7.90 (d, 1 H), 7.45-7.59 (m, 1 H), 7.40-7.45 (m, 1 H), 7.15 (s, 1 H), 6.87-7.11 (m, 2 H), 5.08 (s, 2 H), 4.14 (t, 2 H), 3.94 (s, 3 H), 3.36 (t, 2 H). MS obsd. (ESf) [(M+H)⁺]: 371. Example 75: 6-(2-methoxy-7-quinolyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

Step 1: Preparation of 8-(2-methoxy-7-quinolyl)-l,4-dioxa-8-azaspiro[4.5]decane

—

To a solution of l,4-dioxa-8-azaspiro[4.5]decane (550 mg, 3.06 mmol) and 7-bromo-2- methoxyquinoline (875 mg, 3.67 mmol) in dioxane (5 mL) was added i-BuONa (883 mg, 9.18 mmol) under N₂. After being heated with stirring at 100 °C for 12 hrs, the resulting reaction mixture was cooled to rt and concentrated in vacuo. The residue was diluted with H₂0 (60 mL) and extracted with DCM (150 mL). The organic layer was washed with brine (60 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column to give 8-(2-methoxy-7-quinolyl)-l,4-dioxa-8-azaspiro[4.5]decane (900 mg) as yellow oil.

Step 2: Preparation of l-(2-methoxy-7-quinolyl)piperidin-4-one

—

A solution of 8-(2-methoxy-7-quinolyl)-l,4-dioxa-8-azaspiro[4.5]decane (900 mg, 3 mmol) in 44% formic acid (4 mL) was heated with stirring at 90 °C for 4 hrs. The resulting reaction mixture was concentrated in vacuo, diluted with DCM (150 mL), washed with sat. aqueous solution of NaHC0₃ (50 mL) and brine (50 mL), then dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column to give l-(2-methoxy-7- quinolyl)piperidin-4-one (730 mg) as yellow oil.

Step 3: Preparation of 6-(2-methoxy-7-quinolyl)-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

A solution of l-(2-methoxy-7-quinolyl)piperidin-4-one (730 mg, 2.85 mmol) in

DMFDMA (5 mL) was heated with stirring at 100 °C for 4 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in MeOH (10 mL). To the solution was added pyrimidine-2-carboxamidine hydrochloride (183 mg, 1.16 mmol) and K₂C0₃ (400 mg, 2.89 mmol). After being heated with stirring at 80 °C for 0.5 hr, the resulting mixture was diluted with H₂0 (20 mL) and extracted with DCM (60 mL). The organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford 6-(2-methoxy-7-quinolyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine (51.9 mg) as yellow solid. 1H NMR (400 MHz, DMSO-J₆): δ 3.13 (t, 2 H), 3.89 (t, 2 H), 3.95 (s, 3 H), 4.71 (s, 2 H), 6.73 (d, 1 H), 7.20 (d, 1 H) ,7.39 (dd, 1 H), 7.63 (t, 1 H), 7.74 (d, 1 H), 8.04 (d, 1 H), 8.91 (s, 1 H), 8.99 (d, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 371.

Example 76: 3-methoxy-5-(2^yrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin- 6-yl)benzonitrile

Step 1: Preparation of 3-(l,4-dioxa-8-azas iro[4.5]decan-8-yl)-5-methoxy-benzonitrile

To a solution of l,4-dioxa-8-azaspiro[4.5]decane (800 mg, 4.45 mmol) and 3-bromo-5- methoxybenzonitrile (1.13 g, 5.34 mmol) in dioxane (8 mL) was added i-BuONa (1.28 g, 13.4 mmol), Ruphos (166 mg, 0.36 mmol) and Pd₂(dba)3 (163 mg, 0.18 mmol) under N₂. After being heated with stirring at 100 °C for 12 hrs, the resulting mixture was cooled to rt and concentrated in vacuo. The residue was diluted with H₂0 (50 mL) and extracted with DCM (100 mL). The organic layer was washed with brine (50 mL), concentrated in vacuo and purified by flash column to give 3-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-5-methoxy-benzonitrile (950 mg) as yellow oil.

Step 2: Preparation of 3-methoxy-5-(4-oxo-l-piperidyl)benzonitrile

A suspension of 3-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-5-methoxy-benzonitrile (950 mg, 3.46 mmol) in 44% formic acid (8 mL) was heated with stirring at 90 °C for 2 hrs. The resulting reaction mixture was concentrated in vacuo. The residue was diluted with DCM (150 mL), washed with sat. aqueous solution of NaHCO₃(50 mL) and brine (50 mL) and concentrated in vacuo. The residue was purified by flash column to give 3-methoxy-5-(4-oxo-l- piperidyl)benzonitrile (630 mg) as yellow oil.

Step 3: Preparation of 3-methoxy-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl)benzonitrile

A solution of 3-methoxy-5-(4-oxo-l-piperidyl)benzonitrile (330 mg, 1.4 mmol) in

DMFDMA (5 mL) was heated with stirring at 100 °C for 4 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in MeOH (5 mL). To the solution was added pyrimidine-2-carboxamidine hydrochloride (267 mg, 1.68 mmol) and K₂CO₃ (581 mg, 4.21 mmol). After being heated with stirring at 80 °C for 0.5 hr, the resulting mixture was diluted with H₂0 (20 mL) and extracted with DCM (60 mL). The organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford 3-methoxy-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl)benzonitrile (52 mg) as yellow solid. 1H NMR (400 MHz, DMSO-d₆): δ 3.08 (t, 2 H), 3.74 - 3.85 (m, 5 H), 4.62 (s, 2 H), 6.81 (s, 1 H), 6.90 (t, 1 H), 7.13 (d, 7=1.00 Hz, 1 H) ,7.63 (t, 1 H), 8.82 (s, 1 H), 8.99 (d, 2 H). MS obsd. (ESf) [(M+H)⁺]: 345.

Example 77: 2-fluoro-6-methoxy-4-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl)benzonitrile

Step 1: Preparation of 4-bromo-2-fluoro-6-methoxy-benzonitrile

To a solution of 4-bromo-2,6-difluoro-benzonitrile (3000 mg, 13.8 mmol) in THF (40 mL) was added NaOMe (1100 mg, 20.7 mmol) at rt. The resulting mixture was stirred overnight at rt and then purified by flash column to give 4-bromo-2-fluoro-6-methoxy-benzonitrile (700 mg). Step 2: Preparation of 4-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-fluoro-6-methoxy- benzonitrile

To a mixture of 4-bromo-2-fluoro-6-methoxy-benzonitrile (700 mg, 1.75 mmol) and 1,4- dioxa-8-azaspiro[4.5]decane (276 mg, 1.93 mmol) in dioxane (15 mL) was added CS₂CO₃ (1700 mg, 5.25 mmol), Pd₂(dba)₃ (83 mg, 0.09 mmol) and Ruphos (84 mg, 0.18 mmol) under N₂. After being heated with stirring at 100 °C overnight, the resulting mixture was cooled to rt, diluted with H₂0 (30 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (30 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 4-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-fluoro-6-methoxy-benzonitrile (510 mg), which was used in the next step without further purification.

Step 3: Preparation of 2-fluoro-6-methoxy-4-(4-oxo-l-piperidyl)benzonitrile

A flask containing crude 4-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-2-fluoro-6-methoxy- benzonitrile (510 mg, 1.75 mmol) was added 44% formic acid (10 mL). After being heated with stirring at 90 °C for 8 hrs, the resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 2-fluoro-6-methoxy-4-(4-oxo-l-piperidyl)benzonitrile (430 mg) as brown oil, which was used in the next step without further purification.

Step 4: Preparation of 2-fluoro-6-methoxy-4-(2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl)benzonitrile

A mixture of 2-f uoro-6-methoxy-4-(4-oxo-l-piperidyl)benzonitrile (430 mg, 1.75 mmol) and DMFDMA (10 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20 mL). To the solution was added pyrimidine-2-carboxamidine hydrochloride (277 mg, 1.75 mmol) and K₂CO₃ (480 mg, 3.5 mmol) successively. After being heated with stirring at 80 °C overnight, the resulting reaction mixture was cooled to rt and purified by prep-HPLC to give 2-f uoro-6- methoxy-4-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)benzonitrile (50 mg). 1H NMR (400 MHz, DMSO-J₆): δ 9.00 (d, 2 H), 8.84 (s, 1 H), 7.62 - 7.69 (m, 1 H), 6.68 - 6.76 (m, 1 H), 6.50 - 6.57 (m, 1 H), 4.79 (s, 2 H), 3.97 (s, 3 H), 3.88 - 3.95 (m, 2 H), 3.07 - 3.17 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 363.

Example 78: 6-(4-chloro-3-fluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine

Step 1: Preparation of 5-bromo-2-chloro-l-fluoro-3-methoxy-benzene

To a solution of 5-bromo-2-chloro-l,3-difluoro-benzene (7200 mg, 31.9 mmol) in MeOH (50 mL) was added NaOMe (5200 mg, 95.7 mmol) at rt. The resulting mixture was stirred overnight at rt and then purified by flash column to give 5-bromo-2-chloro-l-fluoro-3-methoxy- benzene (5.2 g).

Step 2: Preparation of 8-(4-chloro-3-fluoro-5-methoxy-phenyl)-l,4-dioxa-8- azaspiro[4.5]decane

To a mixture of 5-bromo-2-chloro-l-fluoro-3-methoxy-benzene (5200 mg, 21.85 mmol) and l,4-dioxa-8-azaspiro[4.5]decane (3440 mg, 24.04 mmol) in dioxane (50 mL) was added t- BuONa (4200 mg, 43.7 mmol), Pd₂(dba)₃ (1000 mg, 1.09 mmol) and Ruphos (1020 mg, 2.18 mmol) under N₂. After being heated with stirring at 100 °C overnight, the resulting reaction mixture was cooled to rt, diluted with H₂0 (50 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 8-(4-chloro-3-fluoro-5-methoxy-phenyl)-l,4-dioxa-8- azaspiro[4.5]decane (800 mg), which was used in the next step without further purification.

Step 3: l-(4-chloro-3-fluoro-5-methox -phenyl)piperidin-4-one

To a flask containing crude 8-(4-chloro-3-fluoro-5-methoxy-phenyl)-l,4-dioxa-8- azaspiro[4.5]decane (800 mg, 2.65 mmol) was added 44% formic acid (10 mL). After being heated with stirring at 90 °C for 8 hrs, the resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous

Na₂S0₄ and concentrated in vacuo to give l-(4-chloro-3-fluoro-5-methoxy-phenyl)piperidin-4- one (680 mg) as brown oil, which was used in the next step without further purification.

Step 4: Preparation of 6-(4-chloro-3-fluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine

A mixture of l-(4-chloro-3-fluoro-5-methoxy-phenyl)piperidin-4-one (680 mg, 2.65 mmol) and DMFDMA (10 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20 mL). To the solution was added pyrimidine-2-carboxamidine hydrochloride (420 mg, 2.65 mmol) and K₂C0₃ (730 mg, 5.3 mmol) successively. After being heated with stirring at 80 °C overnight, the resulting reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(4-chloro-3- fluoro-5-methoxy-phenyl)-2-pyrimidm^ (250 mg).

1H NMR (400 MHz, DMSO-J₆): δ 8.96 - 9.00 (m, 2 H), 8.72 (s, 1 H), 7.62 - 7.68 (m, 1 H), 6.95 - 7.07 (m, 2 H), 4.33 - 4.41 (m, 2 H), 3.82 - 3.86 (m, 3 H), 3.43 - 3.52 (m, 3 H), 2.98 - 3.06 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 372.

Example 79: 6-(3-chloro-4-fluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine

Step 1: Preparation of 8-(3-chloro-4-fluoro-5-methoxy-phenyl)-l,4-dioxa-8- azaspiro[4.5]decane

To a mixture of 5-bromo-l-chloro-2-fluoro-3-methoxy-benzene (1000 mg, 4.2 mmol) and l,4-dioxa-8-azaspiro[4.5]decane (660 mg, 4.6 mmol) in dioxane (20 mL) was added i-BuONa (800 mg, 8.4 mmol), Pd₂(dba)₃ (184 mg, 0.2 mmol) and Ruphos (187 mg, 0.4 mmol) under N₂. After being heated with stirring at 100 °C overnight, the resulting reaction mixture was cooled to rt, diluted with H₂0 (50 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 8-(3-chloro-4-fluoro-5-methoxy-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane (500 mg), which was used in the next step without further purification.

Step 2: Preparation of l-(3-chloro-4-fluoro-5-methoxy-phenyl)piperidin-4-one

A flask containing crude 8-(3-chloro-4-fluoro-5-methoxy-phenyl)-l,4-dioxa-8- azaspiro[4.5]decane (500 mg, 1.66 mmol) was added 44% formic acid (10 mL). After being heated with stirring at 90 °C for 8 hrs, the resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(3-chloro-4-fluoro-5-methoxy-phenyl)piperidin-4- one (420 mg) as brown oil, which was used in the next step without further purification.

Step 3: Preparation of 6-(3-chloro-4-fluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine

A mixture of l-(3-chloro-4-fluoro-5-methoxy-phenyl)piperidin-4-one (420 mg, 1.66 mmol) and DMFDMA (10 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20 mL). To the solution was added pyrimidine-2-carboxamidine hydrochloride (260 mg, 1.66 mmol) and K₂C0₃ (458 mg, 3.32 mmol) successively. After being heated with stirring at 80 °C overnight, the resulting reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(3-chloro-4- fluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (300 mg). 1H NMR (400 MHz, DMSO-J₆): δ 9.00 (d, 7=4.8 Hz, 2 H), 8.83 (s, 1 H), 7.61 - 7.68 (m, 1 H), 6.82 - 6.90 (m, 1 H), 6.70 - 6.77 (m, 1 H), 4.54 (s, 2 H), 3.90 (s, 3 H), 3.68 - 3.77 (m, 2 H), 3.06 3.15 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 372.

Example 80: 6-(4-methylsulfonylphenyl)-2-(2-pyridyl)-3,5,7,8-tetrahydropyrido-[4,3- d]pyrimidin-4-one

Step 1: Preparation of 6-benzyl-2-(2-pyridyl)-3,5,7,8-tetrahydropyrido[4,3- d]pyrimidin-4-one

To a solution of NaOMe (3.39 g, 73.9 mmol) in MeOH (100 mL) was added pyridine-2- carboxamidine hydrochloride (5.82 g, 36.9 mmol) followed by ethyl l-benzyl-4-oxo-piperidine- 3-carboxylate (10 g, 33.6 mmol). After being stirred at 25 °C for 16 hrs, the resulting reaction mixture was concentrated in vacuo. The residue was suspended into EA and H₂0, and the suspension was filtered. The filter cake was dried in vacuo to give 6-benzyl-2-(2-pyridyl)- 3,5,7, 8-tetrahydropyrido[4,3-d]pyrimidin-4-one (7.8 g) as a white solid.

Step 2: Preparation of 2-(2-pyridyl)-5,6,7,8-tetrahydro-3H-pyrido[4,3-d]pyrimidin-4- one

A solution of 6-benzyl-2-(2-pyridyl)-3,5,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-one (7.8 g, 24.5 mmol) in MeOH (800 mL) was hydrogenated in the presence of Pd(OH)₂ (800 mg) at 60 °C under 30 psi of H₂ for 24 hrs. The resulting reaction mixture was filtered. The filtrate was concentrated in vacuo to give 2-(2-pyridyl)-5,6,7,8-tetrahydro-3H-pyrido[4,3-d]pyrimidin-4-one (5.4 g) as a yellow solid, which was used in the next step without further purification.

Step 3: Preparation of 6-(4-methylsulfonylphenyl)-2-(2-pyridyl)-3,5,7,8- tetrahydropyrido[4,3-d]pyrimidin-4-one

To a mixture of 2-(2-pyridyl)-5,6,7,8-tetrahydro-3H-pyrido[4,3-d]pyrimidin-4-one (12 g, 52.6 mmol) and NMP (180 mL) was added Cs₂C0₃ (25.7 g, 78.9 mmol) followed by l-fluoro-4- methylsulfonyl-benzene (11.0 g, 63.1 mmol). After being heated with stirring at 140 °C for 16 hrs, the resulting reaction mixture was cooled to rt and purified by flash column to give 6-(4- methylsulfonylphenyl)-2-(2-pyridyl)-3,5,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-one (5.0 g). 1H NMR (400 MHz, DMSO-J₆): δ 8.74 (d, 1 H), 8.31 (d, 1 H), 7.94-8.06 (m, 1 H), 7.74 (d, 2 H), 7.61-7.72 (m, 1 H), 7.19 (d, 2 H), 4.25 (s, 2 H), 3.77 (t, 2 H), 3.10 (s, 3 H), 2.88 (t, 2 H).

Example 81 : 4-methoxy-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine

Step 1: Preparation of 4-chloro-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine

A mixture of 6-(4-methylsulfonylphenyl)-2-(2-pyridyl)-3,5,7,8-tetrahydropyrido[4,3- d]pyrimidin-4-one (5.0 g, 13 mmol) and POCI₃ (50 mL) was heated with stirring at 120 °C for 2 hrs. After being cooled to rt, the resulting reaction mixture was concentrated in vacuo. The residue was basified with sat. aqueous solution of NaHC0₃ and extracted with DCM. The organic layer was dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by column (eluting with 1% MeOH in DCM) to give 4-chloro-6-(4- methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (5.1 g) as a yellow solid.

Step 2: Preparation of 4-methoxy-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine

To a solution of 4-chloro-6-(4-methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine (100 mg, 0.249 mmol) in MeOH (1.5 mL) was added NaOMe (27 mg, 0.50 mmol). After being stirred at rt for 16 hrs, the resulting reaction mixture was diluted with DCM, washed with water and brine, dried over anhydrous Na₂S0₄, concentrated in vacuo and lyophilized to give 4-methoxy-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine (58 mg) as a light yellow solid. 1H NMR (400 MHz, CDC1₃): δ 8.85 (d, 1 H), 8.50 (d, 1 H), 7.82-7.93 (m, 3 H), 7.42-7.48 (m, 1 H), 7.06 (d, 2 H), 4.45 (s, 2 H), 4.21 (s, 3 H), 3.82 (t, 2 H), 3.25 (t, 2 H), 3.04 (s, 3 H). MS obsd. (ESf) [(M+H)⁺]: 397. Example 82: 4-ethoxy-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

To a solution of 4-chloro-6-(4-methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine (100 mg, 0.249 mmol) in EtOH (1.5 mL) was added NaOEt (34 mg, 0.50 mmol). After being stirred at rt for 16 hrs, the resulting reaction mixture was diluted with DCM, washed with water and brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to give 4-ethoxy-6-(4-methylsulfonylphenyl)-2- pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (44 mg) as a light yellow solid. 1H NMR (400 MHz, CDC1₃): δ 8.85 (dd, 1 H), 8.46 (d, 1 H), 7.81-7.91 (m, 3 H), 7.38-7.43 (m, 1 H), 7.06 (d, 2 H), 4.67 (q, 2 H), 4.44 (s, 2 H), 3.82 (t, 2 H), 3.24 (t, 2 H), 3.03 (s, 3 H), 1.52 (t, 3 H). MS obsd. (ESI⁺) [(M+H)⁺]: 411.

Example 83: 4-benzyloxy-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine

To a mixture of NaH (50 mg, 1.25 mmol, 60% purity in mineral oil) and BnOH (1.5 mL) was added 4-chloro-6-(4-methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine (100 mg, 0.25 mmol). After being stirred at rt for 16 hrs, the resulting reaction mixture was diluted with DCM, washed with water and brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to give 4-benzyloxy-6-(4- methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (54 mg) as a light yellow solid. 1H NMR (400 MHz, CDC1₃): δ 8.87 (s, 1 H), 8.47 (d, 1 H), 7.80-7.89 (m, 1 H), 7.53 (d, 2 H), 7.42-7.51 (m, 2 H), 7.37-7.41 (m, 4 H), 7.04 (d, 2 H), 5.68 (s, 2 H), 4.48 (s, 2 H), 3.82 (t, 2 H), 3.26 (t, 2 H), 3.03 (s, 3 H). MS obsd. (ESf) [(M+H)⁺]: 473.

Example 84: 6-(4-methylsulfonylphenyl)-4-[(E)-prop-l-enyl]-2-pyrimidin-2-yl-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine

To a solution of 4-chloro-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine (300 mg, 0.75 mmol) and 2-allyl-4,4,5,5-tetramethyl- 1,3,2- dioxaborolane (380 mg, 2.25 mmol) in THF (15 mL) was added CsF (342 mg, 2.25 mmol), Pd(PPh₃)₄ (92 mg, 0.08 mmol) under N₂. After being heated under reflux under N₂ atmosphere overnight, the resulting reaction mixture was diluted with H₂0 (10 mL) and extracted with EA (30 mL) for three times. The combined organic layer was dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to give 6-(4- methylsulfonylphenyl)-4-[(E)-prop-l-enyl]-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine (50 mg). 1H NMR (400 MHz, CDC1₃): δ 8.82 - 8.96 (m, 1 H), 8.53 - 8.65 (m, 1 H), 7.81 - 7.93 (m, 3 H), 7.51 - 7.67 (m, 1 H), 7.37 - 7.48 (m, 1 H), 7.08 (d, 2 H), 6.56 - 6.68 (m, 1 H), 4.61 (s, 2 H), 3.74 - 3.92 (m, 2 H), 3.23 - 3.39 (m, 2 H), 3.04 (s, 3 H), 1.99 - 2.22 (m, 3 H). MS obsd. (ESf) [(M+H)⁺] : 407.

Example 85: 6-(4-methylsulfonylphenyl)-4-propyl-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

A solution of 6-(4-methylsulfonylphenyl)-4-[(E)-prop-l-enyl]-2-pyrimidin-2-yl-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine (100 mg) in MeOH (10 mL) was stirred in the presence of 10% Pd/C (50 mg) at rt under H₂ overnight. The resulting reaction mixture was purified by prep- HPLC to give 6-(4-methylsulfonylphenyl)-4-propyl-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine (40 mg). 1H NMR (400 MHz, CDC13): δ 8.81 - 8.95 (m, 1 H), 8.50 - 8.62 (m, 1 H), 7.83 - 7.92 (m, 3 H), 7.37 - 7.48 (m, 1 H), 7.06 (d, 2 H), 4.58 (s, 2 H), 3.76 - 3.90 (m, 2 H), 3.25 - 3.37 (m, 2 H), 3.05 (s, 3 H), 2.81 - 2.92 (m, 2 H), 1.90 - 2.05 (m, 2 H), 1.12 (t, 3 H). MS obsd. (ESI⁺) [(M+H)⁺] : 409.

Example 86 : 4-ethyl-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

Step 1: Preparation of 6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-4-vinyl-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine

To a solution of 4-chloro-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine (250 mg, 0.63 mmol) and 4,4,5,5-tetramethyl-2- vinyl- 1,3,2- dioxaborolane (194 mg, 1.26 mmol) in dioxane (10 mL) and H₂0 (2 mL) was added K₂C0₃ (174 mg, 1.26 mmol) and Pd(PPh₃)₄ (69 mg, 0.06 mmol) under N₂. After being heated under reflux overnight, the resulting reaction mixture was diluted with H₂0 (10 mL) and extracted with EA (30 mL) for three times. The combined organic layer was dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column to give 6-(4- methylsulfonylphenyl)-2-pyrimidin-2-yl-4-vinyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (150 mg).

Step 2: Preparation of 4-ethyl-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine

A solution of 6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-4-vinyl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine (50 mg) in MeOH (10 mL) was stirred in the presence of 10% Pd/C (20 mg) at rt under H₂ overnight. The resulting reaction mixture was purified by prep-HPLC to give 4-ethyl-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (10 mg). 1H NMR (400 MHz, CDC1₃): δ 8.85 - 8.93 (m, 1 H), 8.56 - 8.64 (m, 1 H), 7.82 - 7.96 (m, 3 H), 7.39 - 7.48 (m, 1 H), 7.02 - 7.13 (m, 2 H), 4.58 (s, 2 H), 3.79 - 3.90 (m, 2 H), 3.27 - 3.39 (m, 2 H), 3.05 (s, 3 H), 2.89 - 2.98 (m, 2 H), 1.48 (t, 3 H). MS obsd. (ESI⁺) [(M+H)⁺]: 395.

Example 87: 4-methyl-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

To a solution of 4-chloro-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine (150 mg, 0.38 mmol) and methylboronic acid (46 mg, 0.76 mmol) in toluene (4 mL) and DMF (1 mL) was added Cs₂C0₃ (247 mg, 0.76 mmol) and Pd(PPh₃)₄ (23 mg, 0.02 mmol) under N₂. After being heated with stirring at 140 °C under N₂ atmosphere for 30 minutes in a microwave reactor, the resulting reaction mixture was filtered and the filtrate was purified by prep-HPLC to give 4-methyl-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine (29 mg).1H NMR (400 MHz, CDC1₃): δ 8.85 - 8.97 (m, 1 H), 8.76 (s, 1 H), 8.52 - 8.62 (m, 1 H), 7.88 - 7.98 (m, 1 H), 7.42 - 7.52 (m, 2 H), 6.53 - 6.60 (m, 1 H), 6.40 - 6.46 (m, 1 H), 4.61 (s, 2 H), 3.98 (s, 3 H), 3.79 - 3.87 (m, 2 H), 3.29 - 3.36 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺] : 381.

Example 88: N-methyl-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidin-4-amine

To a solution of 4-chloro-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine (60 mg, 0.05 mmol) in MeOH (2 mL) was added MeNH₂ (0.1 mL, 33 wt. % in EtOH, 0.75 mmol). After being stirred at rt overnight, the resulting reaction mixture was filtered and the filtrate was purified by prep-HPLC to give N-methyl-6-(4- methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-4-amine (20 mg). 1H NMR (400 MHz, CDC1₃): δ 8.74 - 8.82 (m, 1 H), 8.46 - 8.54 (m, 1 H), 7.86 - 7.94 (m, 1 H), 7.71 - 7.80 (m, 2 H), 7.41 - 7.50 (m, 1 H), 7.04 - 7.16 (m, 2 H), 4.31 (s, 2 H), 3.67 - 3.76 (m, 2 H), 3.27 (s, 3 H), 3.11 - 3.20 (m, 2 H), 3.01 (s, 3 H). MS obsd. (ESf) [(M+H)⁺] : 396. Example 89: 6-(4-methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-l,6- naphthyridine

Step 1: Preparation of tert-butyl 2-(2-pyridyl)-7,8-dihydro-5H-l,6-naphthyridine-6- carboxylate

To a reaction vessel containing a solution of iert-butyl 2-chloro-7,8-dihydro-5H-l,6- naphthyridine-6-carboxylate (1.0 g, 3.72 mmol) in NMP (5 mL) was added tributyl(2- pyridyl)stannane (2.06 g, 5.58 mmol) and Pd₂Cl₂(PPh3)₂ (260 mg, 0.37 mmol) under an argon atmosphere. The reaction vessel was sealed and heated at 150 °C for 30 minutes in a microwave reactor. After being cooled to rt, the resulting reaction mixture was diluted with water (10 mL) and extracted with DCM (20 mL) for three times. The combined organic layer was washed with water and brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column to afford ie/t-butyl 2-(2-pyridyl)-7,8-dihydro-5H-l,6-naphthyridine-6- carboxylate (1.1 g) as a white solid.

Step 2: Preparation of 2-(2-pyridyl)-5,6,7,8-tetrahydro-l,6-naphthyridine

A mixture of ie/t-butyl 2-(2-pyridyl)-7,8-dihydro-5H-l,6-naphthyridine-6-carboxylate (1.1 g, 3.53 mmol) and 2.0 N HCl/dioxane (20 mL) was stirred at rt for 16 hrs. The resulting mixture was concentrated in vacuo and the residue was diluted with H₂0 (20 mL). The resulting mixture was stirred for 1 hr and extracted with DCM (50 mL) for two times. The combined organic layer was washed with brine and concentrated in vacuo to give 2-(2-pyridyl)-5,6,7,8-tetrahydro-l,6- naphthyridine (700 mg) as a white solid, which was used in the next step without further purification. Step 3: Preparation of 6-(4-methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-l,6- naphthyridine

To a reaction vessel containing a solution of 2-(2-pyridyl)-5,6,7,8-tetrahydro-l,6- naphthyridine (200 mg, 0.936 mmol) in dioxane (5 mL) was added l-bromo-4-methylsulfonyl- benzene (332 mg, 1.404 mmol), Cs₂C0₃ (892 mg, 6.56 mmol), Xantphos (20 mg, 0.04 mmol) and Pd₂(dba)₃ (20 mg, 0.02 mmol) under an argon atmosphere. The reaction vessel was sealed and heated at 120 °C for 20 minutes in a microwave reactor. The resulting reaction mixture was concentrated in vacuo and the residue was purified by the column chromatography to afford 6- (4-methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-l,6-naphthyridine (38 mg) as white solid. 1H NMR (400 MHz, CDC1₃): δ 3.03 (s, 3 H) 3.27 (t, 2 H) 3.85 (t, 2 H) 4.62 (s, 2 H) 7.01 (d, 2 H) 7.32 (dd, 1 H) 7.64 (d, 1 H) 7.78 - 7.87 (m, 3 H) 8.27 (d, 1 H) 8.40 (d, 1 H) 8.70 (d, 1 H). MS obsd. (ESI⁺) [(M+H)⁺]: 366. Example 90: 6-(4-fluoro-3-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

Step 1: Preparation of 8-(4-fluoro-3-methox -phenyl)-l,4-dioxa-8-azaspiro[4.5]decane

To a mixture of 4-bromo-l-fluoro-2-methoxy-benzene (1.86 g, 9.1 mmol) and l,4-dioxa-8- azaspiro[4.5]decane (1.0 g, 7.0 mmol) in dioxane (20 mL) was added i-BuONa (1010 mg, 10.5 mmol), Pd₂(dba)₃ (128 mg, 0.14 mmol) and Ruphos (130 mg, 0.28 mmol) under N₂. After being heated with stirring at 100 °C overnight, the resulting reaction mixture was cooled to rt, diluted with H₂0 (50 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 8-(4-fluoro-3-methoxy-phenyl)- l,4-dioxa-8-azaspiro[4.5]decane (1200 mg), which was used in the next step without further purification.

Step 2: Preparation of l-(4-fluoro-3-methoxy-phenyl)piperidin-4-one

A mixture of 8-(4-fluoro-3-methoxy-phenyl)- l,4-dioxa-8-azaspiro[4.5]decane (1200 mg, 1.66 mmol) and 44% formic acid (20 mL) was heated with stirring at 90 °C for 8 hrs. The resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(4-fluoro-3-methoxy-phenyl)piperidin-4-one (1000 mg) as brown oil, which was used in the next step without further purification.

Step 3: Preparation of 6-(4-fluoro-3-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

A mixture of crude l-(4-fluoro-3-methoxy-phenyl)piperidin-4-one (1000 mg, 4.49 mmol) and DMFDMA (10 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20 mL). To the solution was added pyridine-2-carboxamidine hydrochloride (710 mg, 4.49 mmol) and K₂C0₃ (1240 mg, 8.98 mmol) successively. After being heated with stirring at 80 °C overnight, the resulting reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(4-fluoro-3- methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (60 mg). 1H NMR (400 MHz, CDC1₃): δ 8.88 - 8.87 (d, 1 H), 8.71 (s, 1 H), 8.54 - 8.52 (d, 1 H), 7.91 - 7.87 (m, 1 H), 7.44 - 7.28 (m, 1 H), 7.07 - 7.02 (m, 1 H), 6.71 - 6.70 (m, 1 H), 6.69 - 6.54 (m, 1 H), 4.41 (s, 2 H), 3.95 (s, 3 H),3.65 - 3.63 (m, 2 H), 3.25 - 3.30 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺] : 337.

Example 91: 6-(3-fluoro-5-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

Step 1: Preparation of 8-(3-fluoro-5-methox -phenyl)-l,4-dioxa-8-azaspiro[4.5]decane

To a mixture of 4-bromo-l-fluoro-2-methoxy-benzene (930 mg, 9.1 mmol) and 1,4-dioxa- 8-azaspiro[4.5]decane (500 mg, 3.5 mmol) in dioxane (20 mL) was added i-BuONa (500 mg, 5.2 mmol), Pd₂(dba)₃ (64 mg, 0.07 mmol) and Ruphos (65 mg, 0.14 mmol) under N₂. After being heated with stirring at 100 °C overnight, the resulting reaction mixture was cooled to rt. The resulting reaction mixture was diluted with H₂0 (50 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 8-(3-fluoro-5-methoxy-phenyl)-l,4-dioxa-8- azaspiro[4.5]decane (700 mg), which was used in the next step without further purification.

Step 2: Preparation of l-(3-fluoro-5-methoxy-phenyl)piperidin-4-one

— O

F y v>°

To a flask containing crude 8-(3-fluoro-5-methoxy-phenyl)-l,4-dioxa-8- azaspiro[4.5]decane (700 mg, 2.62 mmol) was added 44% formic acid (20 mL). After being heated with stirring at 90 °C for 8 hrs, the resulting reaction mixture was concentrated in vacuo. The residue was diluted with sat. aqueous solution of NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(3-fluoro-5-methoxy-phenyl)piperidin-4- one (580 mg) as brown oil, which was used in the next step without further purification.

Step 3: Preparation of 6-(3-fluoro-5-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

A mixture of l-(3-fluoro-5-methoxy-phenyl)piperidin-4-one (580 mg, 2.62 mmol) and DMFDMA (10 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (20 mL). To the solution was added pyridine-2-carboxamidine hydrochloride (410 mg, 2.62 mmol) and K₂CO₃ (720 mg, 5.24 mmol) successively. After being heated with stirring at 80 °C overnight, the resulting reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(3-fluoro-5-methoxy-phenyl)-2- (2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (60 mg). 1H NMR (400 MHz, CDC1₃): δ 3.27 (t, 2 H), 3.70 (t, 2 H), 3.81 (s, 3 H), 4.46 (s, 2 H), 6.18 (d, 1 H), 6.29 - 6.38 (m, 2 H), 7.38 - 7.44 (m, 1 H), 7.84 - 7.91 (m, 1 H), 8.51 (d, 1 H), 8.70 (s, 1 H), 8.86 (d, 1 H). MS obsd. (ESI⁺) [(M+H)⁺]: 337.

Example 92: 6-(3-methoxyphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

Step 1: Preparation of 8-(3-methoxyphenyl)-l,4-dioxa-8-azaspiro[4.5]decane

—

To a mixture of 4-bromo-l-fluoro-2-methoxy-benzene (5.09 g, 27.2 mmol) and 1,4-dioxa- 8-azaspiro[4.5]decane (3.0 g, 20.9 mmol) in dioxane (20 mL) was added i-BuONa (3.02 g, 20.9 mmol), Pd₂(dba)3 (600 mg, 0.66 mmol) and Ruphos (400 mg, 1.32 mmol) under N₂. After being heated with stirring at 100 °C overnight, the resulting reaction mixture was cooled to rt, diluted with H₂0 (50 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give crude 8-(3-methoxyphenyl)-l,4-dioxa-8-azaspiro[4.5]decane (3.8 g), which was used in the next step without further purification.

Step 2: Preparation of l-(3-methoxyphenyl)piperidin-4-one

—

A mixture of crude 8-(3-methoxyphenyl)-l,4-dioxa-8-azaspiro[4.5]decane (3.8 g, 15.26 mmol) and 44% formic acid (30 mL) was heated with stirring at 90 °C for 8 hrs. The reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(3-methoxyphenyl)- piperidin-4-one (3.1 mg) as brown oil, which was used in the next step without further purification.

Step 3: Preparation of 6-(3-methoxyphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

A mixture of l-(3-methoxyphenyl)piperidin-4-one (200 mg, 0.98 mmol) and DMFDMA (10 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (10 mL). To the solution was added pyridine-2-carboxamidine hydrochloride (155 mg, 0.98 mmol) and K₂C0₃ (270 mg, 1.96 mmol) successively. After being heated with stirring at 80 °C overnight, the reaction mixture was cooled to rt and purified by prep-HPLC to give 6-(3-methoxyphenyl)-2-(2-pyridyl)-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine (40 mg). 1H NMR (400 MHz, CDC1₃): δ 3.11-3.17 (m, 2 H), 3.68- 3.77 (m, 5 H), 4.53 (s, 2 H), 6.36 - 6.46 (m, 2 H), 6.42 (s, 1 H), 6.61-6.70 (m, 1H), 7.16 (t, 1 H), 7.66 (s, 1H), 8.11 (s, 1H), 8.51 (s, 1H), 8.76-8.84 (m, 2H). MS obsd. (ESI^1") [(M+H)⁺]: 319.

Example 93: 3-[2,3-difluoro-5-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin- 6-yl] phenoxy ] propan- 1 -ol

Step 1: Preparation of l-(3-benzyloxypropoxy)-5-bromo-2,3-difluoro-benzene

A mixture of 5-bromo-2,3-difluoro-phenol (1.0 g, 4.78 mmol), 3-bromopropoxy- methylbenzene (1.31 g, 5.74 mmol) and Cs₂C0₃ (2.34 g, 7.17 mmol) in MeCN (10 mL) was heated with stirring at 80 °C for 16 hrs. The resulting mixture was filtered and the filtrate was concentrated in vacuo. The residue was diluted with DCM (100 mL), washed with H₂0 (30 mL) and brine (30 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give crude l-(3- benzyloxypropoxy)-5-bromo-2,3-difluoro-benzene (1.25 g), which was used in the next step without further purification.

Step 2: Preparation of 8-[3-(3-benzyloxypropoxy)-4,5-difluoro-phenyl]-l,4-dioxa-8- azaspiro[4.5]decane

To a mixture of l-(3-benzyloxypropoxy)-5-bromo-2,3-difluoro-benzene (1.25 g, 5.45 mmol) and l,4-dioxa-8-azaspiro[4.5]decane (600 mg, 4.19 mmol) in dioxane (20 mL) was added i-BuONa (600 mg, 6.29 mmol), Pd₂(dba)₃ (120 mg, 0.13 mmol) and Ruphos (80 mg, 0.26 mmol) under N₂. After being heated with stirring at 100 °C overnight, the resulting reaction mixture was cooled to rt, diluted with H₂0 (50 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give crude 8-[3-(3-benzyloxypropoxy)-4,5-difluoro-phenyl]-l,4-dioxa- 8-azaspiro[4.5]decane (800 mg), which was used in the next step without further purification.

Step 3: Preparation of l-[3-(3-benzyloxypropoxy)-4,5-difluoro-phenyl]piperidin-4-one

A mixture of 8-[3-(3-benzyloxypropoxy)-4,5-difluoro-phenyl]-l,4-dioxa-8- azaspiro[4.5]decane (700 mg, 1.67 mmol) and 44% formic acid (10 mL) was heated with stirring at 90 °C for 8 hrs. The resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-[3-(3-benzyloxypropoxy)-4,5-difluoro-phenyl]piperidin-4-one (650 mg) as a brown oil, which was used in the next step without further purification.

Step 4: Preparation of 6-[3,4-difluoro-5-(4-phenylbutoxy)phenyl]-2-(2-pyridyl)-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine

A mixture of l-[3-(3-benzyloxypropoxy)-4,5-difluoro-phenyl]piperidin-4-one (600 mg, 1.6 mmol) and DMFDMA (10 mL) was heated with stirring at 90 °C for 3 hrs. The reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (10 mL). To the solution was added pyridine-2-carboxamidine hydrochloride (250 mg, 1.6 mmol) and K₂C0₃ (440 mg, 3.2 mmol) successively. After being heated with stirring at 80 °C overnight, the resulting reaction mixture was cooled to rt and purified by prep-HPLC to give 6-[3-(3-benzyloxypropoxy)-4,5- difluoro-phenyl]-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (400 mg).

Step 5: Preparation of 3-[2,3-difluoro-5-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]phenoxy]propan-l-ol

To a solution of 6-[3-(3-benzyloxypropoxy)-4,5-difluoro-phenyl]-2-(2-pyridyl)-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine (360 mg, 0.73 mmol) in DCM (5 mL) was added BC1₃ (1.46 mL, 1.46 mmol) at -70°C. After being stirred at -70 °C for 3 hrs, the reaction was quenched with sat. aqueous solution of NaHC0₃ (30 mL). The resulting mixture was extracted with DCM (100 mL). The organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to give 3-[2,3-difluoro-5-[2-(2- pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]phenoxy]propan-l-ol (35 mg) as a gray solid. 1H NMR (400 MHz, CDC1₃): δ 8.86 (d, 1 H), 8.70 (s, 1 H), 8.52 (d, 1 H), 7.91-7.87 (m, 1 H), 7.44-7.36 (m, 1 H), 6.36-6.51 (m, 2 H), 4.42 (s, 2 H), 4.39 (t, 2H), 3.91 (t, 2H), 3.62 (t, 2H), 3.28 (t, 2H), 2.01-2.16 (m, 2H). MS obsd. (ESI⁺) [(M+H)⁺]: 399.

Example 94: 2-[2,3-difluoro-5-[2 2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin- 6-yl] phenoxy ] ethanol

Step 1: Preparation of l-(2-benz loxyethoxy)-5-bromo-2,3-difluoro-benzene

A mixture of 5-bromo-2,3-difluoro-phenol (1.5 g, 7.21 mmol), 2- bromoethoxymethylbenzene (1.85 g, 8.65 mmol) and Cs₂C0₃ (3.53 g, 10.82 mmol) in MeCN (15 mL) was heated with stirring at 80 °C for 16 hrs. The mixture was filtered and the filtrate was concentrated in vacuo. The residue was diluted with DCM (100 mL), washed with H₂0 (30 mL) and brine (30 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-(2- benzyloxyethoxy)-5-bromo-2,3-difluoro-benzene (1.6 g), which was used in the next step without further purification.

Step 2: Preparation of 8-[3-(2-benzyloxyethoxy)-4,5-difluoro-phenyl]-l,4-dioxa-8- azaspiro[4.5]decane

To a mixture of l-(2-benzyloxyethoxy)-5-bromo-2,3-difluoro-benzene (3.11 g, 9.09 mmol) and l,4-dioxa-8-azaspiro[4.5]decane (1.0 g, 6.99 mmol) in dioxane (20 mL) was added i-BuONa (1.0 g, 10.49 mmol), Pd₂(dba)₃ (120 mg, 0.13 mmol) and Ruphos (80 mg, 0.26 mmol) under N₂. After being heated with stirring at 100 °C overnight, the resulting reaction mixture was cooled to rt, diluted with H₂0 (50 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give 8-[3-(2-benzyloxyethoxy)-4,5-difluoro-phenyl]-l,4-dioxa-8-azaspiro[4.5]decane (900 mg), which was used in the next step without further purification.

Step 3: Preparation of l-[3- 2-benzyloxyethoxy)-4,5-difluoro-phenyl]piperidin-4-one

A mixture of crude 8-[3-(2-benzyloxyethoxy)-4,5-difluoro-phenyl]-l,4-dioxa-8- azaspiro[4.5]decane (850 mg, 2.1 mmol) and 44% formic acid (10 mL) was heated with stirring at 90 °C for 8 hrs. The resulting reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ (20 mL) and extracted with EA (30 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give l-[3-(2-benzyloxyethoxy)-4,5-difluoro-phenyl]piperidin-4-one (760 mg) as brown oil, which was used in the next step without further purification.

Step 4: Preparation of 6-[3-(2-benzyloxyethoxy)-4,5-difluoro-phenyl]-2-(2-pyridyl)- 7,8-dihydro-5H-pyrido[4,3-d]pyrimidine

A mixture of l-[3-(2-benzyloxyethoxy)-4,5-difluoro-phenyl]piperidin-4-one (760 mg, 2.1 mmol) and DMFDMA (10 mL) was heated with stirring at 90 °C for 3 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in EtOH (10 mL). To the solution was added pyridine-2-carboxamidine hydrochloride (330 mg, 2.1 mmol) and K₂CO₃ (580 mg, 4.2 mmol) successively. After being heated with stirring at 80 °C overnight, the resulting reaction mixture was cooled to rt and purified by prep-HPLC to give 6-[3-(2- benzyloxyethoxy)-4,5-difluoro-phenyl]-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (600 mg).

Step 5: Preparation of 2-[2,3-difluoro-5-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]phenoxy]ethanol

To a solution of 6-[3-(2-benzyloxyethoxy)-4,5-difluoro-phenyl]-2-(2-pyridyl)-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine (2.0 g, crude, 0.42 mmol) in DCM (3 mL) was added BC1₃ (0.84 mmol) at -70 °C and the resulting mixture was slowly warmed to 0 °C and heated with stirring for 3 hrs at 0 °C. The reaction was quenched with sat. aqueous solution of NaHC0₃. The resulting mixture was diluted with DCM, washed with water and brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to give 2-[2,3- difluoro-5-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]phenoxy]ethanol (35 mg). 1H NMR (400 MHz, CDC1₃): δ 3.28 (t, 2 H), 3.62 (t, 2 H), 3.97 - 4.05 (m, 2 H) 4.16 - 4.24 (m, 2 H) 4.38 (s, 2 H) 6.39 - 6.49 (m, 2 H) 7.42 (dd, 1 H), 7.88 (td, 1 H), 8.51 (d, 1 H), 8.70 (s, 1 H), 8.85 (d, 1 H). MS obsd. (ESI⁺) [(M+H)⁺]: 385.

Example 95:2-(3,4-difluoro-5-methoxy-phenyl)-6-pyrimidin-2-yl-3,4-dihydro-lH-2,7- naphthyridine

Step 1: Preparation of 6-methoxypyridine-3-carbaldehyde

To a solution of 5-bromo-2-methoxy-pyridine (95.0 g, 0.51 mol) in THF (2.0 L) was added n-BuLi (212 ml, 0.53 mol) at -78 °C slowly. After the mixture was stirred at -78 °C for 0.5 hr, to the reaction mixture was added anhydrous DMF (44.3 g, 0.61 mmol) slowly. The reaction mixture was stirred at -78 °C for another lhr and then the reaction was quenched with sat.

aqueous solution of NH₄C1. The resulting mixture was extracted with EA. The organic layer was washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column to give 6-methoxypyridine-3-carbaldehyde (66.7 g) as a light yellow solid.

Step 2: Preparation of 4-iodo-6-methoxy-pyridine-3-carbaldehyde

To a cooled and stirred solution of (CH₃)₂NCH₂CH₂NHCH₃ (4.5 g, 0.044 mol) in THF (50 mL) was added n-BuLi (29.0 ml, 2.5 M, 0.073 mol) at -78 °C slowly. The mixture was stirred at -78 °C for 15 minutes. To the resulting mixture was added a solution of 6-methoxypyridine-3- carbaldehyde (5.0 g, 0.036 mol) in THF (50 ml) slowly and the resulting mixture was stirred at - 78 °C for 30 minutes. Then to the resulting reaction mixture was added n-BuLi (29.09 ml, 2.5 M, 0.073 mol) slowly and the resulting mixture was stirred at -78°C for another 1 hr. The resulting reaction mixture was added into a stirred solution of I₂ (19.4 g, 0.077 mol) in THF (200 ml) slowly. The resulting mixture was warmed up to rt and stirred at rt for 16 hrs. The reaction was then quenched with sat. aqueous solution of NH₄C1 and the resulting mixture was extracted with EA. The organic layer was washed with brine dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue purified by the flash column to give 4-iodo-6-methoxy-pyridine-3- carbaldehyde (800 mg) as a yellow solid.

Step 3: Preparation of 6-methoxy-4-(2-trimethylsilylethynyl)pyridine-3-carbaldehyde

A mixture of 4-iodo-6-methoxy-pyridine-3-carbaldehyde (2.38 g, 9.05 mmol),

ethynyltrimethylsilane (1.78 g, 18.10 mmol), Et₃N (2.75 g, 27.15 mmol), Cul (172 mg, 0.90 mmol) and Pd(PPh₃)₂Cl₂ (318 mg, 0.45 mmol) in THF (50 mL) was heated with stirring at 60 °C for 2 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was purified by flash column to afford 6-methoxy-4-(2-trimethylsilylethynyl)pyridine-3-carbaldehyde (1.18 g) as a yellow solid.

Step 4: preparation of 3-methoxy-2,7-naphthyridine

A mixture of 6-methoxy-4-(2-trimethylsilylethynyl)pyridine-3-carbaldehyde (5.6 g, 5.57 mmol) and sat. ammonia solution in EtOH (30 mL) was heated with stirring at 80 °C for 4 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was purified by flash column to give 3-methoxy-2,7-naphthyridine (3 g) as an orange solid.

Step 5: Preparation of 6-methoxy-l,2,3,4-tetrahydro-2,7-naphthyridine

A mixture of 3-methoxy-2,7-naphthyridine (2 g, 12.5 mmol) and Pt0₂ (200 mg) in MeOH (50 mL) was stirred at rt under H₂ (30 psi) for 16 hrs. The resulting reaction mixture was filtered and the filtrate was concentrated in vacuo to give 6-methoxy-l,2,3,4-tetrahydro-2,7- naphthyridine (1.7 g) as a yellow solid, which was used in the next step without further purification.

Step 6: Preparation of 2-(3,4-difluoro-5-methoxy-phenyl)-6-methoxy-3,4-dihydro-lH- 2,7-naphthyridine

To a mixture of 6-methoxy-l,2,3,4-tetrahydro-2,7-naphthyridine (500 mg, 3.04 mmol) and 5-bromo-2,3-difluoroanisole (883 mg, 3.96 mmol) in dioxane (8 mL) was added i-BuONa (438 mg, 4.56 mmol), Pd₂(dba)₃ (40 mg, 0.04 mmol) and Ruphos (30 mg, 0.06 mmol) under N₂. After being heated with stirring at 100 °C for 12 hrs, the resulting reaction mixture was filtered. The filtrate was concentrated in vacuo, diluted with DCM (100 mL), washed with water (30 mL) and brine (30 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column to give 2-(3,4-difluoro-5-methoxy-phenyl)-6-methoxy-3,4-dihydro-lH- 2,7-naphthyridine (560 mg) as a gray solid.

Step 7: Preparation of 7-(3,4-difluoro-5-methoxy-phenyl)-6,8-dihydro-5H-2,7- naphthyridin-3-ol

To a solution of 2-(3,4-difluoro-5-methoxy-phenyl)-6-methoxy-3,4-dihydro-lH-2,7- naphthyridine (800 mg, 2.61 mmol) in AcOH (15 mL) was added concentrated HBr (1.2 mL). The mixture was heated with stirring at 70 °C for 16 hrs. The resulting reaction mixture was concentrated in vacuo. The residue was stirred with a mixture of sat. aqueous solution of

NaHC0₃ (50 mL) and DCM (50 mL). The formed solid was filtered and the filter cake was dried in vacuo to give 7-(3,4-difluoro-5-methoxy-phenyl)-6,8-dihydro-5H-2,7-naphthyridin-3-ol (350 mg) as a yellow solid.

Step 8: Preparation of [7-(3,4-difluoro-5-methoxy-phenyl)-6,8-dihydro-5H-2,7- naphthyridin-3-yl] trifluoromethanesulfonate

To a solution of 7-(3,4-difluoro-5-methoxy-phenyl)-6,8-dihydro-5H-2,7-naphthyridin-3-ol (500 mg, 1.71 mmol) in DCM (10 mL) was added pyridine (675 mg, 8.55 mmol) and Tf₂0 (1.45 g, 5.13 mmol). After being stirred at 20 °C for 3 hrs, the resulting reaction mixture was diluted with DCM (100 mL), washed with water (30 mL) and brine (30 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column to give [7-(3,4- difluoro-5-methoxy-phenyl)-6,8-dihydro-5H-2,7-naphthyridin-3-yl] trifluoromethanesulfonate (350 mg) as a gray solid.

Step 9: Preparation of 2-(3,4-difluoro-5-methoxy-phenyl)-6-pyrimidin-2-yl-3,4- dihydro-lH-2,7-naphthyridine

A mixture of [7-(3,4-difluoro-5-methoxy-phenyl)-6,8-dihydro-5H-2,7-naphthyridin-3-yl] trifluoromethanesulfonate (100 mg, 0.2 mmol), 2-(tributylstannyl)pyrimidine (130 mg, 0.3 mmol) and Pd(PPh₃)₄ (20 mg) in dioxane (1 mL) was heated with stirring at 130 °C for 20 minutes in a microwave reactor. The resulting mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by prep-HPLC to give 2-(3,4-difluoro-5-methoxy-phenyl)-6-pyrimidin- 2-yl-3,4-dihydro-lH-2,7-naphthyridine (6 mg) as a gray solid. 1H NMR (400 MHz, CDC1₃): δ 9.07-9.14 (m, 2 H), 8.95 (s, 1 H), 7.71 (t, 1 H), 6.54-6.68 (m, 2 H), 4.67 (s, 2 H), 3.93 (s, 3 H), 3.71 (t, 2 H), 3.41 (s, 2 H). MS obsd. (ESI^1") [(M+H)⁺]: 355. Example 96:2-(3,4-difluoro-5-methoxy-phenyl)-6-(2-pyridyl)-3,4-dihydro-lH-2,7- naphthyridine

A mixture of [7-(3,4-difluoro-5-methoxy-phenyl)-6,8-dihydro-5H-2,7-naphthyridin-3-yl] trifluoromethanesulfonate (100 mg, 0.2 mmol), 2-(tributylstannyl)pyridine (130 mg, 0.3 mmol) and Pd(PPh₃)₄ (20 mg) in dioxane (1 mL) was heated with stirring at 130 °C for 20 minutes in a microwave reactor. The resulting reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by prep-HPLC to give 2-(3,4-difluoro-5-methoxy-phenyl)-6- (2-pyridyl)-3,4-dihydro-lH-2,7-naphthyridine (15 mg) as a gray solid. 1H NMR (400 MHz, CDC1₃): δ 8.67 (d, 1 H), 8.54 (s, 1 H), 8.36 (d, 1 H), 8.23 (s, 1 H), 7.89-8.01 (m, 1 H), 7.38-7.46 (m, 1 H), 4.49 (s, 2 H), 3.89 (s, 3 H), 3.58 (t, / = 6.0 Hz, 2 H), 3.03 (t, / = 6.0 Hz, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 354.

Example 97: 6-(3,4-difluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-l,6- naphthyridine

Step 1: Preparation of tert-butyl 2-benzyloxy-7,8-dihydro-5H-l,6-naphthyridine-6- carboxylate

To a solution of iert-butyl 2-chloro-7,8-dihydro-5H-l,6-naphthyridine-6-carboxylate (1.0 g, 3.7 mmol) in toluene (10 mL) was added ΚΟΗ (0.6 g, 11.1 mmol) at 0 °C and the mixture was stirred for 0.5 hr. To the resulting mixture was added a solution of BnOH (0.34 g, 5.6 mmol) in toluene (10 mL) followed by 18-crown-6 (100 mg) at 0°C. The resulting mixture was heated with stirring at 130 °C for 2 hrs and then filtered. The filtrate was concentrated in vacuo. The residue was purified by flash column to give tert-butyl 2-benzyloxy-7,8-dihydro-5H-l,6- naphthyridine-6-carboxylate (1 g).

Step 2: Preparation of 2-benzyloxy-5,6,7,8-tetrahydro-l,6-naphthyridine

A mixture of tert-butyl 2-benzyloxy-7,8-dihydro-5H-l,6-naphthyridine-6-carboxylate (800 mg, 2.4 mmol) and a solution of HC1 in EA (1.0 N, 10 mL) was stirred at rt for 12 hrs. The resulting reaction mixture was concentrated in vacuo to give 2-benzyloxy-5,6,7,8-tetrahydro-l,6- naphthyridine (500 mg), which was used in the next step without further purification.

Step 3: Preparation of 2-benzyloxy-6-(3,4-difluoro-5-methoxy-phenyl)-7,8-dihydro- 5H- 1 ,6-naphthyridine

To a solution of 2-benzyloxy-5,6,7,8-tetrahydro-l,6-naphthyridine (500 mg, 2.4 mmol) and 5-bromo-l,2-difluoro-3-methoxy-benzene (696 mg, 3.1 mmol) in dioxane (10 mL) was added t- BuONa (345.6 mg, 3.6 mmol), Pd₂(dba)₃ (44 mg, 0.05 mmol) and RuPhos (34 mg, 0.07 mmol) under N₂. After being heated with stirring at 100 °C for 12 hrs, the resulting mixture was filtered and concentrated in vacuo. The residue was purified to give 2-benzyloxy-6-(3,4-difluoro-5- methoxy-phenyl)-7,8-dihydro-5H-l,6-naphthyridine (500 mg), which was used in the next step without further purification.

Step 4: preparation of 6-(3,4-difluoro-5-methoxy-phenyl)-7,8-dihydro-5H-l,6- naphthyridin-2-ol

To a solution of 2-benzyloxy-6-(3,4-difluoro-5-methoxy-phenyl)-7,8-dihydro-5H-l,6- naphthyridine (400 mg, 1.04 mmol) in MeOH (3 mL) and EA (1 mL) was added Pd/C (40 mg). After being stirred at rt under H₂ (30 Psi) for 12 hrs, the resulting mixture was filtered and the filtrate was concentrated in vacuo to give crude 6-(3,4-difluoro-5-methoxy-phenyl)-7,8-dihydro- 5H-l,6-naphthyridin-2-ol (300 mg), which was used in the next step without further purification.

Step 5: Preparation of [6-(3,4-difluoro-5-methoxy-phenyl)-7,8-dihydro-5H-l,6- naphthyridin-2-yl] trifluoromethanesulfonate

To a solution of 6-(3,4-difluoro-5-methoxy-phenyl)-7,8-dihydro-5H-l,6-naphthyridin-2-ol (120 mg, 0.41 mmol) in DCM (2 mL) was added pyridine (2 mL) and Tf₂0 (1.1 g, 4.1 mmol) at - 30°C. After being stirred at 25 °C for 12 hrs, the reaction mixture was concentrated in vacuo and diluted with DCM. The resulting mixture was filtered and the filtrate was purified by prep-TLC to give [6-(3,4-difluoro-5-methoxy-phenyl)-7,8-dihydro-5H- 1 ,6-naphthyridin-2-yl] trifluoromethanesulfonate (100 mg).

Step 6: Preparation o 6-(3,4-difluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8- dihydro-5H-l,6-naphthyridine

To a solution of [6-(3,4-difluoro-5-methoxy-phenyl)-7,8-dihydro-5H-l,6-naphthyridin-2-yl] trifluoromethanesulfonate (160 mg, 0.37 mmol) in dioxane (2 mL) was added tributyl(pyrimidin- 2-yl)stannane (139 mg, 0.57 mmol) and Pd(dppf)Ci₂ (16 mg) under N₂. The mixture was heated with stirring 130 °C for 0.5 hr in a microwave reactor. The resulting reaction mixture was purified by prep-HPLC to give 6-(3,4-difluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8- dihydro-5H-l,6-naphthyridine (3.3 mg) as white solid. 1H NMR (400 MHz, CDC1₃): δ 9.14 - 9.13 (d, 2 H), 8.92-8.90 (d, 1 H), 8.63 - 8.61 (d, 1 H), 7.75 - 7.72 (t, 1 H), 6.69 - 6.62 (m, 2 H), 4.68 (s, 2 H), 3.95 (s, 3 H), 3.81 - 3.78 (m, 2 H), 3.56 - 3.53 (m, 2 H). MS obsd. (ESf) [(M+H)⁺] : 355.

Example 98: 6-(3-chloro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihyd]

pyrido[4,3-d]pyrimidine

Step 1: Preparation of 8-(3-chloro-5-methoxy-phenyl)-l,4-dioxa-8- azaspiro[4.5]decane

— o To a mixture of l-bromo-3-chloro-5-methoxy-benzene (800 mg, 3.61 mmol) and 1,4- dioxa-8-azaspiro[4.5]decane (500 mg, 2.78 mmol) in dioxane (20 mL) was added i-BuONa (668 mg, 6.95 mmol), Pd₂(dba)₃ (51 mg, 0.05 mmol) and Ruphos (52 mg, 0.1 mmol) under N₂. After being heated with stirring at 100°C overnight, the resulting reaction mixture was cooled to rt, diluted with H₂0 (20 mL) and extracted with EA (50 mL) for three times. The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give crude 8-(3-chloro-5-methoxy-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane (700 mg), which was used in the next step without further purification.

Step 2: Preparation of l-(3-chloro-5-methoxy-phenyl)piperidin-4-one

A solution of 8-(3-chloro-5-methoxy-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane (700, 2.47 mmol) in 44% formic acid (30 mL) was heated with stirring at 90 °C for 2hrs. The reaction mixture was concentrated in vacuo, diluted with sat. aqueous solution of NaHC0₃ and extracted with EA (30 mL) for three times. The combined organic layer was dried and concentrated in vacuo. The residue was purified by flash column to give l-(3-chloro-5-methoxy- phenyl)piperidin-4-one (250 mg).

Step 3: Preparation of 6-(3-chloro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine

A mixture of l-(3-chloro-5-methoxy-phenyl)piperidin-4-one (200 mg, 0.68 mmol), pyrimidine-2-carboxamidine hydrochloride (109 mg, 0.68 mmol) and K₂C0₃ (282 mg, 2.04 mmol) in MeOH (3 mL) was heated with stirring at 60 °C for 2 hrs. The resulting mixture was filtered and the filtrate was concentrated in vacuo, diluted with DCM, washed with brine, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to give 6-(3-chloro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine.1H NMR (400 MHz, DMSO-J₆): δ 3.07 (t, 2 H) 3.68 - 3.86 (m, 5 H) 4.57 (s, 2 H) 6.44 (s, 1 H) 6.56 (s, 1 H) 6.73 (s, 1 H) 7.63 (t, 1 H) 8.83 (s, 1 H) 8.99 (d, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 354. 357.

Example 99: 6-(2-fluoro-6-methoxy-4-pyridyl)-2-pyrimidin-2-yl-7,8-dihyd] pyrido[4,3-d]pyrimidine

Step 1: Preparation of 2,6-difluoro-4-methoxy-pyridine

To a stirred solution of 2,4,6-trifluoropyridine (100.0 g, 0.75 mol) in MeOH (1 L) was added MeONa (81.2 g, 1.5 mol) at 0 °C. After being stirred at 50 °C for 48 hrs, the resulting mixture was concentrated in vacuo. The residue was diluted with DCM (2 L) and the resulting mixture was filtered. The filtrate was washed with brine (500 mL), and then concentrated in vacuo to afford 2,6-difluoro-4-methoxy-pyridine (86.5 g) as a colorless oil which was used directly in the next step without further purification.

Step 2: Preparation of 8-(6-fluoro-4-methoxy-2-pyridyl)-l,4-dioxa-8- azaspiro[4.5]decane

To a stirred solution of l,4-dioxa-8-azaspiro[4.5]decane hydrochloride (110.0 g, 0.61 mol) in DMF (1 L) was added 2,6-difluoro-4-methoxy-pyridine ( 93.3 g, 0.64 mol) and K₂C0₃ (253.9 g, 1.84 mol) successively. After being heated with stirring at 90 °C for 12 hrs, the resulting mixture was diluted with EA (2.5 L), washed with H₂0 (1 L) and brine (1 L), then dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column to give 8-(6-fluoro-4-methoxy-2-pyridyl)-l,4-dioxa-8-azaspiro[4.5]decane (150.0 g) as a colorless oil.

Step 3: Preparation of l-(6-fluoro-4-methoxy-2-pyridyl)piperidin-4-one

A mixture of 8-(6-fluoro-4-methoxy-2-pyridyl)-l,4-dioxa-8-azaspiro[4.5]decane (150.0 g,

0.56 mol), formic acid (750 mL) and H₂0 (750 mL) was heated with stirring at 90 °C for 2 hrs. The resulting mixture was concentrated in vacuo and the residue was diluted with DCM (1.5 L). The resulting solution was washed with H₂0 (500 mL) and brine (500 mL),then dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column to give l-(6-fluoro-4-methoxy-2-pyridyl)piperidin-4-one (100.0 g) as a colorless oil.

Step 4: Preparation of 6-(6-fluoro-4-methoxy-2-pyridyl)-2-pyrimidin-2-yl-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine

A solution of l-(6-fluoro-4-methoxy-2-pyridyl)piperidin-4-one (100.0 g, 0.44 mol) in DMFDMA (1 L) was heated with stirring at 120 °C for 4 hrs. After being cooled down, the resulting reaction mixture was concentrated in vacuo. The residue was dissolved in MeOH (1.3 L) and to the solution was added pyrimidine-2-carboximidamide hydrochloride (88.6 g, 0.56 mol) and K₂C0₃ (160.8 g, 1.16 mol). After being heated with stirring at 80 °C for 2 hrs, the resulting mixture was diluted with DCM (1.5 L), then washed with H₂0 (500 mL) and brine (500 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column to give 6-(6-fluoro-4-methoxy-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine (105.0 g) as a yellow solid. 1H NMR (400 MHz, MeOH-d4) δ: 3.20 - 3.28 (m, 2 H), 3.37 (s, 1 H), 3.86 (s, 3 H), 3.93 - 4.01 (m, 2 H), 4.60 (s, 3 H), 4.62 - 4.62 (m, 1 H), 5.82 - 5.92 (m, 1 H), 6.09 - 6.18 (m, 1 H), 7.51 - 7.61 (m, 1 H), 8.76 - 8.87 (m, 1 H), 8.96 - 9.06 (m, 2 H). MS obsd (ESI) [(M+H)⁺]: 339.

Example 100: 6-[3-methoxy-5-(trifluoromethyl)phenyl]-2-pyrimidin-2-yl-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine

Step 1: Preparation of l-bromo-3-methoxy-5-(trifluoromethyl)benzene

A mixture of 3-(ie/t-butyl)-5-methylphenol (1.5 g, 9.13 mmol), iodomethane (1.43 g, 10 mmol) and K₂CO₃ (1.89 g, 13.7 mmol) in acetone (20 mL) was heated with stirring at 60 °C for 3 hrs. The mixture was cooled down to rt and filtered. The filtrate was concentrated in vacuo to give crude l-bromo-3-methoxy-5-(trifluoromethyl)benzene (1.98 g) which was used in the next step without further purification.

Step 2: Preparation of 8-[3-methoxy-5-(trifluoromethyl)phenyl]-l,4-dioxa-8- azaspiro[4.5]decane

To a mixture of l-bromo-3-methoxy-5-(trifluoromethyl)benzene (500 mg, 1.96 mmol), l,4-dioxa-8-azaspiro[4.5]decane (281 mg, 1.96 mmol) and sodium iert-butoxide (377 mg, 3.92 mmol) in dioxane (10 mL) was added Pd₂(dba)3 (71.8 mg, 78.4 μιηοΐ) and Ruphos (18.3 mg, 39.2 μιηοΐ) under N₂. After being heated with stirring at 100°C overnight, the resulting mixture was cooled down to rt, diluted with H₂0 (10 mL), and then extracted with EA(30 mL) for three times. The organic layers were combined, dried over anhydrous Na₂S0₄ and concentrated in vacuo to give crude 8-(3-methoxy-5-(trifluoromethyl)phenyl)-l,4-dioxa-8-azaspiro[4.5]decane (650 mg) which was used in the next step directly without further purification.

Step 3: Preparation of l-[3-methoxy-5-(trifluoromethyl)phenyl]piperidin-4-one

To a flask containing 8-(3-methoxy-5-(trifluoromethyl)phenyl)-l,4-dioxa-8- azaspiro[4.5]decane (600 mg, 1.89 mmol) was added formic acid ( 7 mL) and H₂0 (7 mL). After being heated with stirring at 100 °C for 2 hrs, the resulting mixture was concentrated in vacuo. The residue was diluted with sat. NaHC0₃ solution and extracted with EA (30 mL) for three times. The organic layers were combined, concentrated in vacuo to give crude l-[3-methoxy-5- (trifluoromethyl)phenyl]piperidin-4-one (530 mg) which was used in the next step directly without further purification.

Step 4: Preparation of 6-[3-methoxy-5-(trifluoromethyl)phenyl]-2-pyrimidin-2-yl-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine

A mixture of l-(3-methoxy-5-(trifluoromethyl)phenyl)piperidin-4-one (600 mg, 2.2 mmol) and DMFDMA (3 mL) was heated with stirring at 90 °C for 2 hrs. The resulting mixture was concentrated in vacuo and the residue was dissolved in EtOH (20 mL). To the solution was added pyrimidine-2-carboximidamide hydrochloride (348 mg, 2.2 mmol) and potassium carbonate (607 mg, 4.39 mmol). The resulting mixture was heated with stirring at 90 °C for 1 hr and then cooled down to rt. The mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by flash column to give 6-[3-methoxy-5-(trifluoromethyl)phenyl]-2- pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (400 mg) as light yellow solid. 1H NMR (400 MHz, DMSO- ) δ: 3.06 - 3.17 (m, 2 H), 3.77 - 3.82 (m, 2 H), 3.84 (s, 3 H), 4.63 (s, 2 H), 6.62 - 6.69 (m, 1 H), 6.83 - 6.90 (m, 1 H), 6.92 - 6.99 (m, 1 H), 7.64 (s, 1 H), 8.86 (s, 1 H), 9.00 (d, 2 H). MS obsd. (ESI⁺) [(M+H)⁺] : 388.

Example 101 : 3-fluoro-5-(2^yrimidin-2-yl-7,8-dihydro-5H^yrido[4,3-d]pyrimidin-6- yl)benzonitrile

Step 1: Preparation of 3-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-5-fluoro-benzonitrile

To a solution of l,4-dioxa-8-azaspiro[4.5]decane hydrochloride (3.5 g, 19.6 mmol) in dioxane (40 mL) was added 3-bromo-5-fluorobenzonitrile (4.3 g, 21.4 mmol) and CS₂CO₃ (15.9 g, 48.7 mmol) followed by Pd₂(dba)₃ (357 mg, 0.39 mmol) and Ruphos (364 mg, 0.22 mmol) under N₂. After being stirred at 100 °C for 16 hrs, the resulting mixture was diluted with EA (500 mL), then washed with H₂0 (150 mL) and brine (150 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column to give 3-(l,4-dioxa-8- azaspiro[4.5]decan-8-yl)-5-fluoro-benzonitrile (4.0 g) as yellow solid.

Step 2: Preparation of 3-fluoro-5-(4-oxo-l-piperidyl)benzonitrile

A mixture of 3-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-5-fluoro-benzonitrile (4.0 g, 15.3 mmol), formic acid (30 mL) and H₂0 (30 mL/30 mL) was heated with stirring at 90 °C for 2 hrs. The reaction mixture was diluted with DCM (300 mL) and washed with saturated aqueous solution of NaHC0₃ (100 mL) and brine (100 mL) successively. The organic phase was dried over anhydrous Na₂S0₄ and concentrated in vacuo to afford 3-fluoro-5-(4-oxo-l- piperidyl)benzonitrile (4.1 g, crude) as a gray solid which was used directly in the next step without further purification.

Step 3: Preparation of 3-[(3Z)-3-(dimethylaminomethylene)-4-oxo-l-piperidyl]-5- fluoro-benzonitrile

A mixture of 3-fluoro-5-(4-oxo-l-piperidyl)benzonitrile (4.1 g, 18.8 mmol) and DMFDMA (40 mL) was heated with stirring at 120 °C for 4 hrs. After being cooled, the formed yellow solid was collected by filtration, then washed with PE (50 mL) and further dried in vacuo to afford3- [(3Z)-3-(dimethylaminomethylene)-4-oxo-l-piperidyl]-5-fluoro-benzonitrile (2.5 g) as light green solid.

Step 4: Preparation of 3-fluoro-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl)benzonitrile

To a solution of 3-[(3Z)-3-(dimethylaminomethylene)-4-oxo-l-piperidyl]-5-fluoro- benzonitrile (500 mg, 1.83 mmol) in MeOH (10 mL) was added K₂C0₃ (758 mg, 5.49 mmol) and pyrimidine-2-carboximidamide hydrochloride (348 mg, 2.20 mmol). The resulting mixture was heated with stirring at 60 °C for 2 hrs and then diluted with DCM (100 mL). The resulting mixture was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford 3-fluoro-5-(2-pyrimidin-2-yl-7,8- dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)benzonitrile (32.8 mg) as white solid. 1H NMR

(400MHz, DMSO-J₆) δ: 8.99 (d, 2 H), 8.81 (s, 1 H), 7.64 (m, 1 H), 7.38 (s, 1 H), 7.28 (d, 1 H), 7.10 (d, 1 H), 4.68 (s, 2 H), 3.84 (m, 2 H), 3.08 (m, 2 H). MS obsd. (ESI⁺) [(M+H)⁺] : 333. Example 102: methyl 3-fluoro-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl)benzoate

Step 1: Preparation of methyl 3-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-5-fluoro- benzoate

To a mixture of methyl 3-bromo-5-fluorobenzoate (2.6 g, 11.2 mmol), l,4-dioxa-8- azaspiro[4.5]decane (1.68 g, 11.7 mmol) and cesium carbonate (7.27 g, 22.3 mmol) in dioxane (50 mL) was added Pd₂(dba)₃ (204 mg, 223 μιηοΐ) and Ruphos (208 mg, 446 μιηοΐ) under N₂. The resulting mixture was heated with stirring at 100°C overnight. After being cooled down to rt, the reaction mixture was diluted with saturated aqueous solution of NH₄C1 and then extracted with EA (50 mL) for three times. The combined organic layers were dried over anhydrous Na₂S0₄ and concentrated in vacuo to give crude methyl 3-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)- 5-fluoro-benzoate as yellow oil which was used in the next step without further purification.

Step 2: Preparation of methyl 3-fluoro-5-(4-oxo-l-piperidyl)benzoate

A mixture of methyl 3-fluoro-5-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)benzoate (3.3 g, 11.2 mmol), formic acid (8 mL) and H₂0 (8 mL) was heated with stirring at 90 °C for 5 hrs. The resulting mixture was concentrated in vacuo and the residue was diluted with saturated aqueous solution of NaHC0₃, and then extracted with EA (50 mL) for 3 times. The combined organic layers were dried over anhydrous Na₂S0₄ and concentrated in vacuo to give crude methyl 3- fluoro-5-(4-oxo-l-piperidyl)benzoate as yellow oil which was used in the next step directly without any further purification.

Step 3: Preparation of methyl 3-fluoro-5-(2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl)benzoate

A mixture of crude methyl 3-fluoro-5-(4-oxopiperidin-l-yl)benzoate (2.9 g, 11.5 mmol) and DMFDMA (5 mL) was heated with stirring at 90°C for 3 hrs. The resulting mixture was concentrated in vacuo and the residue was dissolved in MeOH (20 mL).To the solution was added pyrimidine-2-carboximidamide hydrochloride (1.83 g, 11.5 mmol) and potassium carbonate (3.19 g, 23.1 mmol). The resulting mixture was heated with stirring at 90 °C for 4 hrs, then diluted with saturated aqueous solution of NH₄C1, and extracted with EA (40 mL) for three times. The combined organic layers were dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column to afford methyl 3-fluoro-5-(2-pyrimidin-2-yl- 7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)benzoate (700 mg, 1.92 mmol) as yellow solid. 1H NMR (400 MHz, CDC1₃) : δ 3.37 (t, 2 H), 3.78 (s, 2 H), 3.94 (s, 3 H), 4.57 (s, 2 H), 6.85 - 6.93 (m, 1 H), 7.20 - 7.27 (m, 1 H), 7.39 - 7.55 (m, 2 H), 8.79 - 8.93 (m, 1 H), 8.99 - 9.11 (m, 2 H), 8.99 - 9.11 (m, 2 H). MS obsd (ESI) [(M+H)⁺]: 366.

Example 103: 3-fluoro-N-methyl-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl)benzamide

Step 1: Preparation of 3-fluoro-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl)benzoic acid

To a solution of methyl 3-fluoro-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl)benzoate (650 mg, 1.78 mmol) in MeOH (10 mL) and THF (10 mL) was added a solution of lithium hydroxide (85.2 mg, 3.56 mmol) in H₂0 (2 mL). The resulting mixture was stirred at rt and monitored by LC-MS. After the reaction was complete, the mixture was neutralized with 1.0 N HC1, and concentrated in vacuo. The formed precipitate was collected by suction to give 3-fluoro-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl)benzoic acid (600 mg, 1.71 mmol) as yellow sticky solid.

Step 2: Preparation of 3-fluoro-N-methyl-5-(2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl)benzamide

A mixture of 3-fluoro-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl)benzoic acid (30 mg, 85.4 μιηοΐ), methylamine hydrochloride (17.3 mg, 256 μιηοΐ), HATU (64.9 mg, 171 μιηοΐ) and triethylamine (72.6 mg, 0.1 mL, 717 μιηοΐ) in DMF (2 mL) was stirred at rt overnight. The resulting mixture was purified by prep-HPLC to give 3-fluoro- V-methyl-5- (2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)benzamide (15 mg) as light yellow solid. 1H NMR (400 MHz, MeOH-d4): δ 2.94 (s, 3 H), 3.22 - 3.30 (m, 2 H), 3.79 - 3.88 (m, 2 H), 4.57 - 4.68 (m, 2 H), 6.93 - 7.08 (m, 2 H), 7.35 (s, 1 H), 7.61 - 7.72 (m, 1 H), 8.42 - 8.56 (m, 1 H), 8.99 - 9.12 (m, 2 H). MS obsd (ESI) [(M+H)⁺] : 365.

Example 104: 3-fluoro-5-(2^yrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl)-N-(2,2,2-trifluoroethyl)benzamide

A mixture of 3-fluoro-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl)benzoic acid (30 mg, 85.4 μιηοΐ), 2,2,2-trifluoroethanamine hydrochloride (34.7 mg, 256 μιηοΐ), triethylamine (72.6 mg, 0.1 mL, 717 μιηοΐ) and HATU (64.9 mg, 171 μιηοΐ) in DMF (2 mL) was stirred at rt overnight. The resulting mixture was filtered and the filtrate was purified by prep-HPLC to give 3-fluoro-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)- N-(2,2,2-trifluoroethyl)benzamide (10 mg) as light yellow solid. 1H NMR (400 MHz, MeOU-d₄): δ 3.24 - 3.31 (m, 2 H), 3.83 - 3.91 (m, 2 H), 4.06 - 4.19 (m, 2 H), 4.63 - 4.73 (m, 2 H), 7.00 - 7.13 (m, 2 H), 7.37 - 7.45 (m, 1 H), 7.65 - 7.78 (m, 1 H), 8.87 - 8.97 (m, 1 H), 9.02 - 9.15 (m, 2 H). MS obsd (ESI) [(M+H)⁺]: 433.

Example 105: 3-fluoro-5-(2^yrimidin-2-yl-7,8-dihydro-5H^yrido[4,3-d]pyrimidin-6- yl)benzamide

A mixture of 3-fluoro-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl)benzoic acid (30 mg, 85.4 μιηοΐ), ammonium chloride (13.7 mg, 256 μιηοΐ), triethylamine (72.6 mg, 0.1 mL, 717 μιηοΐ) and HATU (64.9 mg, 171 μιηοΐ) in DMF (2 mL) was stirred at rt overnight. The resulting mixture was purified by prep-HPLC to give 3-fluoro-5-(2-pyrimidin-2- yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)benzamide (10 mg) as light yellow solid. 1H NMR (400 MHz, MeOH-<¾: δ 3.23 - 3.31 (m, 2 H), 3.85 (t, 2 H), 4.65 (s, 2 H), 4.89 (s, 8 H), 7.02 - 7.11 (m, 2 H), 7.43 (t, 1 H), 7.66 (t, 1 H), 8.88 (s, 1 H), 9.05 (d, 2 H). MS obsd (ESI)

[(M+H)⁺]: 351.

Example 106: 3-fluoro-N-(3-methoxypropyl)-5-(2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl)benzamide

A mixture of 3-fluoro-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl)benzoic acid (45 mg, 128 μιηοΐ), 3-methoxypropan- l -amine (22.8 mg, 256 μιηοΐ),

triethylamine (72.6 mg, 0.1 mL, 717 μιηοΐ) and HATU (97.4 mg, 256 μιηοΐ) in DMF (2 mL) was stirred at rt. The resulting mixture was purified by prep-HPLC to give 3-fluoro- V-(3- methoxypropyl)-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)benzamide (15 mg) as light yellow solid. 1H NMR (400 MHz, MeOH-d4) δ: 1.83 - 1.97 (m, 2 H), 3.22 - 3.30 (m, 2 H), 3.37 (s, 3 H), 3.51 (t, 4 H), 3.85 (s, 3 H), 4.61 - 4.71 (m, 2 H), 6.93 - 7.12 (m, 2 H), 7.36 (s, 1 H), 7.59 - 7.77 (m, 1 H), 8.43 - 8.64 (m, 1 H), 8.98 - 9.15 (m, 2 H). MS obsd (ESI) [(M+H)⁺] : 423.

Example 107: 3-fluoro-N-(5-hydroxypentyl)-5-(2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl)benzamide

A mixture of HATU (97.4 mg, 256 μιηοΐ), 3-fluoro-5-(2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl)benzoic acid (45 mg, 128 μιηοΐ), 5-aminopentan- l-ol (26.4 mg, 256 μιηοΐ) and triethylamine (72.6 mg, 0.1 mL, 717 μιηοΐ) in DMF (2 mL) was stirred at rt overnight, The resulting mixture was filtered and the filtrate was purified by prep-HPLC to give 3-fluoro-N- (5-hydroxypentyl)-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)benzamide (15 mg) as light yellow solid. 1H NMR (400 MHz, MeOH-d4): δ 1.40 - 1.75 (m, 6 H), 3.23 - 3.30 (m, 2 H), 3.37 - 3.46 (m, 2 H), 3.54 - 3.65 (m, 2 H), 3.77 - 3.90 (m, 2 H), 4.57 - 4.73 (m, 2 H), 7.02 (s, 2 H), 7.36 (s, 1 H), 7.67 (br. s., 1 H), 8.89 (br. s., 1 H), 9.05 (d, 2 H). MS obsd (ESI) [(M+H)⁺] : 437. Example 108: 6-(6-chloro-4-methoxy-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihyd] pyrido[4,3-d]pyrimidine

Step 1: Preparation of tert-butyl 2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine-6-carboxylate

A solution of l-Boc-4-piperidone (100.0 g, 0.50 mol) in DMFDMA (299.0 g, 2.5 mol) was heated with stirring at 120°C under nitrogen for 4 hrs. The resulting reaction mixture was concentrated in vacuo. The residue was dissolved in MeOH (2.0 L), and to the solution was added 2-amidinopyrimidine hydrochloride (87.8 g, 0.55 mol) and K₂CO₃ (173.9 g, 1.26 mol) successively. After being heated with stirring at 70°C for 3 hrs, the resulting reaction mixture was cooled to rt and filtered. The filtrate was concentrated in vacuo and the residue was diluted with DCM (2.0 L), washed with H₂0 (500 mL) and brine (300 mL), dried over anhydrous Na₂S0₄, and concentrated in vacuo. The residue was purified by the flash column

chromatography to give ie/t-butyl 2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6- carboxylate (47.7 g) as a yellow solid.

Step 2: Preparation of 2-pyrimidin-2-yl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine

To a stirred solution of tert-b tyl 2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine-6-carboxylate (47.7 g, 0.15 mol) in MeOH (500 mL) was added a solution of HCl in MeOH (190 mL, 4.0 M) slowly. The resulting mixture was stirred at 15°C for 16 hrs. The solvent was removed in vacuo and the residue was diluted with MeOH (1.0 L). To the solution was added basic resin (500 g, AMBERLYST(R) A21) portion wise and the resulting mixture was stirred at 15 °C for lhr until pH>7, and then filtered. The solid was washed with a mixture of DCM and MeOH (1200 mL, v/v=l: l). The collected filtrate was concentrated in vacuo to afford 2-pyrimidin-2-yl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine (39.0 g) as a yellow solid.

Step 3: Preparation of 6-(6-chloro-4-methoxy-2-pyridyl)-2-pyrimidin-2-yl-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine

To a solution of 2,6-dichloro-4-methoxypyridine (300 mg, 1.69 mmol) in NMP (3 mL) was added K₂CO₃ (653 mg, 5.06 mmol) and 2-pyrimidin-2-yl-5,6,7,8-tetrahydropyrido[4,3- d]pyrimidine (540 mg, 2.53 mmol). Then the reaction vessel was sealed and heated in

microwave at 150 °C for 1 hr. The reaction mixture was diluted with DCM (100 mL) and the resulting mixture was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and

concentrated in vacuo. The residue was purified by prep-HPLC to afford 6-(6-chloro-4-methoxy- 2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (6.9 mg) as white solid. 1H NMR (400 MHz, CDC1₃): δ 9.04 (d, 1 H), 8.85 (s, 1 H) 7.45 (m, 1 H), 6.33 (d, 1 H), 6.10 (d, 1 H), 4.84 (s, 2 H), 3.98 (m, 2 H), 3.85 (s, 3 H), 3.31 (m, 2 H). MS obsd. (ESI⁺) [(M+H⁺)]: 355.

Example 109 and 110: 6-(2,6-difluoro-4-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine and 6-(4,6-difluoro-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

To a solution of 2,4,6-trifluoropyridine (1.0 g, 7.51 mmol) in l-methyl-2-pyrrolidinone (15 mL) was added K₂C0₃ (3.12 g, 22.5 mmol) and 2-pyrimidin-2-yl-5,6,7,8-tetrahydropyrido[4,3- d]pyrimidine (2.44 g, 9.77 mmol). Then the reaction vessel was sealed and heated in microwave at 150 °C for 1 hr. The reaction mixture was diluted with EA (100 mL).The resulting mixture was washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford 6-(2,6-difluoro-4-pyridyl)-2-pyrimidin-2-yl-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine and (150 mg, Example 109) as yellow solid and 6-(4,6- difluoro-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (150 mg, Example 110) as yellow solid.

Example 109: 6-(2,6-difluoro-4-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine and, 1H NMR (400 MHz, CDC1₃): δ 9.06 (d, 2 H), 8.87 (s, 1 H), 7.47 (t, 1 H), 6.24 (s, 2 H), 4.67 (s, 2 H), 3.83 (t, 2 H), 3.37 (t, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 327 .

Example 110: 6-(4,6-difluoro-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine, 1H NMR (400 MHz, CDC1₃): δ 9.03 (d, 1 H), 8.84 (s, 1 H), 7.44 (t, 1 H), 6.26 (m, 1 H), 5.92 - 6.09 (m, 1 H), 4.83 (s, 2 H), 3.97 (t, 2 H), 3.31 (t, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 327. Example 111: Preparation of 6-(4-fluoro-6-methoxy-2-pyridyl)-2-pyrimidin-2-yl-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine

To a solution of 6-(4,6-difluoro-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine (50 mg, 0.15 mmol) in MeOH (2 mL) was added NaOMe (0.85 mL, 0.15 mmol). The resulting mixture was heated with stirring at 80 °C for 2 hrs and then diluted with DCM (50 mL). The resulting mixture was washed with brine (20 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford 6-(4-fluoro-6-methoxy- 2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (4 mg) as white solid. 1H NMR (400 MHz, CDC1₃): δ 9.04 (d, 2 H), 8.84 (s, 1 H), 7.45 (t, 1 H), 6.03 (m, 1 H), 5.88 (m, 1 H), 4.83 (s, 2 H), 4.00 (t, 2 H), 3.93 (s, 3 H), 3.31 (t, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 339.

Example 112: 6-(2-fluoro-6-methoxy-4-pyridyl)-2-pyrimidin-2-yl-7,8-dihyd] pyrido[4,3-d]pyrimidine

To a solution of 6-(2,6-difluoro-4-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine (50 mg, 0.15 mmol) in MeOH (2 mL) was added NaOMe (0.85 mL, 0.15 mmol). The resulting mixture was heated with stirring at 80 °C for 1 hr and then diluted with DCM (50 mL). The resulting mixture was washed with brine (20 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford 6-(2-fluoro-6-methoxy- 4-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (19 mg) as white solid. 1H NM (400 MHz, CDC1₃): δ 9.05 (d, 2 H), 8.84 (s, 1 H), 7.46 (m, 1 H), 6.04 (s, 2 H), 4.62 (s, 2 H), 3.90 (s, 3 H), 3.79 (t, 2 H), 3.34 (t, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 339.

Example 113: 6-(4,6-dichloro-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

Step 1: Preparation of 8-(2,6-dichloro-4-pyridyl)-l,4-dioxa-8-azaspiro[4.5]decane and 8-(4,6-dichloro-2-pyridyl)-l,4-dioxa-8-azaspiro[4.5]decane

To a solution of l,4-dioxa-8-azaspiro[4.5]decane hydrochloride (2.0 g, 11.0 mmol) in 1- methyl-2-pyrrolidinone (20 mL) was added K₂C0₃ (3.0 g, 21.9 mmol) and 2,4,6- trichloropyridine (2.95 g, 16.4 mmol). Then the reaction vessel was sealed and heated in microwave at 150 °C for 1 hr. The resulting mixture was diluted with EA (100 mL), then washed with brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo . The residue was purified by flash column to afford 8-(2,6-dichloro-4-pyridyl)-l,4-dioxa-8-azaspiro[4.5]decane (400 mg) as yellow oil and 8-(4,6-dichloro-2-pyridyl)-l,4-dioxa-8-azaspiro[4.5]decane ( 300 mg as yellow solid.

Step 2: Preparation of l-(4,6-dichloro-2-pyridyl)piperidin-4-one

A mixture of 8-(4,6-dichloro-2-pyridyl)-l,4-dioxa-8-azaspiro[4.5]decane (300 mg, 1.04 mmol), formic acid (3 mL) and H₂0 (3 mL) was heated with stirring at 90 °C for 2 hrs. The resulting mixture was diluted with DCM (100 mL), then washed with water (50 mL), saturated aqueous solution of NaHC0₃ (50 mL) and brine (50 mL) successively, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column to afford l-(4,6- dichloro-2-pyridyl)piperidin-4-one (240 mg) as white solid.

Step 3: Preparation of 6-(4,6-dichloro-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

A mixture of l-(4,6-dichloro-2-pyridyl)piperidin-4-one (170 mg, 0.69 mmol) and

DMFDMA (5 mL) was heated with stirring at 120 °C for 4 hrs. After being cooled, the reaction mixture was concentrated in vacuo. The residue was dissolved in MeOH (10 mL), and to the solution was added pyrimidine-2-carboximidamide hydrochloride (290 mg, 1.83 mmol) and K₂C0₃ (575 mg, 4.16 mmol) successively. The resulting mixture was heated with stirring at 90°C for 2 hrs, then cooled to rt and concentrated in vacuo. The residue was purified by prep- HPLC to afford 6-(4,6-dichloro-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine (14.3 mg) as white solid. 1H NMR (400 MHz, CDC1₃): δ 9.04 (d, 2 H), 8.87 (s, 1 H), 7.45 (m, 1 H), 6.72 (d, 1 H), 6.64 (d, 1 H), 4.86 (s, 2 H), 4.00 (m, 2 H), 3.32 (t, 2 H). MS obsd. (ESf) [(M+H)⁺]: 359.

Example 114: 6-(2,6-dichloro-4^yridyl)-2^yrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine

Step 1: Preparation of l-(2,6-dichloro-4-pyridyl)piperidin

A mixture of 8-(2,6-dichloro-4-pyridyl)-l,4-dioxa-8-azaspiro[4.5]decane (400 mg, 1.38 mmol) in formic acid (3 mL) and H₂0 (3 mL) was heated with stirring at 90 °C for 2 hrs. The resulting mixture was diluted with DCM (100 mL), then washed with water (50 mL), saturated aqueous solution of NaHC0₃ (50 mL) and brine (50 mL) successively, dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by the flash column to afford 1- (2,6-dichloro-4-pyridyl)piperidin-4-one (210 mg) as white solid.

Step 2: Preparation of 6-(2,6-dichloro-4-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

A mixture of l-(2,6-dichloro-4-pyridyl)piperidin-4-one (210 mg, 0.86 mmol) in

DMFDMA (5 mL) was heated with stirring at 120 °C for 4 hrs. After being cooled, the resulting reaction mixture was concentrated in vacuo. The residue was dissolved in MeOH (10 mL) and to the solution was added pyrimidine-2-carboximidamide hydrochloride (290 mg, 1.83 mmol) and K₂CO₃ (575 mg, 4.16 mmol). The resulting mixture was heated with stirring at 90°C for 2 hrs, then cooled to rt and concentrated in vacuo. The residue was purified by prep-HPLC to afford 6- (2,6-dichloro-4-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (14 mg) as yellow solid. 1H NMR (400 MHz, CDC1₃): δ 9.06 (d, 2 H), 8.87 (s, 1 H), 7.47 (t, 1 H), 6.74 (s, 2 H), 4.65 (s, 2 H), 3.82 (t, 2 H), 3.37 (t, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 359. Example 115 and 116: 6-(4-chloro-6-methoxy-2-pyridyl)-2-pyrimidin-2-yl-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine and 6-(2-chloro-6-methoxy-4-pyridyl)-2-pyrimidin-2- yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine

To a solution of 2,4-dichloro-6-methoxypyridine (150 mg, 0.84 mmol) in l-methyl-2- pyrrolidinone (2 mL) was added K₂CO₃ (233 mg, 1.69 mmol) and 2-pyrimidin-2-yl-5,6,7,8- tetrahydropyrido[4,3-d]pyrimidine (269 mg, 1.26 mmol). Then the reaction vessel was sealed and heated in microwave reactor at 150 °C for 1 hr. The reaction mixture was diluted with EA (100 mL) and the resulting mixture was washed with brine (30 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by prep-HPLC to afford 6-(4- chloro-6-methoxy-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (11.5 mg) and 6-(2-chloro-6-methoxy-4-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine (7.4 mg) both as white solid.

Example 115: 6-(4-chloro-6-methoxy-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine, 1H NMR (400 MHz, CDC1₃): δ 8.53 - 9.33 (m, 3 H), 7.46 (br. s., 1 H), 6.30 (s, 1 H), 6.17 (d, 1 H), 4.83 (s, 2 H), 4.00 (t, 2 H), 3.92 (s, 3 H), 3.31 (t, 2 H). MS obsd. (ESI⁺)

[(M+H)⁺]: 355.

Example 116: 6-(2-chloro-6-methoxy-4-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine, 1H NMR (400 MHz, CDC13): δ 9.05 (d, 2 H), 8.84 (s, 1 H), 7.46 (t, 1 H), 6.53 (d, 1 H), 6.07 (d, 1 H), 4.60 (s, 2 H), 3.92 (s, 3 H), 3.78 (t, 2 H), 3.33 (t, 2 H). MS obsd. (ESI⁺)

[(M+H)⁺]: 355.

Example 117: 6-(3-fluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine

A mixture of 3-bromo-5-fluoroanisole (87.6 g, 0.49 mol), l,4-dioxa-8-azaspiro[4.5]decane hydrochloride (100.0 g, 0.49 mol), te/t-BuONa (117.2 g, 1.22 mol), BINAP (12.1 g, 0.02 mol) and Pd₂dba₃ (8.9 g, 0.01 mol) in toluene (1.3 L) was heated with stirring at 100°C under nitrogen for 16 hrs. The reaction mixture was cooled to rt and filtered. The filtrate was diluted with DCM (3.0 L), washed with H₂0 (500 mL) and brine (200 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by the flash column chromatography to give 8- (3-fluoro-5-methoxy-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane (78.2 g) as a yellow oil.

Step 2: Preparation of l-(3-fluoro-5-methoxy-phenyl)piperidin-4-one

A mixture of 8-(3-fluoro-5-methoxy-phenyl)-l,4-dioxa-8-azaspiro[4.5]decane (78.2 g, 0.29 mol), formic acid (400 mL) and H₂0 (400 mL) was heated with stirring at 90°C for 3 hrs. The resulting reaction mixture was concentrated in vacuo. The residue was diluted with DCM (1.0 L), washed with saturated aqueous solution of Na₂C0₃ (200 mL) and brine (200 mL), then dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by the flash column chromatography to give l-(3-fluoro-5-methoxy-phenyl)piperidin-4-one (42.0 g) as a yellow solid. Step 3: Preparation of 6-(3-fluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine

A mixture of l-(3-fluoro-5-methoxy-phenyl)piperidin-4-one (42.0 g. 0.15 mol) and DMFDMA (400 mL) was heated with stirring at 120 °C for 4 hrs. The resulting reaction mixture was concentrated in vacuo and the residue was dissolved in MeOH (700 mL). To the solution was added pyrimidine-2-carboximidamide hydrochloride (26.2 g, 0.17 mol) and K₂CO₃ (50.3 g, 0.36 mol). The resulting mixture was heated with stirring at 60 °C for 2 hrs, then cooled to rt and filtered. The filtrate was concentrated in vacuo. The residue was diluted with DCM (1.0 L), washed H₂0 (200 mL) and brine (200 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by the flash column chromatography to give 6-(3-fluoro-5- methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine (30.8 g) as a light yellow solid. 1H NMR (400 MHz, CDC1₃): δ 9.03 (d, 2H), 8.79 (s, 1 H), 7.37 - 7.48 (m, 1 H), 6.27 - 6.38 (m, 2 H), 6.17 (dt, 1 H), 4.48 (s, 2 H), 3.79 (s, 3 H), 3.69 (t, 2 H), 3.32 (t, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 338.

Example 118: 6-[3-fluoro-5-(trifluoromethoxy)phenyl]-2-pyrimidin-2-yl-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidine

Step 1: Preparation of l-bromo-3-fluoro-5-(trifluoromethoxy)benzene

A mixture of 3-fluoro-5-(trifluoromethoxy)aniline (4.0 g, 20.5 mmol) in H₂SO₄ (90 mL, 30%) was cooled to 0 °C and to the mixture was added NaN0₂ (2.83 g, 41.0 mmol). After being stirred at 0 °C for 0.5 hr, the resulting mixture was added slowly to a solution of CuBr (5.86 g, 41.0 mmol), CuBr₂ (9.14 g, 41.0 mmol) in HBr (50 mL). The resulting mixture was stirred at 10 °C for 16 hrs, then diluted with EA (200 mL), washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo to give crude l-bromo-3-fluoro-5- (trifluoromethoxy)benzene (2.9 g), which was used directly in the next step without any further purification.

Step 2: Preparation of 8-[3-fluoro-5-(trifluoromethoxy)phenyl]-l,4-dioxa-8- azaspiro[4.5]decane

A mixture of l-bromo-3-fluoro-5-(trifluoromethoxy)benzene (2.9 g, 16.2 mmol), 1,4- dioxa-8-azaspiro[4.5]decane hydrochloride (4.24 g, 16.4 mmol), iert-BuONa (3.89 g, 40.5 mmol), Ruphos (120 mg) and Pd₂dba₃ (80 mg) in dioxane (50 mL) was heated with stirring at 100°C under nitrogen for 16 hrs. The resulting mixture was concentrated in vacuo. The residue was diluted with EA (200 mL), washed with water (50 mL) and brine (50 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column to give 8-[3-fluoro-5-(trifluoromethoxy)phenyl]-l,4-dioxa-8-azaspiro[4.5]decane (1.6 g) as a yellow oil.

Step 3: Preparation of l-[3-fluoro-5-(trifluoromethoxy)phenyl]piperidin-4-one

A mixture of 8-[3-fluoro-5-(trifluoromethoxy)phenyl]-l,4-dioxa-8-azaspiro[4.5]decane (1.6 g, 5.0 mol) in formic acid (15 mL) and H₂0 (15 mL) was heated with stirring at 90°C for 2 hrs. The resulting mixture was concentrated in vacuo. The residue was diluted with DCM (100 mL), then washed with water (30 mL) and brine (30 mL), dried over anhydrousNa₂S0₄ and concentrated in vacuo. The residue was purified by flash column to give l-[3-fluoro-5- (trifluoromethoxy)phenyl]piperidin-4-one (930 mg) as a yellow oil.

Step 4: Preparation of 6-[3-fluoro-5-(trifluoromethoxy)phenyl]-2-pyrimidin-2-yl-7,8- dihydro-5H-pyrido[4,3-d]pyrimidine

A mixture of l-[3-fluoro-5-(trifluoromethoxy)phenyl]piperidin-4-one (830 mg. 3.00 mmol) in DMFDMA (10 mL) was heated with stirring at 100°C for 4 hrs. The resulting mixture was concentrated in vacuo. The residue was dissolved in MeOH (10 mL) and to the solution was added 2-amidinopyrimidine hydrochloride (500 mg, 3.15 mmol) and K₂C0₃ (911 mg, 6.6 mmol). The resulting mixture was heated with stirring at 60°C for 2 hrs and concentrated in vacuo. The residue was diluted with DCM (100 mL), washed with H₂0 (30 mL) and brine (30 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by flash column to give 6-[3-fluoro-5-(trifluoromethoxy)phenyl]-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine (800 mg, yield: 68.4%) as a light yellow solid. 1H NMR (400 MHz, CDC1₃): δ 9.05 (d, 2 H), 8.79 (s, 1 H), 7.45 (t, 1 H), 7.11 (dd, 1 H), 6.79 - 6.97 (m, 2 H), 4.43 (s, 2 H), 3.54 - 3.68 (m, 2 H), 3.38 (t, 2 H). MS obsd (ESI) [(M+H)⁺]: 392. Example 119: 2-(2-p3 imidin-2-yl-7,8-dihydro-5^p3oido[4,3-d]p3 imidin-6- yl)thiazole

Step 1: Preparation of l-thiazol-2-ylpiperidin

To a solution of 2-bromothiazole (10.0 g, 60.97 mmol) in THF (100 mL) was added N,N- diisopropylethylamine (17.3 g, 134.2 mmol) and 4-hydroxypiperidine (9.3 g, 91.45 mmol). The resulting mixture was heated with stirring at 80 °C for 16 hrs. The reaction mixture was dissolved in EA (300 mL), washed with water (100 mL) and brine (100 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by column

chromatography to give l-thiazol-2-ylpiperidin-4-ol (2.3 g) as a yellow oil.

Step 2: Preparation of l-thiazol-2-ylpiperidin-4-one

A solution of l-thiazol-2-ylpiperidin-4-ol (2.10 g, 11.40 mmol) in EA (25 mL) was added

2-iodylbenzoic acid (3.51 g, 12.54 mmol). After being heated with stirring at 80 °C for 16 hrs, the resulting mixture was diluted with EA (500 mL), washed with saturated aqueous solution of Na₂S0₃ (200 mL) and brine (200 mL), dried over anhydrous Na₂S0₄ and concentrated in vacuo. The residue was purified by column chromatography to give l-thiazol-2-ylpiperidin-4-one (450 mg) as a yellow oil.

Step 3: Preparation of 2-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl)thiazole

A mixture of l-thiazol-2-ylpiperidin-4-one (450 mg, 2.47 mmol) and DMFDMA (5 mL) was heated with stirring at 120 °C for 4 hrs. The resulting mixture was concentrated in vacuo. The residue was dissolved in MeOH (8 mL) and to the solution was added K₂CO₃ (705 mg, 5.060 mmol) and pyrimidine-2-carboximidamide hydrochloride (368 mg, 2.318 mmol). The resulting mixture was heated with stirring at 70 °C for 2 hrs and then concentrated in vacuo. The residue was purified by prep-HPLC to give 2-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl)thiazole (33 mg) as a pale yellow solid. 1H NMR (400 MHz, DMSO-J6): δ 8.99 (d, 2 H), 8.90 (s, 1 H), 7.64 (t, 1 H), 7.23 (d, 1 H), 6.93 (d, 1 H), 4.77 (s, 2 H), 3.91 (t, 2 H), 3.13 (t, 2 H). MS obsd. (ESI⁺) [(M+H)⁺]: 297.

BIOLOGICAL EXAMPLES

Example 120 materials and methods

HBV cell line

HepG2.2.15 cells (Acs et al. Proc Natl Acad Sci U SA, 84, (1987), 4641-4), a

constitutively HBV-expressing cell line were cultured in DMEM+Glutamax-I medium

(Invitrogen, Carlsbad, CA, USA), supplemented with 10% fetal bovine serum (Invitrogen) and G418 (Invitrogen) at a final concentration of 200 mg/L and maintained in 5% C0₂ at 37 °C.

HBsAg Assay

HepG2.2.15 cells were seeded in duplicate into white, 96- well plates at 1.5 x 10⁴ cells/well. The cells were treated with a three-fold serial dilution series of the compounds in DMSO. The final DMSO concentration in all wells was 1% and DMSO was used as no drug control.

The HBsAg chemiluminescence immunoassay (CLIA) kit (Autobio Diagnostics Co., Zhengzhou, China, Catalog number: CL0310-2) was used to measure the levels of secreted HBV antigens semi-quantitatively. For the detection 50 μΕΛνεΙΙ culture supernatant was used and HBsAg was quantified using HBsAg chemiluminescence immunoassay (CLIA) kit (Autobio Diagnostics Co., Zhengzhou, China, Catalog number: CL0310-2), 50 μΐ_^ of the supernatant was transferred to the CLIA assay plate and 50 μΐ_^ of enzyme conjugate reagent was added into each well. The plates were sealed and gently agitated for 1 hour at room temperature. The

supernatant-enzyme-mixture was discarded and wells were washed 6 times with 300 μΐ_^ of PBS. The residual liquid was removed by plating the CLIA plate right side down on absorbent tissue paper. 25 μΐ_^ of substrates A and B were added to each well. Luminance was measured using a luminometer (Mithras LB 940 Multimode Microplate Reader) after 10 minutes incubation. Dose- response curves were generated and the IC₅₀ value was extrapolated by using the E-WorkBook Suite (ID Business Solutions Ltd., Guildford, UK). The IC₅₀ was defined as the compound concentration (or conditioned media log dilution) at which HBsAg secretion was reduced by 50% compared to the no drug control.

The compounds according to formula I were tested for their capacity to inhibit HBsAg as described herein. The Examples were tested in the above assay and found to have IC₅₀ below 50 μΜ. Particular compounds of formula I were found to have IC₅₀ below 0.50 μΜ. Results of HBsAg assay are given in Table 1.

Results of HBsAg assay are given in Table 1.

Table 1: Activity data of examples in HBsAg assay

Example IC50 Example IC50 Example IC50 Example IC50 No. (μΜ) No. (μΜ) No. (μΜ) No. (μΜ)

1 4.243 31 16.921 61 3.026 91 0.198

2 10.168 32 9.75 62 1.341 92 2.888

3 9.223 33 0.39 63 1.935 93 0.314

4 17.824 34 0.874 64 1.819 94 0.66

5 42.101 35 8.215 65 18.413 95 0.061

6 18.786 36 1.535 66 13.23 96 0.162

7 5.17 37 4.451 67 7.795 97 16.425

8 4.176 38 17.682 68 1.466 98 0.268

9 16.859 39 9.115 69 0.999 99 0.1

10 2.687 40 0.669 70 1.55 100 0.278

11 17.411 41 0.5 71 0.33 101 0.674

12 13.323 42 0.566 72 1.427 102 11.92

13 1.042 43 1.858 73 1.958 103 2.769

14 9.51 44 18.932 74 2.094 104 1.244

15 9.229 45 3.228 75 2.016 105 18.06 Example ICso Example ICso Example ICso Example ICso No. (μΜ) No. (μΜ) No. (μΜ) No. (μΜ)

16 13.675 46 8.787 76 1.513 106 1.342

17 0.154 47 11.395 77 0.265 107 7.122

18 22.001 48 1.375 78 19.05 108 0.263

19 0.461 49 1.073 79 0.288 109 4.086

20 2.837 50 21.863 80 5.943 110 1.437

21 0.321 51 5.355 81 11.258 111 0.362

22 0.75 52 1.972 82 3.352 112 0.553

23 0.549 53 1.56 83 20.013 113 0.161

24 1.863 54 3.911 84 8.559 114 1.166

25 16.01 55 1.175 85 8.29 115 0.352

26 0.061 56 1.837 86 22.098 116 0.53

27 3.163 57 2.17 87 10.257 117 0.157

28 0.455 58 20.249 88 26.369 118 4.981

29 4.164 59 9.058 89 6.717 119 6.076

30 9.486 60 0.371 90 0.933

HBV DNA assay

The assay employs real-time qPCR (TaqMan) to directly measure extracellular HBV DNA copy number. HepG2.2.15 cells were plated in 96- well microtiter plates. Only the interior wells were utilized to reduce "edge effects" observed during cell culture, the exterior wells were filled with complete medium to help minimize sample evaporation. On the following day, the

HepG2.2.15 cells were washed and the medium was replaced with complete medium containing various concentrations of a test compound in triplicate. 3TC was used as the positive control, while media alone was added to cells as a negative control (virus control, VC). Three days later, the culture medium was replaced with fresh medium containing the appropriately diluted drug. Six days following the initial administration of the test compound, the cell culture supernatant was collected, treated with pronase and then used in a real-time qPCR/TaqMan assay to determine HBV DNA copy numbers. Antiviral activity was calculated from the reduction in HBV DNA levels (IC₅₀).

The compounds of the present invention were tested for their capacity to inhibit HBV DNA as described herein. The Examples were tested in the above assay and found to have IC₅₀ below 50 μΜ.

Results of HBV DNA assay are given in Table 2.

Table 2: Anti HBV DNA production activity in HepG2.2.15 cells

Example No. IC50 (μΜ)

80 0.16

Claims

The use of a compound of formula I

wherein

R¹ is hydrogen, Ci_₆alkyl, or haloCi_₆alkyl;

R is Ci-₆alkyl, C₂-₆alkenyl, Ci_₆alkoxy, hydrogen, hydroxy, haloCi_₆alkyl, phenylCi_₆alkoxy, amino, Ci_₆alkylamino or diCi_₆alkylamino;

R is phenyl; phenyl substituted by one, two or three substituents independently selected from Ci_₆alkyl, C₃_₇cycloalkyl, halogen, haloC_1-6alkyl, cyano, nitro, -C(=0)OR⁴, -OR⁵, -S0₂R⁶ and - C(=0)NR 7 R 8 ; thiophenyl; thiophenyl substituted by one, two or three substituents independently selected from Ci_₆alkyl, Ci_₆alkyoxy and halogen; furanyl; furanyl substituted by one, two or three substituents independently selected from C_halky, Ci_₆alkyoxy and halogen; N-containing heteroaryl; or N-containing heteroaryl substituted with one, two or three substituents

R⁴ is hydrogen or Ci_₆alkyl;

₆alkyl and Ci_₆alkoxyCi_₆alkyl;

Q is hydrogen, Ci_₆alkyl, Ci-₆alkoxy, halogen, or haloCi_₆alkyl;

U, W and Z are independently selected from C and Ν;

one of X and Y is Ν, and the other one is C or Ν;

2. A compound of formula I, wherein

R¹ is hydrogen, Ci_₆alkyl, or haloCi_₆alkyl; R is Ci-₆alkyl, C₂-₆alkenyl, Ci_₆alkoxy, hydrogen, hydroxy, haloCi_₆alkyl, phenylCi_₆alkoxy, amino, Ci_₆alkylamino or diCi_₆alkylamino;

R is phenyl; phenyl substituted by one, two or three substituents independently selected from Ci-₆alkyl, C₃-₇cycloalkyl, halogen, haloCi_₆alkyl, cyano, nitro, -C(=0)OR⁴, -OR⁵, -S0₂R⁶ and - C(=0)NR 7 R 8 ; thiophenyl; thiophenyl substituted by one, two or three substituents independently selected from Ci_₆alkyl, Ci_₆alkyoxy and halogen; furanyl; furanyl substituted by one, two or three substituents independently selected from C_halky, Ci_₆alkyoxy and halogen; N-containing heteroaryl; or N-containing heteroaryl substituted with one, two or three substituents independently selected from C_halky, Ci_₆alkyoxy, halogen, haloCi_₆alkyl, cyano, nitro, - C(=0)OR⁴, -OR⁵ and -S0₂R⁶; wherein,

R⁴ is hydrogen or Ci_₆alkyl;

₆alkyl and Ci_₆alkoxyCi_₆alkyl;

Q is hydrogen, Ci_₆alkyl, Ci-₆alkoxy, halogen, or haloCi_₆alkyl;

U, W and Z are independently selected from C and Ν;

one of X and Y is Ν, and the other one is C or Ν;

or pharmaceutically acceptable salts, or enantiomers thereof.

3. A compound according to claim 2, wherein

R¹ is hydrogen or Ci_₆alkyl;

6alkylamino;

R is phenyl; phenyl substituted by one, two or three substituents independently selected from Ci-₆alkyl, C₃_₇cycloalkyl, halogen, haloCi_₆alkyl, cyano, nitro, -C(=0)OR⁴, -OR⁵, -S0₂R⁶ and - C(=0)NR 7 R 8 ; thiazolyl; quinolyl substituted by Ci_₆alkoxy; isoquinolyl substituted by Ci_

₆alkoxy; pyrimidinyl substituted with one or two substituents independently selected from Ci_ ₆alkyoxy and halogen; pyridinyl; or pyridinyl substituted with one or two substituents independently selected from Ci-₆alkyoxy and halogen; wherein, R⁴ is hydrogen or Ci_₆alkyl;

R⁶ is Ci_₆alkyl, haloCi_₆alkyl, Ci_₆alkyamino or diCi_₆alkyamino;

₆alkyl and Ci_₆alkoxyCi_₆alkyl;

Q is hydrogen, Ci_₆alkyl, Ci_₆alkoxy or halogen;

U is C, W is C, and Z is C; or one of U, W and Z is N, and the other two are C;

one of X and Y is N, and the other one is C or N;

or pharmaceutically acceptable salts, or enantiomers thereof.

4. A compound according to claim 2 or 3, wherein

U is C;

W is C;

X is N;

Y is C or N;

Z is C or N;

or pharmaceutically acceptable salts, or enantiomers thereof.

5. A compound according to any one of claims 2 to 4, or pharmaceutically acceptable salts, or enantiomers thereof, wherein R 1 is hydrogen, R 2 is hydrogen, Q is hydrogen.

6. A compound according to any one of claims 2 to 5, or pharmaceutically acceptable salts, or enantiomers thereof, wherein R is phenyl substituted by one, two or three substituents independently selected from halogen, cyano, nitro, carboxy, -OR⁵ and -S0₂R⁶, wherein R⁵ is Ci_ ₆alkyl, haloCi_₆alkyl, hydroxyCi_₆alkyl, Ci_₆alkoxyCi_₆alkyl or phenylCi_₆alkyl; R⁶ is Ci_₆alkyl; or pyridinyl substituted by one or two substituents independently selected from halogen and Ci_ ₆alkoxy.

7. A compound according to any one of claims 2 to 6, or pharmaceutically acceptable salts, or enantiomers thereof, wherein R is phenyl substituted by one, two or three substituents independently selected from fluoro, chloro, cyano, nitro, carboxy, methoxy, ethoxy, propoxy, difluoromethoxy, trifluoromethoxy, hydroxyethoxy, hydroxypropoxy, methoxyethoxy, methoxypropoxy, benzyloxy and methylsulfonyl; or pyridinyl substituted by one or two substituents independently selected from fluoro, chloro and methoxy.

8. A compound according to claim 2 or 3, wherein

R¹ is hydrogen;

R is hydrogen;

R is phenyl substituted by one, two or three substituents independently selected from halogen, cyano and -OR⁵, wherein R⁵ is Ci_₆alkyl, hydroxyCi_₆alkyl or Ci_₆alkoxyCi_₆alkyl; or pyridinyl substituted by one or two substituents independently selected from halogen and Ci_₆alkoxy; Q is hydrogen;

U is C;

W is C, Z is C; or one of W and Z is N, and the other one is C;

X is N;

Y is C or N;

or pharmaceutically acceptable salts, or enantiomers thereof.

9. A compound according to claim 2, 3 or 8, wherein

R¹ is hydrogen;

R is hydrogen;

Q is hydrogen;

U is C;

W is C, Z is C; or one of W and Z is N, and the other one is C;

X is N;

Y is C or N;

or pharmaceutically acceptable salts, or enantiomers thereof.

10. A compound according to claim 2, selected from

6-(4-Methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

2-(5-Fluoro-2-pyridyl)-6-(4-methylsulfonylphenyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine; 2-(5-Methyl-2-pyridyl)-6-(4-methylsulfonylphenyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

2-(3-Methyl-2-pyridyl)-6-(4-methylsulfonylphenyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

2-(5-Methoxy-2-pyridyl)-6-(4-methylsulfonylphenyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

N-Methyl-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl] benzenesulf onamide ;

N,N-Dimethyl-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl] benzenesulf onamide ;

6-(3,4-Difluorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(3,5-Difluorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(2,4-Difluorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

Methyl 2-fluoro-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzoate; Methyl 5-bromo-2-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzoate; 6-(3,4-Difluoro-5-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 2,3-Difluoro-5-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]phenol;

6-(3-Ethoxy-4,5-difluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-(3,4-Difluoro-5-propoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-[3,4-Difluoro-5-(2-methoxyethoxy)phenyl]-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine; 6-(3,4-Difluoro-5-methoxy-phenyl)-2-(4-methoxy-2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(3,4-Difluoro-5-methoxy-phenyl)-2-(6-methoxy-2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(3,4-Difluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

4-[2-(2-Pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzoic acid;

6-(2-Nitrophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(5-Chloro-2-pyridyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

2-(2-Pyridyl)-6-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(4-Chlorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(4-Benzyloxyphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(7-Tolyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

6-(3,4-Dichlorophenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 4-Methoxyphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

3- Bromo-4-fluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

4- Bromo-3-fluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 4-Benzyloxy-3-fluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 4-Ethoxy-3-fluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 3-Fluoro-4-propoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 3-Fluoro-4-(3-methoxypropoxy)phenyl]-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrim dine;

6 3- Methoxy-4-(2-methoxyethoxy)phenyl]-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrim dine;

6 4- Methoxy-3-(2-methoxyethoxy)phenyl]-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrim dine;

3,4-Dimethoxyphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

2-Methoxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzonitrile;

6-(2,3-Difluoro-4-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(4-Chloro-3-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-r3-(Difluoromethoxy)phenyl]-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidm^ 6-(4-Benzyloxy-3,5-difluoro-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

2-Methoxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzoic acid; 2-Ethoxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzoic acid; 2-Butoxy-4-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]benzoic acid; 6-(5-Chloro-4-methoxy-pyrimidin-2-yl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(3,5-Dimethoxyphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-(8-Methoxy-3-isoquinolyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-(2-Methoxy-7-quinolyl)-2-pyrimidin-2-yl-7_^

3- Methoxy-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)benzonitrile;

2- Fluoro-6-methoxy-4-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl)benzonitrile;

6-(4-Chloro-3-fluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(4-Methylsulfonylphenyl)-2-(2-pyridyl)-3,5,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-one;

4- Methoxy-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(4-Methylsulfonylphenyl)-4-[(E)-prop- l-enyl]-2-pyrimidin-2-yl-7,8-dihydro-5H- pyrido [4, 3 -d] pyrimidine ;

6-(4-Methylsulfonylphenyl)-4-propyl-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

4-Ethyl-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

4-Methyl-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

N-Methyl-6-(4-methylsulfonylphenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-4-amine;

6-(4-Methylsulfonylphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-l,6-naphthyridine;

6-(4-Fluoro-3-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-(3-Fluoro-5-methoxy-phenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-(3-Methoxyphenyl)-2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine;

3- [2,3-Difluoro-5-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl]phenoxy]propan- l-ol;

2-[2,3-Difluoro-5-[2-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl]phenoxy]ethanol; 2-(3,4-Difluoro-5-methoxy-phenyl)-6-pyrimidin-2-yl-3,4-dihydro- lH-2,7-naphthyridine;

2- (3,4-Difluoro-5-methoxy-phenyl)-6-(2-pyridyl)-3,4-dihydro- lH-2,7-naphthyridine;

6-(3,4-Difluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-l,6-naphthyridine; 6-(3-Chloro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-di ydro-5H-pyrido[4,3-d]pyrimidine^ 6-(6-Fluoro-4-methoxy-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

3- Fluoro-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)benzonitrile; Methyl 3-fluoro-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6- yl)benzoate;

3-Fluoro-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)-N-(2,2,2- trifluoroethyl)benzamide;

3-Fluoro-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)benzamide;

3-Fluoro-N-(3-methoxypropyl)-5-(2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl)benzamide;

6-(4,6-Dichloro-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-(2,6-Dichloro-4-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-(4-Chloro-6-methoxy-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine; 6-(2-Chloro-6-methoxy-4-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(3-Fluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-[3-Fluoro-5-(trifluoromethoxy)phenyl]-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

2-(2-Pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)thiazole;

or pharmaceutically acceptable salts, or enantiomers thereof.

11. A compound according to claim 2, selected from

3- [2,3-Difluoro-5-[2-(2-pyridyl)-7,8-dihydro-5 H -pyrido[4,3-d]pyrimidin-6- yl]phenoxy]propan- l-ol;

2-(3,4-Difluoro-5-methoxy-phenyl)-6-pyrimidin-2-yl-3,4-dihydro- 1 H -2,7-naphthyridine; 2-(3,4-Difluoro-5-methoxy-phenyl)-6-(2-pyridyl)-3,4-dihydro- 1 H -2,7-naphthyridine; 6-(3-Chloro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5 H -pyrido[4,3- d]pyrimidine;

6-(6-Fluoro-4-methoxy-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine; 6-(6-Chloro-4-methoxy-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine;

6-(4,6-Dichloro-2-pyridyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; 6-(3-Fluoro-5-methoxy-phenyl)-2-pyrimidin-2-yl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine; or pharmaceutically acceptable salts, or enantiomers thereof.

12. A process for the preparation of a compound according to any one of claims 2 to 11 comprising

(a) cyclization of a compound of formula (A)

(A)

with a compound of formula (B)

(B);

(b) coupling of a compound of formula (C)

with a compound of formula (D)

R— FG

(D);

(c) coupling of a compound of formula (E)

(E) with a compound of formula (F)

(d) coupling of a compound of formula (G)

with a compound of formula (H)

wherein R 1 to R 3 , Q, U, W and Z are defined as in any one of claims 1 to 11, FG is OH, NH₂, boronic acid or pinacol ester, L is CI, Br, I, O-mesyl or O-tosyl.

13. A compound according to any one of claims 1 to 11 for use as therapeutically active substance.

14. A pharmaceutical composition comprising a compound in accordance with any one of claims 1 to 10 and a therapeutically inert carrier.

15. The use of a compound according to any one of claims 1 to 11 for the treatment or prophylaxis of HBV infection.

16. The use of a compound according to any one of claims 1 to 11 for the preparation of a medicament for the treatment or prophylaxis of HBV infection.

17. The use of a compound according to any one of claims 1 to 11 for the inhibition of HBsAg production or secretion, or for the inhibition of HBV DNA production.

18. A compound according to any one of claims 1 to 11 for the treatment or prophylaxis HBV infection.

19. A compound according to any one of claims 1 to 11, when manufactured according to a process of claim 12.

20. A method for the treatment or prophylaxis of HBV infection, which method comprises administering an effective amount of a compound as defined in any one of claims 1 to 11.

21. The invention as hereinbefore described.